Compound based on sulfo-glutaryl imidoisoindolinone skeleton and application thereof

Abstract

Provided are a compound of formula (I) or a salt, an enantiomer, a stereoisomer, a solvate, and a polymorphic substance thereof, a pharmaceutical composition containing the compound of formula (I) or the salt, the enantiomer, the stereoisomer, the solvate, and the polymorphic substance thereof as an active ingredient, and an application of the compound or the composition. The compound can be used for effectively preventing or treating diseases or symptoms related to the cerebron protein, including tumors or cancers. # imgabs0 #

Description

Compounds based on thioglutarimidoisoindolinone skeleton and their applications Technical Field

[0001] The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, polymorph thereof and uses thereof, in particular, uses thereof for preventing or treating tumors or cancers. Background Art

[0002] Phthalimide immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide, are highly effective in treating multiple myeloma and autoimmune diseases. However, it wasn't until 2010 that their direct binding protein, the E3 ubiquitin ligase cereblon (CRBN), was identified. Subsequently, it was demonstrated that upon binding to CRBN, these drugs act as molecular glues to recruit substrate proteins (such as the transcription factors IKZF1 / 3), enabling protein-protein interactions between CRBN and substrate proteins and subsequently ubiquitination of these substrate proteins. Polyubiquitinated substrate proteins are then recognized and degraded by the proteasome, resulting in pharmacological effects including anti-tumor and immunomodulatory effects. Molecular glue protein degraders directly target and degrade target proteins, offering potential advantages such as targeting undruggable targets. Furthermore, molecular glue degraders typically have a small molecular weight and good drugability, making their development highly valued. Based on the CRBN E3 ubiquitin ligase and molecular glue degradation mechanism, a series of compounds have been developed, including the marketed pomalidomide, as well as CC-122, CC-220, CC-90009, CC-99282, and CC-92480 from Bristol-Myers Squibb (BMS), DKY709 from Novartis, and CFT7455 from C4 Therapeutics, all currently undergoing clinical trials. The degradation substrates of these molecular glues have also expanded from the initially discovered transcription factors IKZF1 / 3 to casein kinase 1α (CK1α), zinc finger protein 91 (ZFP91), and translation factor GSPT1. The degradation of these protein substrates enables the molecular glues to exert pharmacological activities such as immunomodulation, anti-inflammatory, and anti-tumor effects. The structural novelty of the molecular glue candidates discovered so far is very limited, and the design of diversified scaffolds and the development of more molecular glues have become research hotspots in this field.

[0003] Therefore, there is an urgent need for a series of novel CRBN E3 ubiquitin ligase ligands that can serve as effective molecular glue degraders for the treatment and / or prevention of diseases or conditions mediated by or associated with degraded proteins.

[0004] Summary of the Invention

[0005] In view of the above, the object of the present disclosure is to provide novel thioglutarimidyl isoindolinone derivative protein degradation drugs, their preparation methods, uses, and methods of using them.

[0006] To achieve the above-mentioned and other related purposes, in one aspect, the present disclosure provides a compound of formula (I) or its salt, stereoisomer (including enantiomer, diastereomer), solvate, or polymorph:

[0007] in

[0008] Z1 represents C(O), C(S), CH2 or CD2, Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S);

[0009] R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy;

[0010] (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, or C 2-6 Alkynyl;

[0011] m represents an integer 0, 1, 2 or 3;

[0012] R represents O, S, S(O), S(O)2, alkenylene, alkynylene or N(R a6 ), where R a6 Indicates H or C 1-3 Alkyl, or R represents a bond; or

[0013] R stands for:

[0014] Among them, each ring A 1 are the same or different and each independently represent a nitrogen-containing heterocyclic group, an arylene group or a heteroarylene group, y1 represents an integer of 1 or 2, (R y1 ) a1 Represents each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20;

[0015] Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y2 represents an integer of 0 or 1, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen,

[0016] Amino, hydroxyl, thiol, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20;

[0017] L means:

[0018] where R w1 Connect R, R w2 Connect X;

[0019] R w2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl;

[0020] Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20;

[0021] Each ring A 4 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y4 represents an integer of 0, 1, 2 or 3, (R y4 ) a4 Represents each ring A 4 Independently optionally by a4 R y4 Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a4 represents an integer of 0-20;

[0022] Each ring A 5 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y5 represents an integer of 0, 1, 2 or 3, (R y5 ) a5 Represents each ring A 5 Independently optionally a5 R y5 Group substitution, each R y5 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy,

[0023] Halogen, amino, hydroxyl, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a5 represents an integer of 0-20;

[0024] R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1- 20Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof;

[0025] X means:

[0026] NR1R2, C(O)NR3R4, NHC(O)R5, NHC(O)NR6R7, OR8, SR9, S(O)2NR 10 R11 or N(R 12 )S(O)2R 13 , where R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, and wherein R2, R8 and R 13 each independently represents an optionally substituted straight-chain or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclyl group or an optionally substituted heteroaryl group, or wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 30-membered nitrogen-containing heterocyclyl group; or

[0027] wherein ring A represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 )n1 Indicates that ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1- 6 alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20;

[0028] R c Indicates NR c1 、C(O),CR c2 R c3 or key, where R c1 represents H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, R c2 and R c3 each independently represents H, halogen, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclyl group, or an optionally substituted heteroaryl group;

[0029] Each ring B is the same or different and independently represents a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, m1 represents an integer of 0, 1, 2 or 3, (R d2 ) n2 Indicates that each ring B is independently optionally substituted with n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C z-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20;

[0030] R e Indicates S, O, CR e1 R e2 or key, where R e1 and R e2 each independently represents H, halogen, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; and

[0031] Each ring C is the same or different and independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group, m2 represents an integer of 0, 1, 2 or 3, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer from 0 to 20; or

[0032] Where -X1-X2- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1- 5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-;

[0033] p1, p2, p3 each independently represent an integer of 1, 2, 3 or 4; and

[0034] The ring containing -X1-X2- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 Alkenyl or any combination thereof; or

[0035] Where -X3-X4- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1- 5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-;

[0036] p4, p5 each independently represent an integer of 1, 2, 3 or 4; and

[0037] The benzo-fused ring containing -X3-X4- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1- 6 alkyl, C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

[0038] In another aspect, the present disclosure provides a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier.

[0039] In another aspect, the present disclosure further provides a medicine box or a test kit comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.

[0040] In another aspect, the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate, prodrug or polymorph thereof, for use as a medicament.

[0041] On the other hand, the present disclosure provides the compound of formula (I), or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph or the pharmaceutical composition of the present disclosure, which is used for treating or preventing tumors or cancer.

[0042] On the other hand, the present disclosure also provides the use of the compound of formula (I) or its pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph or the pharmaceutical composition described in the present disclosure, which is used to prepare a drug for treating or preventing tumors or cancer.

[0043] In another aspect, the present disclosure also provides a method for treating or preventing tumors or cancer, comprising administering to a subject a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer (including enantiomers, diastereomers), solvate, isotopically enriched analog, prodrug or polymorph thereof, or the pharmaceutical composition.

[0044] In another aspect, the present disclosure also provides a method for preparing a compound of formula (II), comprising reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0045] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein; and

[0046] in

[0047] (i) The group LE represents Cl, Br, I, methanesulfonyloxy (OMs), p-toluenesulfonyloxy (OTs), or o-nitrobenzenesulfonyl (ONs), and R of formula (M2) b1 -X a -R b2 is R1-NH-R2, and X b Correspondingly represents NR1R2, wherein R1 and R2 are as defined in the compounds of formula (I) and its various subembodiments disclosed herein; or

[0048] (ii) the group LE represents Cl, Br, I, OMs, OTs, or ONs, and the group X a represents NH, group R b1 and group R b2 Together with their connected X a The nitrogen atoms together form the formula The substituent represented by n1 substituents R d1 Substituted nitrogen-containing heterocycle A a , that is, the compound of formula (M2) has the following structure:

[0049] And X b The structure represented by the following general formula is represented accordingly:

[0050] , wherein the nitrogen-containing heterocyclic ring A a represents a 4- to 30-membered nitrogen-containing heterocyclic group (preferably, a 4- to 20-membered nitrogen-containing heterocyclic group; more preferably, a 4- to 15-membered nitrogen-containing heterocyclic group), (R d1 ) n1 、n1、R c , Ring B, m1, (R d2 ) n2 、n2、R e 、C、m2、(R d3 ) n3and n3 is as defined in the compounds of formula (I) and its subembodiments disclosed herein; or

[0051] (iii) the group LE represents C(O)Cl, COOH or S(O)2Cl, and X of formula (M2) a R b1 R b2 is R3-NH-R4 or R 10 -NH-R 11 , and X b Correspondingly represents C(O)NR3R4 or S(O)2NR 10 R 11 , where R3, R4, R 10 and R 11 As defined in the compounds of formula (I) and its various subembodiments disclosed herein; or

[0052] (iv) The group LE represents NH2, and R of formula (M2) b1 -X a -R b2 are: R5-C(O)-OH, R5-C(O)-Cl, R 13 -S(O)2-OH, or R 13 -S(O)2-Cl, and X b Correspondingly represents NHC(O)R5 or NHS(O)2R 13 , where R5 and R 13 As defined in the compounds of formula (I) and its various subembodiments disclosed herein; or

[0053] (v) The group LE represents Cl, Br or I, and R of formula (M2) b1 -X a -R b2 is: R8-OH or R9-SH, and X b Correspondingly represents OR8 or SR9, wherein R8 and R9 are as defined in the compounds of formula (I) and various subembodiments thereof disclosed herein.

[0054] In another aspect, the present disclosure also provides a method for preparing a compound of formula (M1),

[0055] wherein the group LE represents a methanesulfonyloxy group, and the method comprises reacting a compound of formula (M3) with methanesulfonic anhydride or methanesulfonyl chloride to obtain a compound of formula (M1):

[0056] The group R in the compound of formula (M1) and the compound of formula (M3) a1 、R a2 、R a3 、R a4, R, Z1, Z2, Z3, Z4 and (R a5 ) m As defined in the compounds of formula (I) and its various subembodiments disclosed herein.

[0057] In another aspect, the present disclosure also provides a method for preparing a compound of formula (M1),

[0058] wherein the group LE represents Cl, Br or I, and the method comprises preparing a compound of formula (M1) by subjecting a compound of formula (M3) to a halogenation reaction with a hydrohalic acid:

[0059] The group R in the compound of formula (M1) and the compound of formula (M3) a1 、R a2 、R a3 、R a4 , R, Z1, Z2, Z3, Z4 and (R a5 ) m As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0060] In another aspect, the present disclosure also provides a method for preparing a compound of formula (M4), comprising subjecting a carbonyl compound of formula (M5) to a sulfurization reaction with a sulfurizing agent to prepare a thiocarbonyl compound of formula (M4):

[0061] wherein Z6 of the carbonyl compound of formula (M5) represents C(O), CH2 or CD2; and group R a1 、R a2 、R a3 、R a4 , Z1, Z2, Z3, Z4 and (R a5 ) m As defined in the compounds of formula (I) and its various subembodiments disclosed herein.

[0062] In another aspect, the present disclosure also provides a method for preparing a compound of formula (I), comprising subjecting a compound of formula (A) to a sulfiding reaction with a sulfiding agent to obtain a compound of formula (I):

[0063] wherein Z7 of the compound of formula (A) represents C(O), CH2 or CD2;

[0064] In the compound of formula (I), Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); and

[0065] The group Ra1 、R a2 、R a3 、R a4 、(R a5 ) m , R, L and X are as defined in the compounds of formula (I) and its various subembodiments disclosed herein.

[0066] Detailed Description of the Invention

[0067] The following detailed description is provided as an exemplary embodiment to help those skilled in the art understand and implement the present disclosure. However, it should be understood that such description is not intended to limit the scope of the present disclosure. Without departing from the spirit and scope of the present disclosure, the specific embodiments described in the present disclosure may be subjected to various modifications and changes, and these changes and improvements all fall within the scope of the present disclosure as claimed.

[0068] I. Compounds

[0069] Compound of formula (I)

[0070] The present disclosure provides a compound of formula (I) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog, prodrug or polymorph:

[0071] Among them, Z1, Z2, Z3, Z4, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, L and X are as defined above for the compounds of formula (I) and its embodiments.

[0072] The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs provided herein have binding affinity for CRBN, help recruit substrate proteins, and can act as molecular glues to bind to CRBN E3 ubiquitin ligases. The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs disclosed herein can also degrade substrate proteins (e.g., IKZF1 / 2 / 3 / 4 proteins, WEE1 proteins, CK1α proteins, GSPT1 proteins, ZFP91 proteins, etc.). The compounds of formula (I) or their salts (including pharmaceutically acceptable salts), stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs, or polymorphs disclosed herein have anti-tumor activity or excellent pharmacokinetic properties and can be used as therapeutic drugs for cancer patients.

[0073] In some embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 The same or different and each independently represents H, deuterium (ie, D), C 1-6 Alkyl (e.g. C 1-3 Alkyl, such as methyl, ethyl, or propyl), halo C 1-6 Alkyl (e.g. halo-C 1-4 alkyl, such as trifluoromethyl), deuterated C 1-6 Alkyl, C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, such as methoxy), deuterated C 1-6 Alkoxy or halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 In some sub-embodiments of the present disclosure, R a1 、R a2 、R a3 and R a4 Each independently represents H.

[0074] In some embodiments of the present disclosure, at least one of Z1, Z2, Z3 and Z4 represents C(S).

[0075] In some embodiments of the present disclosure, at least two of Z1, Z2, Z3, and Z4 represent C(S).

[0076] In some embodiments of the present disclosure, at least three of Z1, Z2, Z3, and Z4 represent C(S).

[0077] In some embodiments of the present disclosure, Z1, Z2, Z3 and Z4 all represent C(S).

[0078] In some embodiments of the present disclosure, Z1 represents C(S).

[0079] In some embodiments of the present disclosure, Z2 represents C(S).

[0080] In some embodiments of the present disclosure, Z3 represents C(S).

[0081] In some embodiments of the present disclosure, Z4 represents C(S).

[0082] In some embodiments of the present disclosure, Z1 and Z4 represent C(S).

[0083] In some embodiments of the present disclosure, Z2 and Z4 represent C(S).

[0084] In some embodiments of the present disclosure, Z3 and Z4 represent C(S).

[0085] In some embodiments of the present disclosure, Z1 and Z2 represent C(S).

[0086] In some embodiments of the present disclosure, Z1, Z3, and Z4 represent C(S).

[0087] In some embodiments of the present disclosure, Z2, Z3, and Z4 represent C(S).

[0088] In some embodiments of the present disclosure, Z1, Z2, and Z3 represent C(S).

[0089] In some embodiments of the present disclosure, Z1, Z2, and Z4 represent C(S).

[0090] In some embodiments of the present disclosure, Z1 represents CH2, Z2 represents C(S), and Z3 and Z4 represent C(O).

[0091] In some embodiments of the present disclosure, Z1 represents CH2, Z2 represents C(S), Z3 represents C(O), and Z4 represents C(S).

[0092] In some embodiments of the present disclosure, Z1 represents CH2, Z2 represents C(S), and Z3 and Z4 represent C(S).

[0093] In some embodiments of the present disclosure, Z1 and Z2 represent C(S), Z3 represents C(O), and Z4 represents C(S).

[0094] In some embodiments of the present disclosure, Z1, Z2, Z3, and Z4 represent C(S).

[0095] In some embodiments of the present disclosure, (R a5 ) m represents that the isoindoline ring of formula (I) attached thereto is optionally substituted by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 Alkyl (e.g. halo-C 1-4Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1- 4 alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 Alkenyl (e.g. vinyl), or C 2-6 alkynyl (e.g., ethynyl), and m represents an integer of 0, 1, 2, or 3. Alternatively, in some sub-embodiments of the present disclosure, m represents an integer of 0, 1, or 2. Alternatively, in some sub-embodiments of the present disclosure, each R a5 The same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-).

[0096] In the embodiments of the present disclosure, the number of substituents is in principle not subject to any restrictions or automatically limited by the size of the building block.

[0097] In some embodiments of the present disclosure, R represents O, S, S(O), S(O)2, alkenylene, alkynylene, or N(R a6 ), where R a6 Indicates H or C 1-3 Alternatively, in some sub-embodiments of the present disclosure, R represents O, S, S(O), S(O)2, C 2-6 Alkenylene (e.g. vinylene), C 2-6 Alkyne (e.g., ethynylene), NH or N(CH3).

[0098] In some embodiments of the present disclosure, R represents a bond.

[0099] In some embodiments of the present disclosure, R represents:

[0100] Among them, each ring A 1 are the same or different and each independently represent a nitrogen-containing heterocyclic group, an arylene group or a heteroarylene group, y1 represents an integer of 1 or 2, (R y1 ) a1 Represents each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; and / or

[0101] Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y2 represents an integer of 0 or 1, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each Ry2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20.

[0102] In some embodiments of the present disclosure, y1 represents an integer of 1 or 2, and each ring A 1 the same or different and each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0103] In some embodiments of the present disclosure, y1 represents an integer of 1 or 2, and each ring A 1 Each independently represents:

[0104] piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaoctinylene, diazaoctinylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene alkylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[3.2.1]octanylene, diazabicyclo[2.2.2]octanylene, 3-azaspiro[5.5]undecylene, 8-azaspiro[4.5]decylene, 2-oxa-8-azaspiro[4.5]decylene, 3-methyl-2-oxa-8-azaspiro[4.5]decylene, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, phenylene thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenylyl, indazolyl, benzimidazolylene, benzoxazolylene, benzisoxazolyl, benzothiazolylene, benzisothiazolylene, benzotriazole, benzo[2,1,3]oxadiazole, benzo[2,1,3]thiadiazolylene yl, benzo[1,2,3]thiadiazolylene, quinolylene, isoquinolylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0105] In some embodiments of the present disclosure, y1 represents an integer of 1 or 2, and each ring A 1 Each independently represents:

[0106] In some embodiments of the present disclosure, y1 represents an integer of 1 or 2, and each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C2-6 Alkynyl or C 2-6 Alkenyl, and a1 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y1 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 Alkoxy, for example, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0107] In some embodiments of the present disclosure, y2 represents an integer 0 or 1.

[0108] In some embodiments of the present disclosure, Ring A 2 represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0109] In some embodiments of the present disclosure, Ring A 2 express:

[0110] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0111] In some embodiments of the present disclosure, y2 represents an integer of 0 or 1, and Ring A 2 express:

[0112] In some embodiments of the present disclosure, y2 represents an integer of 0 or 1, and Ring A 2 Optionally a2 R y2 Group substitution, each R y2Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a2 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y2 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 Alkoxy, for example, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a2 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0113] In some embodiments of the present disclosure, R represents:

[0114] wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0115] In some embodiments of the present disclosure, L represents:

[0116] where R w1 Connect R, R w2 Connect X;

[0117] R w2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl;

[0118] Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20;

[0119] Each ring A 4 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y4 represents an integer of 0, 1, 2 or 3, (R y4 ) a4 Represents each ring A 4 Independently optionally by a4 R y4 Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a4 represents an integer of 0-20;

[0120] Each ring A 5 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y5 represents an integer of 0, 1, 2 or 3, (R y5 ) a5 Represents each ring A5 Independently optionally a5 R y5 Group substitution, each R y5 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a5 represents an integer of 0-20; and / or

[0121] R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more (e.g., 1-15, 1-10, 1-6, 1-4, 2-6, or 1) methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1- 6 alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b Each is independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof.

[0122] In some embodiments of the present disclosure, R w2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl.

[0123] In some embodiments of the present disclosure, R w2 Indicates a key.

[0124] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0125] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently represents:

[0126] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene

[0014] 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene.

[0127] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently represents:

[0128] In some embodiments of the present disclosure, y3 represents an integer of 0, 1, 2 or 3, and each ring A 3 Each independently optionally represented by a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a3 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y3 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a3 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0129] In some embodiments of the present disclosure, y4 represents an integer of 0, 1, 2 or 3, and each ring A 4 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0130] In some embodiments of the present disclosure, y4 represents an integer of 0, 1, 2 or 3, and each ring A 4 Each independently represents:

[0131] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazacycloheptanediylene, diazacyclooctanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene

[0014] 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene, 1H-pyrrolo[2,1-b]thiazolylene.

[0132] In some embodiments of the present disclosure, y4 represents an integer of 0, 1, 2 or 3, and each ring A 4 Each independently represents:

[0133] In some embodiments of the present disclosure, y4 represents an integer of 0, 1, 2 or 3, and each ring A 4 Each independently optionally represented by a4 R y4Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a4 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y4 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a4 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0134] In some embodiments of the present disclosure, y5 represents an integer of 0, 1, 2 or 3, and each ring A 5 Each independently represents a 4- to 30-membered heterocyclylene group (e.g., a 4- to 20-membered heterocyclylene group, or a 4- to 15-membered heterocyclylene group), a C 3-30 Cycloalkyl (e.g. C 3- 20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15arylene) or a 5- to 30-membered heteroarylene (e.g., a 5- to 20-membered heteroarylene, or a 5- to 15-membered heteroarylene).

[0135] In some embodiments of the present disclosure, y5 represents an integer of 0, 1, 2 or 3, and each ring A 5 Each independently represents:

[0136] Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazepanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene 1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene.

[0137] In some embodiments of the present disclosure, y5 represents an integer of 0, 1, 2 or 3, and each ring A5 Each independently represents:

[0138] In some embodiments of the present disclosure, y5 represents an integer of 0, 1, 2 or 3, and each ring A 5 Each independently optionally represented by a5 R y5 Group substitution, each R y5 Each independently is deuterium, c 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Alkenyl, and a5 represents an integer from 0 to 20. Alternatively, in some sub-embodiments of the present disclosure, each R y5 Each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, amino, cyano, C 1-4 Alkyl (e.g. C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-4 Alkyl (e.g. halo-C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-4 Alkoxy (e.g. C 1-3 Alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-4 Alkoxy (e.g., halo-C 1-3 or alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Alternatively, in some sub-embodiments of the present disclosure, a5 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

[0139] In some embodiments of the present disclosure, in the general formula of L Partially indicates:

[0140] wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0141] In some embodiments of the present disclosure, R w1 Indicates a key.

[0142] In some embodiments of the present disclosure, R w1 represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1-20 Any one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) methylene groups of the main carbon chain backbone of the alkylene group are optionally replaced by one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) groups selected from the following: R a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 Alkyl), and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkenylene, alkynylene, and any combination thereof. bare each independently selected from optionally substituted C 3-30 Cycloalkylene, optionally substituted C 5-30 arylene, an optionally substituted 4- to 30-membered heterocyclylene, an optionally substituted 5- to 30-membered heteroarylene, C 2-6 Alkenylene or C 2-6 Alkyne (preferably, optionally substituted C 3-20 Cycloalkylene, optionally substituted C 5-20 arylene, an optionally substituted 4- to 20-membered heterocyclylene, an optionally substituted 5- to 20-membered heteroarylene, C 2-4 Alkenylene or C 2-4 Alkynylidene; or more preferably, optionally substituted C 3-15 Cycloalkylene, optionally substituted C 5-15 arylene, an optionally substituted 4- to 15-membered heterocyclylene, an optionally substituted 5- to 15-membered heteroarylene, C 2-4 Alkenylene or C 2-4 In some sub-embodiments, the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In some subembodiments, the straight or branched C 1-2 One or more (e.g., 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) hydrogen atoms of an alkylene group may be optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0143] In some embodiments of the present disclosure, R w1 express:

[0144] -C 1-15 Alkylene-;

[0145] -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a1 1)) r2 ) s1 -*;

[0146] -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a1 1)) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -*;

[0147] -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a1 1)) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -(R a (C(R a14 )(R a15 )) r4 ) s3 -*;

[0148] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1 -*;

[0149] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1-((C(R a12 )(R a13 )) r3 R a ) s2 -*;

[0150] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 R a ) s1 -((C(R a12 )(R a13 )) r3 R a ) s2 -((C(R a14 )(R a15 )) r4 R a ) s3 -*;

[0151] -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -*;

[0152] -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3 ) s2 -*;

[0153] -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3) s2 -(R b (C(R a14 )(R a15 )) r4 ) s3 -*;

[0154] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 R b ) s1 -*;

[0155] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R b ) s2 -*;

[0156] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R b ) s2 -((C(R a14 )(R a15 )) r4 R b ) s3 -*;

[0157] -(C(R a8 )(R a9 )) r1 -(R a -R b -(C(R a10 )(R a1 1)) r2 ) s1 -*;

[0158] -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a1 1)) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3 ) s2 -*;

[0159] -(C(R a8 )(R a9 )) r1 -(R b -R a -(C(R a10 )(R a1 1)) r2 ) s1 -*;

[0160] -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -*;

[0161] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -R a -R b ) s1 -*;

[0162] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1 -((C(R a12 )(R a13 )) r3 Rb ) s2 -*;

[0163] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -R b -R a ) s1 -*;or

[0164] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R a ) s2 -*;

[0165] Among them, each group R a independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl; each group R b are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0166] R a8 、R a9 、R a10 、R a11 、R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halo 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and

[0167] r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0168] The symbol * indicates the point of attachment to R; and

[0169] The C 1-15 Any one or more (e.g., 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) hydrogens of the main carbon chain skeleton of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl and any combination thereof. w1 The total number of carbon atoms in each general formula (excluding R a 、R bThe number of carbon atoms in the group), that is, the sum of R1+R2*S1, the sum of R1+R2*S1+R3*S2, and the sum of R1+R2*S1+R3*S2+R4*S5, are all less than or equal to 20.

[0170] In some embodiments of the present disclosure, R w1 Indicates -C 1-15 Alkylene-, wherein the C 1-15 Any one or more (e.g., 1-30, 1-25, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) hydrogens of the main carbon chain skeleton of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0171] In some embodiments of the present disclosure, R w1 represents the following groups: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11-、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -or-(CH2) 15 -; wherein any one or more hydrogen atoms of the group may be further replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halo, C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 Alkyl (e.g., perdeuterated C 1-6 Alkyl, fully deuterated C 1-5 Alkyl or perdeuterated C 1- 4 alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0172] In some embodiments of the present disclosure, R w1 express:

[0173] -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2 ) s1 -*;

[0174] -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2) s1 -(O(C(R a12 )(R a13 )) r3 ) s2 -*;

[0175] -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2 ) s1 -(O(C(R a12 )(R a13 )) r3 ) s2 -(O(C(R a14 )(R a15 )) r4 ) s3 -*;

[0176] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 O) s1 -*;

[0177] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 O) s1 -((C(R a12 )(R a13 )) r3 O) s2 -*;

[0178] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 O) s1 -((C(R a12 )(R a13 )) r3 O) s2 -((C(R a14 )(R a15 )) r4 O) s3 -*;

[0179] -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -*;

[0180] -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -(N(R a7 )(C(R a12 )(R a13 )) r3 ) s2 -*;

[0181] -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -(N(R a7 )(C(R a12 )(R a13 )) r3 ) s2 -(N(R a7 )(C(R a14 )(R a15 )) r4 ) s3 -*;

[0182] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 N(R a7 )) s1 -*;

[0183] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 N(Ra7 )) s1 -((C(R a12 )(R a13 )) r3 N(R a7 )) s2 -*;

[0184] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 N(R a7 )) s2 -((C(R a14 )(R a15 )) r4 N(R a7 )) s3 -*;

[0185] -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -*;

[0186] -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) r3 ) s2 -*;

[0187] -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 )s1 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) r3 ) s2 -(C(O)N(R a7 )-(C(R a14 )(R a15 )) r4 ) s3 -*;

[0188] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -C(O)N(R a7 )) s1 -*;

[0189] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 -C(O)N(R a7 )) s2 -*;

[0190] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 -C(O)N(R a7 )) s2 -((C(R a14 )(R a15 )) r4 -C(O)N(R a7 )) s3 -*;

[0191] -(C(R a8 )(R a9 ))r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -(O-(C(R a12 )(R a13 )) r3 ) s2 -*;

[0192] -(C(R a8 )(R a9 )) r1 -C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 -(O(C(R a12 )(R a13 )) r3 ) s1 -*;

[0193] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 O) s2 -*;

[0194] -(C(R a8 )(R a9 )) r1 -(C(R a10 )(R a1 1)) r2 -C(O)N(R a7 )-((C(R a12 )(R a13 )) r3 O) s1 -*;

[0195] -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a1 1)) r2 ) s1 -*;

[0196] -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a1 1)) r2 ) s1 -(O-(C(R a12 )(R a13 ))) r3 ) s2 -*;

[0197] -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 ) s1 -(O-(C(R a12 )(R a13 )) r3 ) s2 -(O-(C(R a14 )(R a15 )) r4 ) s3 -*;

[0198] -(C(R a8 )(R a9 )) r1 -N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 -(O(C(R a12 )(R a13 )) r3 ) s1 -*;

[0199] -(C(R a8 )(R a9 )) r1 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a1 1)) r2 -*;

[0200] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(Ra1 1)) r2 -N(R a7 )C(O)) s1 -*;

[0201] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -N(R a7 )C(O)) s1 -((C(R a12 )(R a13 ))) r3 -O) s2 -*;

[0202] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -N(R a7 )C(O)) s1 -((C(R a12 )(R a13 )) r3 O) s2 ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​r1 -(arylene-(C(R a10 )(R a1 1)) r2 ) s1 -arylene-(C(R a12 )(R a13 )) r3 -*;

[0206] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -arylene) s1 -*;

[0207] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -arylene) s1 -(C(R a12 )(R a13 )) r3 -arylene-*;

[0208] -(C(R a8 )(R a9 )) r1 -(Heterocyclylene-(C(R a10 )(R a1 1)) r2 ) s1 -*;

[0209] -(C(R a8 )(R a9 )) r1 -(Heterocyclylene-(C(R a10 )(R a11 )) r2 ) s1 -(Heterocyclylene-(C(R a12 )(R a13 )) r3 ) s2 -*;

[0210] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -heterocyclylene) s1 -*;

[0211] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -heterocyclylene) s1 -((C(R a12 )(R a13 )) r3 -heterocyclylene) s2 -*;

[0212] -(C(R a8 )(R a9 )) r1 -(heteroarylene-(C(R a10 )(R a1 1)) r2 ) s1 -*;

[0213] -(C(R a8 )(R a9 )) r1 -(heteroarylene-(C(R a10 )(R a11 )) r2 ) s1 -(heteroarylene-(C(R a12 )(R a13 )) r3 ) s2 -*;

[0214] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heteroarylene) s1 -*;

[0215] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heteroarylene) s1 -((C(R a12 )(R a13 )) r3 -heteroarylene) s2 -*;

[0216] -(C(R a8 )(R a9)) r1 -(cycloalkylene-(C(R a10 )(R a11 )) r2 ) s1 -*;

[0217] -(C(R a8 )(R a9 )) r1 -(cycloalkylene-(C(R a10 )(R a11 )) r2 ) s1 -(cycloalkylene-(C(R a12 )(R a13 )) r3 ) s2 -*;

[0218] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -cycloalkylene) s1 -*;or

[0219] -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -cycloalkylene) s1 -((C(R a12 )(R a13 )) r3 -cycloalkylene) s2 -*;

[0220] Among them, each R a7 independently represents H or C 1-6 alkyl ；

[0221] The cycloalkylene group (eg C 3-20 Cycloalkylene), the arylene group (such as C 5-20 arylene), the heterocyclylene (e.g., 4- to 20-membered heterocyclylene) and the heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0222] R a8 、R a9 、R a10 、R a11 、R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and

[0223] r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

[0224] The symbol * indicates the point of attachment to R.

[0225] In some embodiments, R w1 Examples of cycloalkylene in the above general structure include but are not limited to C 3-20 Cycloalkylene, C 3-15 Cycloalkylene and C 3-11 Cycloalkylene, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (for example, C 5-15 The cycloalkylene group is optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0226] In some embodiments, R w1 Examples of arylene groups in the above general structure include, but are not limited to, C 5-20 Arylene, C 6-20 Arylene, C 5-15 Arylene and C 6-15 Arylene, such as phenylene or naphthylene. Arylene is optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0227] In some embodiments, R w1 Examples of heterocyclylene groups in the above general structure include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclylene groups, such as azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thio ... The heterocyclyl group may be selected from deuterium, hydroxy, amino, sulfhydryl, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0228] In some embodiments, R w1 Examples of heteroarylene groups in the above general structure represented by include, but are not limited to, 5- to 20-membered heteroarylene groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroarylene groups, such as oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, azoles, benzothiazolylidenes, benzisothiazolylidenes, benzotriazoles, benzo[2,1,3]oxadiazoles, benzo[2,1,3]thiadiazolylidenes, benzo[1,2,3]thiadiazolylidenes, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidenes, or imidazo[2,1-b]thiazolylidenes. Heteroarylene is optionally selected from deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0229] In some embodiments, R w1 Examples include, but are not limited to, the following groups:

[0230] -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10-、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH 2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-( CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1- 、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2) 10-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2 )2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2- (O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-C H2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、 -(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2 )3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4- (O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-( CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2 )2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)7-、-(CH2)1-N(R a7 )-(CH2)8-、-(CH2)1-N(R a7 )-(CH2)9-、-(CH2)1-N(R a7 )-(CH2) 10 -、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)7-、-N(R a7 )-(CH2)8-、-N(R a7 )-(CH2)9-、-N(R a7 )-(CH2) 10 -、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(Ra7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)7-、-(CH2)2-N(R a7 )-(CH2)8-、-(CH2)2-N(R a7 )-(CH2)9-、-(CH2)2-N(R a7 )-(CH2) 10 -、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(Ra7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-CH(CH3)-N(R a7 )-(CH2)7-、-CH(CH3)-N(R a7 )-(CH2)8-、-CH(CH3)-N(R a7 )-(CH2)9-、-CH(CH3)-N(R a7 )-(CH2) 10 -、-(CH2)1-N(R a7 )-、-(CH2)2-N(R a7 )-、-(CH2)3-N(R a7 )-、-(CH2)4-N(R a7 )-、-(CH2)5-N(R a7 )-、-(CH2)6-N(R a7 )-、-(CH2)7-N(R a7 )-、-(CH2)8-N(R a7 )-、-(CH2)9-N(R a7 )-、-(CH2) 10 -N(R a7)-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O) NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(C H2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH 2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC(O)( CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene-C H2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-,-(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene -(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, - (CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6-phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2) Phenyl-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-, -(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-,-(CH2)8-phenylene-(CH2)7-、-N(R、 a7 )-CH2-phenylene-CH2-、-N(R a7 )-CH2-phenylene-(CH2)2-, -N(R a7 )-CH2-phenylene-(CH2)3-、-N(R a7 )-CH2-phenylene-(CH2)4-、-N(R a7 )-CH2-phenylene-(CH2)5-、-N(R a7 )-CH2-phenylene-(CH2)6-、-N(R a7 )-CH2-phenylene-(CH2)7-、-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)3-, -CH2-N(R a7 )-CH2-phenylene-(CH2)4-, -CH2-N(R a7 )-CH2-phenylene-(CH2)5-, -CH2-N(R a7 )-CH2-phenylene-(CH2)6-, -CH2-N(R a7 )-CH2-phenylene-(CH2)7-, -CH2-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-(CH2)2-phenylene-CH2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)7-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R a7 )-CH2-phenylene-CH2-, -(CH2)2-N(R a7)-CH2-phenylene-(CH2)2-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R a7 )-CH2-phenylene-CH2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R a7 )-CH2-phenylene-CH2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-CH2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R a7)-CH2-phenylene-(CH2)5-, -(CH2)8-N(R a7)-CH2-phenylene-(CH2)6-, -piperidinylene-CH2-, -piperidinylene-(CH2)2-, -piperidinylene-(CH2)3-, -piperidinylene-(CH2)4-, -piperidinylene-(CH2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7- , -(CH2)2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -( -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2) -(CH2)4-piperidinylene-(CH2)8-, -(CH2)5-piperidinylene-(CH2)1-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-,-(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene -(CH2)4-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, a7 )-CH2-piperidinyl-CH2-、-N(R a7 )-CH2-piperidinyl-(CH2)2-、-N(R a7 )-CH2-piperidinyl-(CH2)3-、-N(R a7 )-CH2-piperidinyl-(CH2)4-、-N(R a7 )-CH2-piperidinyl-(CH2)5-、-N(R a7 )-CH2-piperidinyl-(CH2)6-、-N(R a7 )-CH2-piperidinyl-(CH2)7-、-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-CH2-piperidinyl-CH2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7)-(CH2)2-piperidinyl-CH2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R a7)-CH2-piperidinyl-(CH2)8-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)4-、-(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R a7)-CH2-piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7 -, -CH2-piperazinylene-(CH2)8-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)6-, -(CH2)2-piperazinylene-(CH2)7-, -(CH2)2-piperazinylene-(CH2)8-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2) -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-;

[0231] Among them, each R a7 independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl);

[0232] Each phenylene group is independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted with a cycloalkyl group, a 4- to 10-membered heterocyclic group, and any combination thereof; and

[0233] The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 In this article, unless otherwise specified, any end of the above groups can be connected to R of the compound of formula (I), and the other end can be connected to ring A. 3 For example, the O in the group -O-CH2- can be connected to R of the compound of formula (I), and CH2 can be connected to ring A of the compound of formula (I).3 ,vice versa.

[0234] In some embodiments, L represents a bond.

[0235] In some embodiments, examples of L include, but are not limited to, the following groups:

[0236] C(O), C(O)NH, NHC(O), -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -、-(CH2) 11 -、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -, -(CH2)1-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O-, -(CH2)5-O-, -(CH2)6-O-, -(CH2)7-O-, -(CH2)8-O-, -(CH2)9-O-, -(CH2) 10-O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5 -、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(Ra7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7)-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-、-(CH2)2-N(R a7 )-、-(CH2)3-N(R a7 )-、-(CH2)4-N(R a7 )-、-(CH2)5-N(R a7 )-、-(CH2)6-N(R a7 )-、-(CH2)7-N(R a7 )-、-(CH2)8-N(R a7 )-、-(CH2)9-N(R a7 )-、-(CH2) 10 -N(R a7)-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O)N H(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2- , -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4 -、-(CH2)4NHC(O)(CH2)4-、-(CH2)5NHC(O)(CH2)5-、-(CH2)2NHC(O)(CH2)2-O-(CH2)2-、-(CH2)4NHC(O)CH2-、-CH2-phenylene-CH2-、-CH2-phenylene-(CH2)2-、-CH2-phenylene-(CH2)3-、-CH2-phenylene-(CH2)4-、-CH2-phenylene-(CH2)5-、-CH2-phenylene-(CH2)6-、-(CH2)2-phenylene-(CH2)1-、-(CH2)2-phenylene-(CH2)2-、-(CH2)2-phenylene-(CH2)3- , -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -CH2-piperidinylene-CH2-,-CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH 2) 3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-( -(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2) 4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8-piperazinylene-(CH2)5-;

[0237] Among them, each R a7 Each independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl);

[0238] Each phenylene group is independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof;

[0239] The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

[0240] In some embodiments, examples of L include, but are not limited to, the following groups:

[0241] wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0242] In some embodiments, X represents:

[0243] NR1R2, C(O)NR3R4, NHC(O)R5, NHC(O)NR6R7, OR8, SR9, S(O)2NR 10 R 11 or N(R 12 )S(O)2R 13 , where R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents H, an optionally substituted linear or branched alkyl group (e.g., an optionally substituted linear or branched C 1-10 Alkyl, or optionally substituted linear or branched C 1-6 alkyl), optionally substituted cycloalkyl (e.g., optionally substituted C3-30 Cycloalkyl, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted aryl (e.g., optionally substituted C 5-30 Aryl, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), optionally substituted heterocyclyl (e.g., optionally substituted 4- to 30-membered heterocyclyl, optionally substituted 4- to 20-membered heterocyclyl, or optionally substituted 4- to 15-membered heterocyclyl), or optionally substituted heteroaryl (e.g., optionally substituted 5- to 30-membered heteroaryl, optionally substituted 5- to 20-membered heteroaryl, or optionally substituted 5- to 15-membered heteroaryl), and R2, R8, and R 13 Each independently represents an optionally substituted straight-chain or branched alkyl group (for example, an optionally substituted straight-chain or branched C 1-10 Alkyl, or optionally substituted linear or branched C 1-6 alkyl), optionally substituted cycloalkyl (e.g., optionally substituted C 3-30 Cycloalkyl, optionally substituted C 3-200 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted aryl (e.g., optionally substituted C 5-30 Aryl, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), optionally substituted heterocyclyl (e.g., optionally substituted 4-30 membered heterocyclyl, optionally substituted 4-20 membered heterocyclyl, or optionally substituted 4-15 membered heterocyclyl) or optionally substituted heteroaryl (e.g., optionally substituted 5-30 membered heteroaryl, optionally substituted 5-20 membered heteroaryl, or optionally substituted 5-15 membered heteroaryl), or wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted nitrogen-containing heterocyclyl (e.g., optionally substituted 4-30 membered nitrogen-containing heterocyclyl, optionally substituted 4-20 membered nitrogen-containing heterocyclyl, or optionally substituted 4-15 membered nitrogen-containing heterocyclyl). In some embodiments, each straight or branched alkyl group is independently optionally selected from deuterium, halogen, amino, hydroxyl, thiol, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6In some embodiments, each cycloalkylene, each arylene, each heterocyclylene, each heteroarylene, each cycloalkyl, each aryl, each heterocyclyl, each heteroaryl and nitrogen-containing heterocyclyl is each independently optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0244] In some embodiments, R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents: H;

[0245] Straight chain or branched chain C 1-10 Alkyl (e.g. straight chain or branched C 1-6 alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl), which may be substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 Substitution of alkenyl groups by substituents;

[0246] Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptyl, 2-oxobicyclo[2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents;

[0247] azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptyl, 4,5-diazacycloheptyl, 1,3-diazacycloheptyl), diazacyclooctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octanyl , 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents;

[0248] Phenyl or naphthyl, which may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or

[0249] furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3] Thiadiazole, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6 ,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H -pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0250] In some embodiments, R2, R8 and R 13 Each independently represents:

[0251] Straight chain or branched chain C 1-10 Alkyl, which may be substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 Substitution of alkenyl groups by substituents;

[0252] Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptyl, 2-oxobicyclo[2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents;

[0253] azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptyl, 4,5-diazacycloheptyl, 1,3-diazacycloheptyl), diazacyclooctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octanyl , 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]decanyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents;

[0254] Phenyl or naphthyl, which may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or

[0255] furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3] Thiadiazole, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6 ,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H -pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6The alkynyl group and any combination thereof are substituted with substituents.

[0256] In some embodiments, X represents C(O)NR3R4, wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 30-membered nitrogen-containing heterocyclyl (e.g., a 4- to 20-membered nitrogen-containing heterocyclyl or a 4- to 15-membered nitrogen-containing heterocyclyl). In some embodiments, examples of 4- to 30-membered nitrogen-containing heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazacycloheptyl, diazacyclooctanyl, nitrogen-bridged heterocyclic groups (e.g., 6- to 20-membered nitrogen-bridged heterocyclic groups, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[2.2.2]octanyl, 2,5- 1-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or a nitrogen-containing spiroheterocyclic group (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclic group, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl group. In some embodiments, the 4- to 30-membered nitrogen-containing heterocyclic group is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0257] In some embodiments, X represents:

[0258] wherein ring A represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 )n1 Indicates that ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20;

[0259] R c Indicates NR c1 、C(O),CR c2 R c3 or key, where R c1 represents H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, R c2 and R c3 each independently represents H, halogen, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclyl group, or an optionally substituted heteroaryl group;

[0260] Each ring B is the same or different and independently represents a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, m1 represents an integer of 0, 1, 2 or 3, (R d2 ) n2 Indicates that each ring B is independently optionally substituted with n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20;

[0261] R e Indicates S, O, CR e1 R e2 or key, where R e1 and R e2 each independently represents H, halogen, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; and

[0262] Each ring C is the same or different and independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group, m2 represents an integer of 0, 1, 2 or 3, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer of 0-20.

[0263] In some embodiments, ring A represents a 4- to 30-membered heterocyclylene (eg, a 4- to 20-membered heterocyclylene, or a 4- to 15-membered heterocyclylene), C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 arylene) or 5 to 30 membered heteroarylene (e.g., 5 to 20 membered heteroarylene, or 5 to 15 membered heteroarylene). In some embodiments, Ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy or C 1-3 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy or halogenated C 1-3alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl (e.g., ethynyl) or C 2-6 an alkenyl group (e.g., a vinyl group), and n1 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0264] In some embodiments, each ring B is the same or different and each independently represents a 4- to 30-membered heterocyclylene (eg, a 4- to 20-membered heterocyclylene, or a 4- to 15-membered heterocyclylene), C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 Cycloalkylene), C 5-30 Arylene (e.g. C 5-20 Arylene, or C 5-15 In some embodiments, m1 represents an integer of 0, 1, 2 or 3. In some embodiments, each ring B is optionally substituted by n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1- 6 alkoxy (e.g. C 1-4 Alkoxy or C 1-3 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy or halogenated C 1-3alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl (e.g., ethynyl) or C 2-6 an alkenyl group (e.g., a vinyl group), and n2 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0265] In some embodiments, each of Ring A and Ring B independently represents C 3-30 Cycloalkylene (e.g. C 3-20 Cycloalkylene, or C 3-15 In some embodiments, C 3-30 Examples of cycloalkylene include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, spirocycloalkylene (e.g., C5-C 20 Spirocycloalkylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[5.5]undecanylene), p-menthanylene, m-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 In some embodiments, C 3-30 The cycloalkylene group is optionally substituted by one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6The alkynyl group and any combination thereof are substituted with substituents.

[0266] In some embodiments, each ring A and ring B each independently represents a 4- to 30-membered heterocyclylene (e.g., a 4- to 20-membered heterocyclylene, or a 4- to 15-membered heterocyclylene). In some embodiments, examples of 4- to 30-membered heterocyclylene include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, tetrahydropyridinylene, dihydroxypiperidinylene, difluoropiperidinylene, morpholinylene, thiopyranylene, morpholinyl, azepanyl, azepanyl, dioxanyl, azepanyl, azepanyl, diazepanyl, diazepanylidene (e.g., 1,4-diazepanylidene, 4,5-diazepanylidene, 1,3-diazepanylidene), diazepanylidene, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptane subunit, 2,5-diazabicyclo[2.2.1]heptane subunit, 3,6-diazabicyclo[3.1.1]heptane subunit, 3-azabicyclo[3.2.1]octanyl subunit, 3,8-diazabicyclo[3.2.1]octanyl subunit, 3,8-diazabicyclo[3.2.1]octanyl subunit, 2,5-diazabicyclo[2.2.2]octanyl subunit and quinuclidinyl subunit), azaspirocyclic subunit (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecanyl, 3-azaspiro[5.5]undecanyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrroleyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0267] In some embodiments, each of Ring A and Ring B independently represents C 5-30Arylene (e.g. C 5-20 Arylene, or C 5-15 In some embodiments, C 5-30 Examples of arylene groups include, but are not limited to, phenylene or naphthylene. 5-30 The arylene group may be optionally substituted by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0268] In some embodiments, each ring A and ring B each independently represents a 5- to 30-membered heteroarylene group (e.g., a 5- to 20-membered heteroarylene group, or a 5- to 15-membered heteroarylene group). In some embodiments, examples of 5- to 30-membered heteroarylene groups include, but are not limited to, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolinylene, benzofuranylene, chromanylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pyridin ... Quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d] pyrimidine subunit, pyrazolo[1,5-a]pyrimidine subunit, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyrimidine subunit, 1H-pyrrolo[3,2-b]pyridinyl subunit, 1H-pyrrolo[2,3-b]pyridinyl subunit, pyrrolo[2,1-b]thiazolyl subunit, imidazo[2,1-b]thiazolyl subunit, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine subunit, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidine subunit. In some embodiments, the 5- to 30-membered heteroarylene group is optionally replaced by one or more (e.g., 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0269] In some embodiments, each ring C is the same or different and each independently represents a 4- to 30-membered heterocyclyl (eg, a 4- to 20-membered heterocyclyl, or a 4- to 15-membered heterocyclyl), C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkyl, or C 3-15 Cycloalkyl), C 5-30 Aryl (e.g. C 5-20 Aryl, or C 5-15 In some embodiments, m2 represents an integer of 0, 1, 2 or 3. In some embodiments, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl (e.g. C 1-4 Alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl (e.g. halo-C 1-4 Alkyl or halogenated C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy or C 1-3 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 Alkoxy (e.g., halo-C 1-4 Alkoxy or halogenated C 1-3 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), halogen (such as fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl (e.g., ethynyl) or C 2-6an alkenyl group (e.g., a vinyl group), and n3 represents an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0270] In some embodiments, each ring C is the same or different and each independently represents C 3-30 Cycloalkyl (e.g. C 3-20 Cycloalkyl, or C 3-15 In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be substituted by one or more (eg, 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0271] In some embodiments, each ring C is the same or different and each independently represents a 4- to 30-membered heterocyclyl (eg, a 4- to 20-membered heterocyclyl, or a 4- to 15-membered heterocyclyl). In some embodiments, examples of 4- to 30-membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[3.1.1]heptanyl, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclic group is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0272] In some embodiments, each ring C is the same or different and each independently represents C 5-30 Aryl (e.g. C 5-20 Aryl, or C 5-15 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30The aryl group may be optionally substituted by one or more (eg, 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0273] In some embodiments, each ring C is the same or different and each independently represents a 5- to 30-membered heteroaryl group (e.g., a 5- to 20-membered heteroaryl group, or a 5- to 15-membered heteroaryl group). In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole [1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl group is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0274] In some embodiments, R c represents C(O) or a bond.

[0275] In some embodiments, R c Indicates NR c1 , where R c1 represents H, an optionally substituted straight or branched chain C 1-10 Alkyl (e.g., optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (eg, optionally substituted C 5- 20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl).

[0276] In some embodiments, R c Indicates NR c1 , where R c1 Indicates H or straight or branched chain C 1-10 Alkyl (e.g. straight chain or branched C 1-6 In some embodiments, the linear or branched C 1-10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. In some embodiments, the linear or branched C 1-10 The alkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, amino, hydroxyl, thiol, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

[0277] In some embodiments, R c Indicates NRc1 , where R c1 represents an optionally substituted C 3-30 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0278] In some embodiments, R c Indicates NR c1 , where R c1represents an optionally substituted 4- to 30-membered heterocyclyl (eg an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl). In some embodiments, examples of 4- to 30-membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[3.1.1]heptanyl, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0279] In some embodiments, R c Indicates NR c1 , where R c1 represents an optionally substituted C 5-30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C5-15 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1- 6 alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0280] In some embodiments, R c Indicates NR c1 , where R c1represents an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl). In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl group is optionally replaced by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6The alkynyl group and any combination thereof are substituted with substituents.

[0281] In some embodiments, R c Indicates CR c2 R c3 , where R c2 and R c3 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl (e.g., optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3- 30 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5- 30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl). In some embodiments, the straight chain or branched chain C 1-10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. In some embodiments, the linear or branched C 1-10 The alkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, amino, hydroxyl, thiol, cyano, nitro, oxo, C 1- 6-alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 In some embodiments, C 3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6Alkynyl and any combination thereof. In some embodiments, examples of 4 to 30 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxane, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptane, 4,5-diazacycloheptane, 1,3-diazacycloheptane), diazacycloheptane, bridged heterocyclic groups (e.g., 6 to 20 membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptane, 2,5-diazabicyclo[3.1.1]heptane, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,1-b]thiazolyl, 1H-imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl group is optionally replaced by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0282] In some embodiments, R e Represents S, O, or a bond.

[0283] In some embodiments, R e Indicates CR e1 R e2 , where R e1 and R e2 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl (e.g., optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3- 30 Cycloalkyl (eg, optionally substituted C 3-20 Cycloalkyl, or optionally substituted C 3-15 cycloalkyl), optionally substituted C 5- 30 Aryl (eg, optionally substituted C 5-20 Aryl, or optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (e.g., an optionally substituted 4- to 20-membered heterocyclyl, or an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (e.g., an optionally substituted 5- to 20-membered heteroaryl, or an optionally substituted 5- to 15-membered heteroaryl). In some embodiments, the straight chain or branched chain C 1-10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. In some embodiments, the linear or branched C 1-10 The alkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, amino, hydroxyl, thiol, cyano, nitro, oxo, C 1- 6-alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 In some embodiments, C3-30 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 bridged ring group, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]heptenyl). In some embodiments, C 3-30 The cycloalkyl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6Alkynyl and any combination thereof are substituted with substituents. In some embodiments, examples of 4 to 30 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxane, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazacycloheptane, 4,5-diazacycloheptane, 1,3-diazacycloheptane), diazacycloheptane, bridged heterocyclic groups (e.g., 6 to 20 membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptane, 2,5-diazabicyclo[3.1.1]heptane, ]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., a 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[4.5]decanyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonanyl), or octahydropyrrolo[3,4-c]pyrrolyl. In some embodiments, the 4- to 30-membered heterocyclyl is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 In some embodiments, C 5-30 Examples of aryl groups include, but are not limited to, phenyl or naphthyl. 5-30 The aryl group may be optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) groups selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 In some embodiments, examples of 5- to 30-membered heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl , benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4- Tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazole pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. In some embodiments, the 5- to 30-membered heteroaryl group is optionally replaced by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6, or 1) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

[0284] In some embodiments, X represents:

[0285] Where -X1-X2- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1-5 NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-;

[0286] p1, p2, p3 each independently represent an integer of 1, 2, 3 or 4; and

[0287] The ring containing -X1-X2- is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

[0288] In some embodiments, p1, p2, and p3 each independently represent an integer of 1, 2, or 3.

[0289] In some embodiments, X represents:

[0290] Where -X3-X4- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1-5 NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-;

[0291] p4, p5 each independently represent an integer of 1, 2, 3 or 4; and

[0292] The benzo-fused ring containing -X3-X4- is optionally substituted by one or more (e.g., 1-20, 1-15, 1-10, 1-6, 1-4, 2-6 or 1) selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

[0293] In some embodiments, p4, p5 each independently represent an integer of 1, 2, or 3.

[0294] In some embodiments, X represents:

[0295] In some embodiments, examples of X include, but are not limited to:

[0296] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-1), a compound of formula (I-2), a compound of formula (I-3), or a compound of formula (I-4):

[0297] The group R a1 、R a2 、R a3 、R a4 、Z1、Z2、Z3、Z4、(R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0298] In some embodiments of the present disclosure, the compound of formula (I) is also a compound of formula (I-5):

[0299] Among them, Z1, Z2, Z3, Z4, (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0300] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-1):

[0301] Among them, Z1, (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0302] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-1A):

[0303] Among them (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0304] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-1B):

[0305] Among them (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0306] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-2):

[0307] Among them, Z1, (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0308] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-2A):

[0309] Among them (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0310] In some embodiments of the present disclosure, the compound of formula (I-5) is also a compound of formula (I-5-2B):

[0311] Among them (R a5 ) m , R, L and X are as defined above for the compound of formula (I) and its embodiments.

[0312] Particularly preferred are the compounds of the present invention in Table 1 and their salts (especially pharmaceutically acceptable salts, such as their hydrochlorides), enantiomers, diastereomers, solvates, or polymorphs:

[0313] Table 1 Compounds of the present invention

[0314] II. Other Forms of the Compound (including Salts, Enantiomers, Stereoisomers, Solvates, Isotopically Enriched Analogs, Prodrugs, or Polymorphs of the Compound)

[0315] The compounds of the present disclosure have the structure of any one of Formula (I), Formula (I-1), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-5-1), Formula (I-5-1A), Formula (I-5-1B), Formula (I-5-2), Formula (I-5-2A), or Formula (I-5-2B). Unless otherwise indicated, when referring to the compounds of the present disclosure, it refers to compounds including any one of Formula (I), Formula (I-1), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-5-1), Formula (I-5-1A), Formula (I-5-1B), Formula (I-5-2), Formula (I-5-2A), or Formula (I-5-2B), as well as specific compounds falling within the scope of these general formulas.

[0316] It will be appreciated that the compounds of the present disclosure (including compounds of Formula (I), (I-1), (I-2), (I-3), (I-4), (I-5), (I-5-1), (I-5-1A), (I-5-1B), (I-5-2), (I-5-2A), or (I-5-2B)) may have stereo configurations and, therefore, may exist as more than one stereoisomer. The present disclosure also relates to optically enriched compounds having stereo configurations, such as about greater than 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, and mixtures thereof, including racemic mixtures. As used herein, "optically enriched" means that the mixture of enantiomers is composed of a significantly greater proportion of one enantiomer and can be described by enantiomeric excess (ee%). Purification of isomers and separation of isomeric mixtures can be achieved by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, asymmetric synthesis (e.g., by using chiral intermediates) and / or chiral resolution, etc.).

[0317] In some embodiments, polymorphic forms of compounds of the present disclosure or salts of compounds of the present disclosure are also provided. The salts of compounds of the present disclosure can be pharmaceutically acceptable salts, including but not limited to hydrohalides (including hydrochlorides, hydrobromides), sulfates, maleates, sulfonates, citrates / citrates, lactates, lactobionates, L-tartrates, fumarates, L-malates, L-lactates, α-ketoglutarate, hippurates, D-glucuronates, D-gluconates, α-D-glucoheptonates, glycolates, mucates, L-ascorbic acid salts, orotates, picrates, glycinates, alanine salts, arginine salts, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2-dichloroacetate, trimethylacetate, propionate, pentanoate, thiazolinone ... The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. The compounds of the present invention may be present in the form of unsolvated or solvated pharmaceutically acceptable solvents such as water, ethanol, etc. In some embodiments, the compounds of the present disclosure can be prepared as prodrugs or prodrugs. Prodrugs can be converted into parent drugs in the body and exert their effects. In some embodiments, isotope-labeled compounds of the present disclosure are also provided. Examples of isotopes include deuterium (D or 2 H).

[0318] III. Pharmaceutical Compositions / Formulations

[0319] In some embodiments, the present disclosure provides a pharmaceutical composition comprising as an active ingredient a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, and at least one pharmaceutically acceptable carrier.

[0320] In some embodiments, pharmaceutically acceptable carriers include, but are not limited to, fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, colorants, solvents, or encapsulating materials. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compounds useful in the present disclosure) and is not harmful to the patient. Some examples of materials that are pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline surfactants; polyoxyethylene, polyvinyl pyrrolidone, polyacrylamide, poloxamer; and other nontoxic compatible substances used in pharmaceutical formulations.

[0321] The pharmaceutical composition of the present disclosure further includes at least one second therapeutic agent, such as an anticancer agent. The second therapeutic agent can be combined with the compound of formula (I) described herein to treat the disease or condition described herein. The second therapeutic agent includes, but is not limited to, a chemotherapeutic agent, an immunotherapeutic agent, a gene therapy agent, and the like.

[0322] The pharmaceutical composition of the present disclosure comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared into a suitable dosage form according to a suitable administration route (including but not limited to nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration and intravenous administration), such as spray preparations, patches, tablets (such as conventional tablets, dispersible tablets, orally disintegrating tablets), capsules (such as soft capsules, hard capsules, enteric-coated capsules), dragees, lozenges, powders, granules, powder injections, suppositories, or liquid preparations (such as suspensions (such as aqueous or oily suspensions), solutions, emulsions or syrups), or conventional injection forms such as injectable solutions (such as sterile injection solutions prepared according to methods known in the art using water, Ringer's solution or isotonic sodium chloride solution as a carrier or solvent) or lyophilized compositions. Those skilled in the art can also prepare the compound of formula (I) into conventional, dispersible, chewable, orally rapidly disintegrating or rapidly dissolving preparations, or sustained-release capsules or controlled-release capsules as needed.

[0323] As the active ingredient, the compound of formula (I) as described in the present disclosure is contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to the subject a therapeutically effective amount for the indication to be treated without causing serious toxic effects in the treated subject. The dosage of the active compound for all diseases or conditions mentioned herein is, for example, from about 5 ng / kg subject weight / day to 500 mg / kg subject weight / day, from about 10 ng / kg subject weight / day to 300 mg / kg subject weight / day, for example, from 0.1 to 100 mg / kg subject weight / day, or from 0.5 to about 25 mg / kg subject weight / day.

[0324] The compound of formula (I) or a pharmaceutically acceptable salt thereof described in the present disclosure can be conveniently administered in any suitable dosage form, and the specifications of the suitable dosage form include but are not limited to less than 1 mg, 1 mg to 3000 mg, 5 mg to 1000 mg, for example, 5 to 500 mg, 25 to 250 mg of active ingredient per unit dosage form.

[0325] IV.Kits / Packaging Products

[0326] The compound of formula (I) described in the present disclosure, or its pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers, is used as a medicament. The medicament of the present disclosure or the pharmaceutical composition of the present disclosure may be present in a medicine box / packaged product. The medicine box / packaged product may include packaging or container. The packaging or container includes but is not limited to ampoules, blister packs, pharmaceutical plastic bottles, vials, pharmaceutical glass bottles, containers, syringes, laminated flexible packaging, co-extruded film infusion containers, test tubes and dispensing devices, etc. The medicine box / packaged product may include product instructions for use.

[0327] V. Treatment Methods and Uses

[0328] The compounds of formula (I) described in the present disclosure, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, can also be used as medicaments. In particular, the compounds of formula (I) described in the present disclosure, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof can be used to prepare drugs for preventing and / or treating diseases or conditions. The diseases or conditions include diseases or conditions associated with cereblon protein. In some embodiments, the diseases or conditions include: tumors or cancers, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes. In some embodiments, the disease or condition includes, but is not limited to: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphoblastic leukemia, B-cell leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma Tumor, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma , refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; glioma; peripheral neuroepithelial tumor;Extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; Richter syndrome sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis; keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS ), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

[0329] The present disclosure provides a method for preventing and / or treating a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) as an active ingredient or a pharmaceutically acceptable salt thereof as described herein. In some embodiments, the disease or condition includes a disease or condition associated with cereblon protein. In some embodiments, the disease or condition includes: tumors or cancer, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes. In some embodiments, the disease or condition includes, but is not limited to, myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and leukemia. B-cell leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, small cell lung cancer carcinoma; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; glioblastoma; astrocytoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and patients with Cowden's disease; pancreatic cancer; central nervous system cancer; neuroblastoma; glioma; peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer;Brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; bone cancer; cervical cancer; skin cancer; and Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis; keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS ), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

[0330] In the method for preventing and / or treating the disease or condition, a therapeutically effective amount of a compound of formula (I) described herein, or a pharmaceutical composition comprising a compound of formula (I) as an active ingredient described herein, is administered to the subject by at least one administration route selected from nasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural space administration, intrathecal administration, and intravenous administration.

[0331] The term "treatment" or "treating" refers to administering to a subject a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, to slow (mitigate) the development of an undesirable disease or condition (e.g., a tumor). Beneficial or desired clinical outcomes of the present disclosure include, but are not limited to, alleviating symptoms, reducing the severity of the disease, stabilizing the state of the disease, delaying or slowing the progression of the disease, improving or alleviating the condition, and alleviating the disease.

[0332] A "therapeutically effective amount" of a compound of the present disclosure depends on a variety of factors, including the activity of the particular compound used, the metabolic stability and duration of action of the compound, the age, sex, and weight of the patient, the patient's overall medical condition, the route and timing of administration, the rate of excretion, concomitant medications, and the progression of the disease or condition being treated in the patient. One skilled in the art will be able to determine an appropriate dosage based on these and other factors.

[0333] It should be understood that the choice of using one or more active compounds and / or compositions and their dosages depends on the individual's basic conditions (generally, the individual's conditions should be optimized). Administration and dosing regimens should be within the capabilities of those skilled in the art, and appropriate dosages depend on many factors including the knowledge and ability level of the ordinary skilled physician, veterinarian, or researcher (see, for example, Li Jun, ed., "Clinical Pharmacology," 4th edition, People's Medical Publishing House (2008)).

[0334] The patients or subjects for treatment mentioned above refer to animals, such as mammals, including but not limited to primates (such as humans), cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice, etc.

[0335] VI. Preparation Method

[0336] The compounds of formula (II) mentioned below are sub-embodiments of the compounds of formula (I) disclosed herein. The present disclosure provides a method for preparing the compounds of formula (II), which is selected from any one of methods (i), (ii), (iii), (iv) and (v):

[0337] The method (i) comprises reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0338] Wherein the group LE represents Cl, Br, I, methanesulfonyloxy (ie OMs), p-toluenesulfonyloxy (ie OTs), or o-nitrobenzenesulfonyl (ie ONs), and the group X a represents NH, group R b1 Represents R1, group R b2 R2 (i.e., R in formula (M2) b1 -X a -R b2 is R1-NH-R2), and X of the compound of formula (II) b Correspondingly represents NR1R2, wherein the groups R1, R2, R a1 、R a2 、R a3 、R a4 、(R a5 ) m, Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein;

[0339] The method (ii) comprises reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0340] wherein the group LE represents Cl, Br, I, OMs, OTs, or ONs, and the group X a represents NH, group R b1 and group R b2 Together with their connected X a The nitrogen atoms together form the formula The substituent represented by n1 substituents R d1 Substituted nitrogen-containing heterocycle A a , that is, the compound of formula (M2) has the following structure:

[0341] And X of the compound of formula (II) b The structure represented by the following general formula is represented accordingly:

[0342] The nitrogen-containing heterocyclic ring A a represents a 4- to 30-membered nitrogen-containing heterocyclic group (e.g., a 4- to 20-membered nitrogen-containing heterocyclic group or a 4- to 15-membered nitrogen-containing heterocyclic group), (R d1 ) n1 、n1、R c , Ring B, m1, (R d2 ) n2 、n2、R e 、C、m2、(R d3 ) n3 、n3、R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein;

[0343] The method (iii) comprises reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0344] Wherein (a) group LE represents C(O)Cl or COOH, R of formula (M2) b1 -X a -R b2 is R3-NH-R4, and X of the compound of formula (II)b correspondingly represents C(O)NR3R4; or

[0345] (b) The group LE represents S(O)2Cl, and R of formula (M2) b1 -X a -R b2 It is R 10 -NH-R 11 , and X of the compound of formula (II) b Correspondingly represents S(O)2NR 10 R 11 ,as well as

[0346] Among them, R3, R4, R 10 、R 11 、R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein;

[0347] The method (iv) comprises reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0348] Wherein the group LE represents NH2, the group R b1 -X a Indicates R5-C(O) or R 13 -S(O)2, group R b2 represents OH or Cl, (i.e. R in formula (M2) b1 -X a -R b2 are: R5-C(O)-OH, R5-C(O)-Cl, R 13 -S(O)2-OH, or R 13 -S(O)2-Cl), and X of the compound of formula (II) b Correspondingly represents NHC(O)R5 or NHS(O)2R 13 , where R5, R 13 、R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein;

[0349] The method (v) comprises reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II):

[0350] wherein the group LE represents Cl, Br or I, and the group R b1 -X a Represents R8-O or R9-S, group R b2 represents H, (i.e. R in formula (M2) b1 -X a -R b2 is: R8-OH or R9-SH), and X of the compound of formula (II) b Correspondingly represents OR8 or SR9, where R8, R9, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0351] In the method (i) of the present disclosure, the compound of formula (M2) is represented by the structure of the following formula (M2-1), and the compound of formula (II) is represented by the structure of the following formula (II-1):

[0352] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4, R, R1 and R2 are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0353] In the method (ii) of the present disclosure, the compound of formula (M2) is represented by the structure of the following formula (M2-2), and the compound of formula (II) is represented by the structure of the following formula (II-2):

[0354] The nitrogen-containing heterocyclic ring A a represents a 4- to 30-membered nitrogen-containing heterocyclic group (e.g., a 4- to 20-membered nitrogen-containing heterocyclic group or a 4- to 15-membered nitrogen-containing heterocyclic group), the group R a1 、R a2 、R a3 、R a4 、(R a5 ) m 、Z1、Z2、Z3、Z4、R、(R d1 ) n1、n1、R c , Ring B, m1, (R d2 ) n2 、n2、R e 、C、m2、(R d3 ) n3 and n3 are as defined in the disclosed compounds of formula (I) and various subembodiments thereof.

[0355] In the method (iii) of the present disclosure, the compound of formula (M2) is represented by the formula R3-NH-R4, and the compound of formula (II) is represented by the structure of the following formula (II-3):

[0356] Among them, R3, R4, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0357] In the method (iii) of the present disclosure, the compound of formula (M2) is composed of the formula R 10 -NH-R 11 The compound of formula (II) is represented by the structure of the following formula (II-4):

[0358] where R 10 、R 11 、R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0359] In the method (iv) of the present disclosure, the compound of formula (M2) can be represented by the formula R5-C(O)-OH or R5-C(O)-Cl, and the compound of formula (II) is represented by the structure of the following formula (II-5):

[0360] Among them, R5, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0361] In the method (iv) of the present disclosure, the compound of formula (M2) can be prepared by 13 -S(O)2-OH or R 13 -S(O)2-Cl, and the compound of formula (II) is represented by the structure of the following formula (II-6):

[0362] where R 13 、R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0363] In the method (v) of the present disclosure, the compound of formula (M2) can be represented by the formula R8-OH, and the compound of formula (II) is represented by the structure of the following formula (II-7):

[0364] Among them, R8, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0365] In the method (v) of the present disclosure, the compound of formula (M2) can be represented by the formula R9-SH, and the compound of formula (II) is represented by the structure of the following formula (II-8):

[0366] Among them, R9, R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0367] In methods (i) and (ii) of the present disclosure, the compound of formula (M1) undergoes an amine alkylation reaction with the compound of formula (M2). The amine alkylation reaction can be carried out, for example, in the presence of an organic base and sodium iodide at room temperature to 80°C (e.g., 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). Examples of organic bases include, but are not limited to, DIEA or triethylamine.

[0368] The molar ratio of the compound of formula (M1) to the compound of formula (M2) can be, for example, 1:1.1-2, 1:1.1-1.5, 1:1.1-1.2, or 1:1.2-1.3.

[0369] In some embodiments, when the group LE represents Cl, Br or I, the compound of formula (M1) can be prepared by a halogenation reaction of a compound of formula (M3) with a hydrohalic acid:

[0370] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the disclosed compounds of formula (I) and its various subembodiments. In some embodiments, R may represent a bond.

[0371] In some embodiments, the halogenation reaction can be carried out at room temperature in the presence of, for example, a hydrohalic acid and acetic acid.

[0372] In some embodiments, when the group LE represents a methanesulfonyloxy group, the compound of formula (M1) can be prepared by reacting a compound of formula (M3) with methanesulfonic anhydride or methanesulfonyl chloride:

[0373] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and various sub-embodiments thereof disclosed herein.

[0374] In some embodiments, R of the compound of formula (M1), the compound of formula (II), and the compound of formula (M3) represents a bond.

[0375] In some embodiments, the compound of formula (M3) (wherein R represents a bond) can be prepared by coupling a compound of formula (M4) with (tributyltin)methanol in the presence of a palladium catalyst:

[0376] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3 and Z4 are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein.

[0377] In some embodiments, the coupling reaction can be carried out, for example, in the presence of tetrakis(triphenylphosphine)palladium and 1,4-dioxane (or DMF) at 40°C to 120°C.

[0378] In some embodiments, the thiocarbonyl compound of formula (M4) can be prepared by thionization of the carbonyl compound of formula (M5) with a thionating agent:

[0379] wherein Z6 of the carbonyl compound of formula (M5) represents C(O), CH2 or CD2; Z1 of the thiocarbonyl compound of formula (M4) represents C(O), C(S), CH2 or CD2, Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents CA(S); and the group R a1 、R a2 、R a3 、R a4 and (R a5 ) m As defined in the compounds of formula (I) and its various sub-embodiments of the present disclosure. When Z6 of the carbonyl compound of the starting material formula (M5) represents CH2 or CD2, the corresponding Z1 in the thiocarbonyl compound of the product formula (M4) represents CH2 or CD2. When Z6 of the carbonyl compound of the starting material formula (M5) represents C(O), the corresponding Z1 in the thiocarbonyl compound of the product formula (M4) represents C(O) or C(S).

[0380] In some embodiments, examples of sulfurizing agents include, but are not limited to, carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent (CAS No.: 19172-47-5), Belleau's Reagent (CAS No.: 88816-02-8), and Davy's Reagent (CAS No.: 82737-61-9), etc.

[0381] In some embodiments, the carbonyl compound of formula (M5) reacts with a sulfiding reagent (eg, Lawesson's reagent) in a solvent (eg, 1,4-dioxane) at 40° C. to 150° C. to prepare a thiocarbonyl compound of formula (M4).

[0382] In some embodiments, at least one of Z1, Z2, Z3, and Z4 of the thiocarbonyl compound of formula (M4) represents C(S). In some embodiments, at least two of Z1, Z2, Z3, and Z4 of the thiocarbonyl compound of formula (M4) represent C(S). In some embodiments, at least three of Z1, Z2, Z3, and Z4 represent C(S). In some embodiments, Z1, Z2, Z3, and Z4 all represent C(S).

[0383] In another aspect, the present disclosure provides a method for preparing a compound of formula (I), comprising subjecting a compound of formula (A) to sulfidation with a sulfiding agent to prepare a compound of formula (I):

[0384] wherein Z7 of the compound of formula (A) represents C(O), CH2 or CD2;

[0385] In the compound of formula (I), Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); and

[0386] The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, L and X are as defined in the compounds of formula (I) and its various subembodiments disclosed herein.

[0387] When Z7 of the compound of formula (A) of the starting material represents CH2 or CD2, the corresponding Z1 in the compound of formula (I) of the product represents CH2 or CD2. When Z7 of the compound of formula (A) of the starting material represents C(O), the corresponding Z1 in the compound of formula (I) of the product represents C(O) or C(S).

[0388] In some embodiments of the method for preparing the compound of formula (I), examples of the sulfurizing agent include, but are not limited to, carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent, Belleau's Reagent, and Davy's Reagent, etc.

[0389] In some embodiments of the method for preparing a compound of formula (I), a compound of formula (A) is reacted with a sulfurizing agent (such as Lawesson's reagent) in a solvent (such as 1,4-dioxane) at 40° C. to 150° C. to prepare a compound of formula (I).

[0390] In some embodiments of the method for preparing a compound of formula (I), at least one of Z1, Z2, Z3, and Z4 of the compound of formula (I) represents C(S). In some embodiments, at least two of Z1, Z2, Z3, and Z4 of the compound of formula (I) represent C(S). In some embodiments, at least three of Z1, Z2, Z3, and Z4 represent C(S). In some embodiments, Z1, Z2, Z3, and Z4 all represent C(S).

[0391] VII. Definitions

[0392] Unless otherwise specified, the following words, phrases and symbols used in this specification generally have the meanings described below.

[0393] In general, the nomenclature used herein (including IUPAC nomenclature) and the laboratory procedures described below (including for cell culture, organic chemistry, analytical chemistry and pharmacology, etc.) are those well known and commonly used in the art. Unless otherwise defined, all scientific and technical terms used herein in conjunction with the present disclosure described herein have the same meaning as commonly understood by those skilled in the art. In addition, in the claims and / or the specification, when the term "one" or "an" is used in conjunction with the term "comprising" or a noun, its meaning may be "one", but is also consistent with the meaning of "one or more", "at least one" and "one or more than one". Similarly, the term "another" or "other" can mean at least a second or more.

[0394] It should be understood that whenever various aspects are described herein using the terms "including" or "comprising," other similar aspects described by "consisting of" and / or "consisting essentially of" are also provided.

[0395] The term "about," used alone or in combination, is used herein to mean approximately, roughly, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​recited. Generally, the term "about" can modify a numerical value above and below the recited value by a variation, for example, 10%, 5%, 2%, or 1%, above or below the recited value.

[0396] As used herein, the phrase "... represents a bond" used alone or in combination means that it is a bond linker (i.e., it does not exist). For example, the phrase "R represents a bond" means that R is a bond linker. In other words, when R is a bond, the group L of the structure of formula (I) is directly connected to the benzene ring of the benzo-fused ring in the structure of formula (I). For example, the phrase "R represents a bond" means that R is a bond linker. w2 "Represents a key" means R w2 is a bond linker. In other words, when R w2 When the ring A in the group L is a bond, 5Connect directly to X.

[0397] As used herein, the term "optionally substituted" used alone or in combination means that the indicated group may be unsubstituted or substituted with one or more substituents as defined herein. The terms "optionally substituted with" and "unsubstituted or substituted" are used interchangeably herein. The term "substituted" generally means that one or more hydrogen atoms in the structure being referred to are replaced with the same or different specific substituents. The number of substituents is not subject to any limitation in principle, or is automatically limited by the size of the building block (i.e., the total number of hydrogen atoms of the building block that can be replaced), or as explicitly defined herein.

[0398] In this document, a bond broken by a wavy line shows the point of attachment of the depicted group to the rest of the molecule. For example, the monovalent group X shown below

[0399] The ring A representing the group X is connected to the group L of the structure of formula (I). In this article, unless otherwise explicitly stated, the two bonds of a divalent group broken by a wavy line show the two points of connection of the group depicted to the rest of the molecule. For example, in the structure of the group L depicted below: As defined herein, R w1 Connect R, R w2 Connect X. For example, R w1 The group -O-CH2- represented by any end can be connected to R of the compound of formula (I), and the other end can be connected to ring A 3 In other words, R w1 The O in the group -O-CH2- represented by the formula (I) can be connected to R, and CH2 can be connected to the ring A of the compound of formula (I) 3 , and vice versa. For example, the divalent group R shown below

[0400] Any end thereof can be connected to the isoindoline ring of the compound of formula (I), and the other end can be connected to the group L. In other words, the ring A of the divalent group R 1 The isoindoline ring of the compound of formula (I) may be linked to the other end of the isoindoline ring while the group L is linked to the other end, or vice versa.

[0401] As used herein, the expression "straight-chain or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof” has the definition known in the art, that is, it can refer to one or more groups R a 、R b or the group Ra With R b C can be optionally replaced by any combination of 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group. In this article, examples of the above terms may include but are not limited to C 1-20 Any one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) methylene groups of the alkylene main carbon chain backbone are optionally replaced by one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R as defined herein. a and / or one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R b and / or one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups R a With R b The main chain groups formed by the above-mentioned straight or branched C 1-20 The two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a When the straight or branched C 1-20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by one or more groups R a and / or one or more groups R b and / or one or more groups R a With R b When any combination of the above is replaced, the main chain group formed may contain one or more (e.g., 1-20, or 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2, or 1) of the following fragments, such as but not limited to "-(CH2) 0-5 -R a -(CH2) 0-5- "Fragment,"-R a -(CH2) 1-5 -R a -" fragment, "-(CH2) 0-5 -(R b ) 0-5 -(CH2) 0-5 -" fragment, "-(R b ) 0-5-(CH2) 1-5 -(R b ) 0-5 -" fragment, "-(CH2) 0-5 -R a -(R b ) 0-5 -(CH2) 0-5 -"fragment,"-R a -(CH2) 0-5 -(R b ) 0-5 -(CH2) 0-5 -" fragment, "-(CH2) 0-5 -R a -(CH2) 0-5 -(R b ) 0-5 -" fragments, etc., where each R a Same or different, each R b the same or different, and as defined herein.

[0402] In this document, the term "the C x-y One or more hydrogen atoms of an alkylene group are optionally replaced by ... x-y Any one or more hydrogen atoms in the alkylene group are replaced by substituents as defined herein. x-y The alkylene group may optionally have one or more substituents as defined herein. As used herein, the term "one or more" may refer to some or all of the hydrogen atoms in the alkylene group, including but not limited to 1-40 hydrogen atoms, such as 1-30, for example 1-25, 1-20, 1-15, 1-10, 1-5, 1-4, 1-3, 1-2, or 1 hydrogen. This number is not subject to any limitation or is automatically limited by the size of the building block.

[0403] As used herein, the term "deuterated," alone or in combination, means that one or more hydrogens of the referenced group are replaced by a deuterium atom.

[0404] As used herein, the term "oxo" or "oxo," alone or in combination, refers to =0.

[0405] As used herein, the term "carbonyl," alone or in combination, refers to C(O) or C(=O).

[0406]

[0046] As used herein, the term "thiocarbonyl" or "thiocarbonyl," used alone or in combination, refers to C(S) or C(=S).

[0407] As used herein, the term "halogen atom" or "halogen" alone or in combination refers to fluorine, chlorine, bromine or iodine.

[0408] As used herein, the term "alkyl" used alone or in combination refers to a straight chain or branched chain alkyl group. x -C y Alkyl" or "C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms. The term "C1-C 10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms. The term "C1-C 10 Examples of "alkyl" include C 1-9 Alkyl, C 1-8 Alkyl, C 2-8 Alkyl, C 1-7 Alkyl, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Representative examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl. The term "C1-C3 alkyl" in this disclosure refers to a group consisting of a C1-C2 alkyl group and a C1-C2 alkyl group. 1-3 "C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms, representative examples of which include methyl, ethyl, n-propyl and isopropyl. In the present disclosure, the "alkyl" is optionally substituted, and the substituents are optionally one or more selected from halogen, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Alkoxy, halogenated C 1-6 Alkoxy, halogenated C 1-6 Alkyl (e.g. trifluoromethyl), C 3-6 a cycloalkyl group, a 4-membered to 7-membered heterocyclic group, or a combination thereof.

[0409] As used herein, the term "haloalkyl" alone or in combination refers to a linear or branched alkyl group substituted with one or more halogens, wherein one or more hydrogen atoms in the alkyl group are replaced with halogens. x -C y Alkyl" or "halogenated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more halogens. The term "halogenated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more halogens. 1-10 Examples of alkyl groups include halo-C 1-9 Alkyl groups, such as halogenated C 1-8 Alkyl, halogenated C 2-8 Alkyl, halogenated C 1-7 Alkyl, halogenated C 1-6Alkyl, halogenated C 1-5 Alkyl, or halogenated C 1-4 Representative examples include halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, halogenated sec-butyl, halogenated tert-butyl, halogenated pentyl, halogenated isopentyl, halogenated neopentyl, halogenated tert-pentyl, halogenated hexyl, halogenated heptyl, halogenated octyl, halogenated nonyl and halogenated decyl. The term "halogenated C 1-3 "Alkyl" or "halogenated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more halogens, representative examples of which include halomethyl (e.g., trifluoromethyl), haloethyl, halo-n-propyl, and halo-isopropyl.

[0410] As used herein, the term "deuterated alkyl" alone or in combination refers to a straight or branched chain alkyl group substituted with one or more deuterium atoms, wherein one or more hydrogen atoms in the alkyl group are replaced with deuterium atoms. x -C y Alkyl" or "deuterated C x-y "alkyl" (x and y are each an integer) refers to a straight or branched chain alkyl group containing x to y carbon atoms substituted by one or more deuterium atoms. The term "deuterated C 1-10 "Alkyl" refers to a straight or branched chain alkyl group containing 1 to 10 carbon atoms substituted by one or more deuterium atoms. 1-10 Examples of alkyl groups include deuterated C 1-9 Alkyl groups, such as deuterated C 1-8 Alkyl, deuterated C 2-8 Alkyl, deuterated C 1-7 Alkyl, deuterated C 1-6 Alkyl, deuterated C 1-5 Alkyl, or deuterated C 1-4 Representative examples include perdeuterated methyl (CD3), perdeuterated ethyl (CD3CD2), perdeuterated n-propyl, perdeuterated isopropyl, perdeuterated n-butyl, perdeuterated isobutyl, perdeuterated sec-butyl, perdeuterated tert-butyl, perdeuterated pentyl, perdeuterated isopentyl, perdeuterated neopentyl, perdeuterated tert-pentyl, and perdeuterated hexyl. The term "deuterated C 1-3 "Alkyl" or "deuterated C1-C3 alkyl" refers to an alkyl group containing 1 to 3 carbon atoms substituted by one or more deuterium atoms, representative examples of which include perdeuterated methyl (CD3-) and perdeuterated ethyl (CD3CD2).

[0411] As used herein, the term "alkylene" (which is used interchangeably with "alkylene chain"), used alone or in combination, refers to a straight or branched divalent saturated hydrocarbon group consisting of carbon and hydrogen, which is a divalent radical form of a straight or branched alkyl group. x -C y"Alkylene" or "C x-y "alkylene" (x and y are each an integer) refers to a straight or branched chain alkylene containing x to y carbon atoms. The term "C1-C 20 "Alkylene" refers to a straight or branched chain alkylene group containing 1 to 20 carbon atoms, examples of which include but are not limited to C1-C 20 Alkylene, C1-C 15 Alkylene, C1-C 14 Alkylene, C1-C 13 Alkylene, C1-C 12 Alkylene, C1-C 11 Alkylene, C1-C 10 C1-C9 alkylene, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, and C1-C2 alkylene. Representative examples include, but are not limited to, methylene (i.e., -CH2-), ethylene (e.g., -CH2CH2-), propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, pentylene, isopentylene, neopentylene, tert-pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tridecylene, tetradecylene, and pentadecylene. In the present disclosure, the "alkylene" is optionally substituted, and the substituents are optionally one or more selected from C1-C3 alkyl, C1-C8 alkylene, C1-C7 alkylene, C1-C6 alkylene, C1-C5 alkylene, C1-C4 alkylene, C1-C3 alkylene, and C1-C2 alkylene. 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0412] As used herein, the term "alkoxy" used alone or in combination refers to a straight or branched chain alkoxy group having the formula alkyl-O-. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Representative examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, and the like. The term "C1-C3 alkoxy" or "C 1-3 "Alkoxy" refers to a straight or branched chain alkoxy group containing 1 to 3 carbon atoms. 1-3 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, and isopropoxy.

[0413] As used herein, the term "haloalkoxy" alone or in combination refers to an alkoxy group substituted with one or more halogens. Optionally, the alkyl portion of the alkoxy group may contain 1-10 (e.g., 1-6, 1-4, or 1-3) carbon atoms. Examples of "haloalkoxy" include halogenated C 1-6 Alkoxy and halogenated C 1-4 Representative examples include, but are not limited to, F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0414] In the present invention, the term "heteroaryl" used alone or in combination refers to a 5- to 30-membered (optionally 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon group containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. Bicyclic or polycyclic heteroaryl groups include bicyclic, tricyclic, or tetracyclic heteroaryl groups, one of which is an aromatic ring having one or more heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, tetrazolyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, isoindolinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, oxazolopyridinyl, furopyridinyl, pteridinyl, purinyl, pyridopyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, chromanyl and 6,7-dihydrothieno[3,2-d]pyrimidinyl. Examples of tricyclic or polycyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, xanthenyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl. The heteroaryl groups may be unsubstituted or substituted. Substituted heteroaryl refers to heteroaryl groups substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0415] In the present invention, the term "heteroarylene" used alone or in combination refers to a divalent group of a 5- to 30-membered (optionally 5- to 20-membered, 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, 5- to 6-membered, 6- to 15-membered, 6- to 9-membered, or 6- to 20-membered) monocyclic or bicyclic or polycyclic hydrocarbon containing at least one aromatic ring having 1 or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur. Bicyclic or polycyclic heteroarylene groups include bicyclic, tricyclic, or tetracyclic heteroarylene groups, one of which is an aromatic ring having one or more heteroatoms independently selected from O, S, and N, and the other rings may be saturated, partially unsaturated, or aromatic and may be carbocyclic or contain one or more heteroatoms independently selected from O, S, and N. Examples of monocyclic heteroarylene groups include, but are not limited to, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, tetrazolylene, and triazinylene. Examples of bicyclic heteroarylene groups include, but are not limited to, indolylene, isoindolylene, isoindolylene, benzofurylene, isobenzofurylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolin ... quinoxalinyl, phthalazinyl, oxazolopyridyl, furopyridyl, pteridyl, purinyl, pyridopyridyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1b]thiazolylene, imidazo[2,1-b]thiazolylene, chromanyl and 6,7-dihydrothieno[3,2-d]pyrimidinyl. Examples of tricyclic or polycyclic heteroarylene groups include, but are not limited to, acridinylene, benzindolylene, carbazolylene, dibenzofuranylene, xanthenylene, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinylene, and 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinylene. The heteroarylene groups may be unsubstituted or substituted. Substituted heteroarylene refers to heteroarylene groups that are substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) with substituents, wherein the substituents are optionally selected from C1-C3 alkyl, C 3-6Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0416] As used herein, the term "aryl" alone or in combination refers to a monovalent aromatic hydrocarbon group comprising 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, or 6-20) carbon atoms and optionally comprising one or more fused rings, such as phenyl, naphthyl, or fluorenyl. In the present disclosure, the "aryl" is an optionally substituted aryl. A substituted aryl refers to an aryl substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, for example, an aryl group is monosubstituted, disubstituted, trisubstituted, or polysubstituted by a substituent, wherein the substituent is optionally selected, for example, from C1-C3 alkyl, ... 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0417] In the present disclosure, the term "arylene", used alone or in combination, refers to a divalent aromatic hydrocarbon group containing 5 to 30 (e.g., 5-20, 5-15, 5-12, 5-10, 5-9, 5-8, 5-7, 5-6, 6-15, 6-9, or 6-20) carbon atoms and optionally containing one or more fused rings, such as phenylene (e.g., ) or naphthylene or fluorenylene. In the present disclosure, the "arylene" is an optionally substituted arylene. Substituted arylene refers to an arylene substituted one or more times (e.g., 1-4, 1-3, or 1-2 times) by a substituent, for example, the arylene is monosubstituted, disubstituted, trisubstituted, or polysubstituted by a substituent, wherein the substituent is optionally selected from, for example, C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0418] The term "cycloalkyl" as used herein, alone or in combination, refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) monocyclic, bicyclic, tricyclic, or polycyclic hydrocarbon radical having, in some embodiments, 3 to 30 carbon atoms (i.e., C 3-30 cycloalkyl), or 3 to 25 carbon atoms (i.e., C 3-25 cycloalkyl), or 3 to 20 carbon atoms (i.e., C 3-20 cycloalkyl), or 3 to 15 carbon atoms (i.e., C 3-15 Cycloalkyl), 3 to 12 carbon atoms (i.e., C 3-12 cycloalkyl), or 3 to 11 carbon atoms (i.e., C 3-11 cycloalkyl), or 3 to 10 carbon atoms (i.e., C 3-10 cycloalkyl), or 3 to 8 carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 7 carbon atoms (i.e., C 3-7 cycloalkyl), or 3 to 6 carbon atoms (i.e., C 3-6 cycloalkyl), or 4 to 20 carbon atoms (i.e., C 4-20 cycloalkyl), or 4 to 15 carbon atoms (i.e., C 4-15 cycloalkyl), or 4 to 12 carbon atoms (i.e., C 4-12 cycloalkyl), or 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkyl" includes monocyclic, bicyclic, tricyclic and polycyclic cycloalkyl groups having 3 to 30 carbon atoms. Examples of the term "cycloalkyl" include, but are not limited to, monocyclic cycloalkyl groups, bridged cycloalkyl groups (e.g., C 5-30 Bridged cycloalkyl or C 5-20 Bridged cycloalkyl or C 5-15 Bridged cycloalkyl or C 7-15 Bridged cycloalkyl), fused cycloalkyl (e.g. C 5-30 Condensed cycloalkyl, C 5-20 Condensed cycloalkyl, C 5-15 Condensed cycloalkyl, C 6-30 Condensed cycloalkyl, C 6-20 Condensed cycloalkyl, C 6-15 Condensed cycloalkyl, C 7-30 Condensed cycloalkyl, C 7-20 Condensed cycloalkyl, C 7-15 Condensed cycloalkyl, and C 8-15 fused cycloalkyl) and spirocycloalkyl (e.g. C 5-30 Spiroalkyl, C 5-20 Spiroalkyl, C 5-15 Spiroalkyl, C 6-30 Spiroalkyl, C 6-20 Spiroalkyl, C 6-15 Spiroalkyl, C 7-30 Spiroalkyl, C 7-20Spiroalkyl, C 7-15 Spiroalkyl, and C 8-15 Representative examples of monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Examples of fused cycloalkyl groups, spirocycloalkyl groups, and bridged cycloalkyl groups include, but are not limited to, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, C 5-20 Spiroalkyl, C 5-15 Spirocycloalkyl, adamantyl, noradamantyl, bornyl and norbornyl (IUPAC system named bicyclo[2.2.1]heptanyl). Herein, the "cycloalkyl" is optionally monosubstituted or polysubstituted, for example but not limited to, 2,2-, 2,3-, 2,4-, 2,5-, or 2,6-disubstituted cyclohexyl. The substituents of the substituted "cycloalkyl" are optionally one or more (e.g., 1-5, 1-4, 1-3, 1-2, or 1) selected from C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(b)-, ​​C 1-3 Alkyl-C(b)NH-, cyano or any combination thereof. The term "C 3-6 Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, and cyclohexyl.

[0419] In this document, the term “C x-y Spirocycloalkyl" (x and y are each an integer) refers to a spirocycloalkyl group containing x to y carbon atoms. The term "C 5-30 Spiroalkyl" refers to a spiroalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, and 7-9) carbon atoms. The term "C 5-30 Spirocyclyl" includes "C 5-20 Spirocyclyl", "C 5-15 Spirocyclyl", "C 7-15 Spirocycloalkyl" and "C 7-20 Spirocycloalkyl”, representative examples of which include, but are not limited to, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl or spiro[5.5]undecyl. The “C 5-30 The spirocycloalkyl group is optionally further selected from C 1-3 Alkyl, halogenated C 1-3 Alkyl, C 1-3 Alkoxy, deuterated C1-3 Alkoxy, C 1-3 The alkylamino group is substituted with one or more of alkylamino, amino, oxo, halogen, hydroxyl, cyano, or any combination thereof.

[0420] In this document, the term “C x-y "bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C 5-30 The term "bridged cycloalkyl" refers to a bridged cycloalkyl group containing 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. 5-30 "Bridged cycloalkyl" includes "C5-C 20 Bridged ring group", "C6-C 20 Bridged ring group", "C7-C 20 Bridged ring group", "C 5-15 Bridged cycloalkyl", and "C7-C 15 "bridged ring group", representative examples of which include but are not limited to adamantyl, noradamantyl, bornyl, norbornyl (systematically named bicyclo[2.2.1]heptyl), 2-oxobicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl and cubanyl. The "C 5-30 The "bridged cycloalkyl" is optionally substituted with 1 to 10 substituents selected from the following: 1-3 Alkyl, deuterated C 1-3 Alkyl, C 1-3 Alkoxy, halogen, halogenated C 1-3 Alkyl, C 1-3 alkylamino, amino, hydroxy, cyano, oxo, or any combination thereof.

[0421] In the present invention, the term "cycloalkylene" used alone or in combination refers to a saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) monocyclic or bicyclic or tricyclic or polycyclic hydrocarbon divalent group, which in some embodiments has 3 to 30 carbon atoms (i.e., C 3-30 cycloalkyl), or 3 to 25 carbon atoms (i.e., C 3-25 cycloalkyl), or 3 to 20 carbon atoms (i.e., C 3-20 cycloalkylene), or 3 to 15 carbon atoms (i.e., C 3-15 Cycloalkylene), 3 to 12 carbon atoms (i.e., C 3-12 cycloalkylene), or 3 to 11 carbon atoms (i.e., C 3-11 cycloalkylene), or 3 to 10 carbon atoms (i.e., C 3-10 cycloalkylene), or 3 to 8 carbon atoms (i.e., C3-8 cycloalkylene), or 3 to 7 carbon atoms (i.e., C 3-7 cycloalkylene), or 3 to 6 carbon atoms (i.e., C 3-6 cycloalkylene), or 4 to 20 carbon atoms (i.e., C 4-20 cycloalkylene), or 4 to 15 carbon atoms (ie, C 4-15 cycloalkylene), or 4 to 12 carbon atoms (i.e., C 4-12 cycloalkylene), or 4 to 10 carbon atoms (i.e., C 4-10 The term "cycloalkylene" includes monocyclic, bicyclic, tricyclic and polycyclic hydrocarbon divalent groups having 3 to 30 carbon atoms. Examples of the term "cycloalkylene" include, but are not limited to, monocyclic cycloalkylene, bridged cycloalkylene (e.g., C 5-30 Cycloalkylene bridged, C 5-20 Cycloalkylene bridged, C 5-15 Cycloalkylene or C 7-15 bridged cycloalkylene), fused cycloalkylene (e.g. C 5-30 Fused cycloalkylene, C 5-20 Fused cycloalkylene, C 5-15 Fused cycloalkylene, C 6-30 Fused cycloalkylene, C 6-20 Fused cycloalkylene, C 6-15 Fused cycloalkylene, C 7-30 Fused cycloalkylene, C 7-20 Fused cycloalkylene, C 7-15 fused cycloalkylene, and C 8-15 fused cycloalkylene) and spirocycloalkylene (e.g. C 5-30 Spirocycloalkylene, C 5-20 Spirocycloalkylene, C 5-15 Spirocycloalkylene, C 6-30 Spirocycloalkylene, C 6-20 Spirocycloalkylene, C 6-15 Spirocycloalkylene, C 7-30 Spirocycloalkylene, C 7-20 Spirocycloalkylene, C 7-15 Spirocycloalkylene, and C 8-15 Representative examples of monocyclic cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, and cyclooctylene. Examples of fused cycloalkylene groups, spirocycloalkylene groups, and bridged cycloalkylene groups include, but are not limited to, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-20 Spirocyclylene (e.g. C 5-15cyclohexyl, ... 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 alkyl-C(O)NH-, cyano or any combination thereof.

[0422] In this document, the term “C x-y Spirocycloalkylene" or "C x-y Spirocyclylene" (x and y are each an integer) refers to a spirocycloalkylene group containing x to y carbon atoms. The term "C 5-30 Spirocycloalkylene refers to a spirocycloalkylene group containing 5 to 30 (e.g., 5-20, 5-15, 7-20, 7-15, 5-11, 5-10, 7-9) carbon atoms. The term "C 5-30 Spirocycloalkylene" includes "C 5-20 Spirocycloalkylene", "C 5-15 Spirocycloalkylene", "C 7-15 Spirocycloalkylene" and "C 7-20 Spirocycloalkylene”, representative examples of which include but are not limited to spiro[3.3]heptanediyl, spiro[2.5]octandiyl, spiro[3.5]nonanediyl, spiro[4.4]nonanediyl, spiro[4.5]decanediyl and spiro[5.5]undecanediyl. The “C 5-30 The spirocycloalkylene group is optionally further substituted with one or more C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted C 1-3 Alkylene, C 1-3 Alkyl-NHC(O)-, C 1-3 The group is substituted with alkyl-C(O)NH-, cyano or any combination thereof.

[0423] In this document, the term “C x-y "C-bridged cycloalkyl" or "C x-y"C-bridged cycloalkyl" (x and y are each an integer) refers to a bridged cycloalkyl group containing x to y carbon atoms. The term "C-bridged cycloalkyl" used alone or in combination in the present invention refers to a bridged cycloalkyl group containing x to y carbon atoms. 5-30 "Cycloalkylene" refers to a cycloalkylene group containing from 5 to 30 (for example, but not limited to, 5-20, 6-20, 7-20, 5-15, 7-15, 5-11, 5-10, and 7-9) carbon atoms. The term "C 5-30 "Cycloalkylene bridged" includes "C 5-20 Sub-bridged cycloalkyl", "C 6-20 Sub-bridged cycloalkyl", "C 7-20 Sub-bridged cycloalkyl", "C 5-15 "Cycloalkylene", and "C 7-15 "C-bridged cycloalkylene", representative examples of which include, but are not limited to, adamantylene, noradamantylene, bornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[2.2.1]heptanylene, bicyclo[2.2.1]heptenylene and cubanylene. The "C-bridged cycloalkylene" is a cycloalkylene radical having a cycloalkylene radical, ... 5-30 The "bridged cycloalkyl" may be further substituted with one or more C1-C3 alkyl, C 3-6 Cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3 alkoxy, C1-C3 alkylamino, halogenated C1-C3 alkyl, amino-substituted CA 1-3 Alkylene, CA 1-3 Alkyl-NHC(O)-, CA 1-3 The group is substituted with alkyl-CA(O)NH-, cyano or any combination thereof.

[0424] As used herein, the term "heterocyclyl" or "heterocycloalkyl," alone or in combination, refers to a 4- to 30-membered (alternatively 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “heterocyclyl” include, but are not limited to, monocyclic heterocyclyl (e.g., 4- to 30-membered monocyclic heterocyclyl, and 4- to 20-membered monocyclic heterocyclyl), bridged heterocyclyl (e.g., 5- to 30-membered bridged heterocyclyl, 5- to 20-membered bridged heterocyclyl, 7- to 20-membered bridged heterocyclyl, and 7- to 15-membered bridged heterocyclyl), fused heterocyclyl (e.g., 5- to 30-membered fused heterocyclyl, and 5- to 20-membered fused heterocyclyl), and spiro heterocyclyl (e.g., 5- to 30-membered spiro heterocyclyl, and 5- to 20-membered spiro heterocyclyl). Representative examples of monocyclic heterocyclyl groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazacyclooctanyl. Examples of bridged heterocyclic groups, fused heterocyclic groups, and spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, octahydro-1H-indolyl, and azaspirocyclic groups (e.g., a 5- to 20-membered azaspirocyclic group, such as 3-azaspiro[5.5]undec-3-yl). The heterocyclyl group may be unsubstituted or substituted as defined (e.g. mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0425] As used herein, the term "nitrogen-containing heterocyclyl" or "nitrogen-containing heterocycloalkyl", alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 13-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclic group” include, but are not limited to, nitrogen-containing monocyclic heterocyclic groups (e.g., 4- to 30-membered nitrogen-containing monocyclic heterocyclic groups and 4- to 20-membered nitrogen-containing monocyclic heterocyclic groups), nitrogen-containing bridged heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing bridged heterocyclic groups, 5- to 20-membered nitrogen-containing bridged heterocyclic groups, 5- to 15-membered nitrogen-containing bridged heterocyclic groups, 7- to 20-membered nitrogen-containing bridged heterocyclic groups, or 7- to 15-membered nitrogen-containing bridged heterocyclic groups), nitrogen-containing fused heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing fused heterocyclic groups and 5- to 20-membered nitrogen-containing fused heterocyclic groups), and nitrogen-containing spiro heterocyclic groups (e.g., 5- to 30-membered nitrogen-containing spiro heterocyclic groups and 5- to 20-membered nitrogen-containing spiro heterocyclic groups). Representative examples of nitrogen-containing monocyclic heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepan-1-yl), and diazacyclooctanyl. Examples of nitrogen-containing bridged heterocyclic groups, nitrogen-containing fused heterocyclic groups, and nitrogen-containing spiro heterocyclic groups include, but are not limited to, 6-azabicyclo[3.1.1]heptan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 3,6-diazabicyclo[3.1.1]heptan-3-yl, 3-azabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-8-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, octahydro-1H-indolyl, and azaspirocyclic groups (e.g., a 5- to 20-membered azaspirocyclic group, such as 3-azaspiro[5.5]undec-3-yl). The nitrogen-containing heterocyclic group may be unsubstituted or substituted as defined (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 alkyl-C(O)NH- or any combination thereof.

[0426] As used herein, the term "heterocyclylene" or "heterocycloalkylene", used alone or in combination, refers to a 4- to 30-membered monocyclic, bicyclic, tricyclic or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2 or 1) heteroatoms independently selected from sulfur, oxygen and nitrogen. Examples of the term “heterocyclylene” include, but are not limited to, monocyclic heterocyclylene (e.g., 4- to 30-membered monocyclic heterocyclylene, and 4- to 20-membered monocyclic heterocyclylene), bridged heterocyclylene (e.g., 5- to 30-membered bridged heterocyclylene, 5- to 20-membered bridged heterocyclylene, 7- to 20-membered bridged heterocyclylene, or 7- to 15-membered bridged heterocyclylene), fused heterocyclylene (e.g., 5- to 30-membered fused heterocyclylene, and 5- to 20-membered fused heterocyclylene), and spiro heterocyclylene (e.g., 5- to 30-membered spiro heterocyclylene, and 5- to 20-membered spiro heterocyclylene). Representative examples of monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azoctanylene, dioxanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazaoctanylene. Examples of bridged heterocyclylenes, fused heterocyclylenes, and spiro heterocyclylenes include, but are not limited to, 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene, octahydro-1H-indolylidene, and azaspiroylidene (e.g., a 5- to 20-membered azaspiroylidene, such as 3-azaspiro[5.5]undecanylidene). The heterocyclylene group may be unsubstituted or substituted as defined above (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6 Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 Alkyl-C(O)NH- or any combination thereof.

[0427] As used herein, the term “nitrogen-containing heterocyclylene” or “nitrogen-containing heterocycloalkylene”, alone or in combination, refers to a 4- to 30-membered (e.g., 4- to 30-membered, 4- to 25-membered, 4- to 20-membered, 4- to 15-membered, 4- to 14-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 4- to 5-membered, 5- to 9-membered, 5- to 30-membered, 5- to 20-membered, or 5- to 15-membered) monocyclic, bicyclic, tricyclic, or polycyclic saturated or partially unsaturated (i.e., having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one nitrogen atom and optionally containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of the term “nitrogen-containing heterocyclylene” include, but are not limited to, nitrogen-containing monocyclic heterocyclylene (e.g., a 4- to 30-membered nitrogen-containing monocyclic heterocyclylene, and a 4- to 20-membered nitrogen-containing monocyclic heterocyclylene), nitrogen-containing bridged heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing bridged heterocyclyl, a 5- to 20-membered nitrogen-containing bridged heterocyclyl, a 7- to 20-membered nitrogen-containing bridged heterocyclyl, or a 7- to 15-membered nitrogen-containing bridged heterocyclyl), nitrogen-containing fused heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing fused heterocyclyl and a 5- to 20-membered nitrogen-containing fused heterocyclyl), and nitrogen-containing spiro heterocyclyl (e.g., a 5- to 30-membered nitrogen-containing spiro heterocyclyl and a 5- to 20-membered nitrogen-containing spiro heterocyclyl). Representative examples of nitrogen-containing monocyclic heterocyclylene groups include, but are not limited to, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, diazepanylene (e.g., 1,4-diazepanylene, 4,5-diazepanylene, 1,3-diazepanylene), and diazepanylene. Examples of nitrogen-containing bridged heterocyclyl groups, nitrogen-containing fused heterocyclyl groups, and nitrogen-containing spiro heterocyclyl groups include, but are not limited to, 6-azabicyclo[3.1.1]heptanylidene, 2,5-diazabicyclo[2.2.1]heptanylidene, 3,6-diazabicyclo[3.1.1]heptanylidene, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene, octahydro-1H-indolylidene, and azaspirocyclyl groups (e.g., a 5- to 20-membered azaspirocyclyl group, such as 3-azaspiro[5.5]undecylidene). The nitrogen-containing heterocyclylene group may be unsubstituted or substituted as defined above (e.g., mono-, di-, tri-, or polysubstituted), wherein the substituents are optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, optionally deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, optionally deuterated C 3-6 Cycloalkyl, optionally deuterated C 1-6 Alkoxy, optionally deuterated C 1-6Alkyl-NH-, NH2-C 1-6 Alkylene, optionally deuterated C 1-6 Alkyl-NHC(O)-, optionally deuterated C 1-6 alkyl-C(O)NH- or any combination thereof.

[0428] As used herein, the term "alkynylene" alone or in combination refers to a straight or branched divalent hydrocarbon group containing 2 to 8 (e.g., 2 to 6, 2 to 5, 2 to 4, or 2) carbon atoms having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon triple bonds. Examples of "alkynylene" include C 2-8 Alkynylidene, C 2-6 Alkynylidene or C 2-4 Alkynylenyl, representative examples of which include, but are not limited to, ethynylene, 1-propynylene, 1-butynylene, and 1,3-diynylene.

[0429] As used herein, the suffix "alkylene" in the name of a group means that the group is connected to the rest of the molecule through one single bond and one double bond and is a trivalent group.

[0430] As used herein, the term "alkynyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 (e.g., 2 to 6, 2 to 5, 2 to 4, more preferably 2) carbon atoms and having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon triple bonds. Examples of "alkynyl" include C 2-8 Alkynyl, C 2-6 Alkynyl or C 2-4 Alkynyl, representative examples of which include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, and 1,3-diynyl.

[0431] As used herein, the term "alkenylene," alone or in combination, refers to a straight or branched chain divalent hydrocarbon radical containing 2 to 8 carbon atoms (e.g., 2 to 6, 2 to 5 carbon atoms, or 2 to 4, 2 to 3, or 2 carbon atoms) having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon double bonds. Examples of alkenylene include C 2-8 Alkenylene, C 2-6 Alkenylene or C 2-4Alkenylene, representative examples of which include, but are not limited to, ethenylene (e.g., —CH═CH—), 1-propenylene, allylene, 1-butenylene, 2-butenylene, 3-butenylene, isobutenylene, pentenylene, n-penta-2,4-dienylene, 1-methyl-but-1-enylene, 2-methyl-but-1-enylene, 3-methyl-but-1-enylene, 1-methyl-but-2-enylene, 2-methyl-but-2-enylene, 3-methyl-but-2-enylene, 1-methyl-but-3-enylene, 2-methyl-but-3-enylene, 3-methyl-but-3-enylene, and hexenylene.

[0432] As used herein, the term "alkenyl" alone or in combination refers to a straight or branched monovalent hydrocarbon group containing 2 to 8 carbon atoms (e.g., 2 to 6, 2 to 5 carbon atoms, or 2 to 4, 2 to 3 or 2 carbon atoms) having one or more (e.g., 1 to 3, 1 to 2, or 1) carbon-carbon double bonds. Examples of "alkenyl" include C 2-8 Alkenyl, C 2-6 Alkenyl or C 2-4 Alkenyl, representative examples of which include, but are not limited to, vinyl (e.g., CH2=CH-), 1-propenyl, allyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, pentenyl, n-penta-2,4-dienyl, 1-methyl-but-1-enyl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 1-methyl-but-2-ylidene, 2-methyl-but-2-ylidene, 3-methyl-but-2-ylidene, 1-methyl-but-3-enyl, 2-methyl-but-3-enyl, 3-methyl-but-3-enyl, and hexenyl.

[0433] As used herein, the term "bornyl" or "bornane" (also known as 1,7,7-trimethylbicyclo[2.2.1]heptane; camphane; bomylane) has the definition known to those skilled in the art. As used herein, the term "bornyl" or "bornyl" refers to a monovalent radical of bornane, i.e., the radical remaining after any one of the hydrogen atoms in bornane is removed. Representative examples of "bornyl" include, but are not limited to, 1,7,7-trimethylbicyclo[2.2.1]heptane-2-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-3-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-4-yl, 1,7,7-trimethylbicyclo[2.2.1]heptane-5-yl, or 1,7,7-trimethylbicyclo[2.2.1]heptane-6-yl,

[0434] As used herein, the term "bicyclo[2.2.1]heptane" (also known as bicyclo[2.2.1]heptane) or "norbornane" has the meaning known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptane" or "norbornane" refers to a monovalent radical of bicyclo[2.2.1]heptane, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptane is removed. Representative examples of "bicyclo[2.2.1]heptane" include, but are not limited to, bicyclo[2.2.1]heptane-2-yl, bicyclo[2.2.1]heptane-3-yl, bicyclo[2.2.1]heptane-4-yl, bicyclo[2.2.1]heptane-5-yl, or bicyclo[2.2.1]heptane-6-yl.

[0435] As used herein, the term "bicyclo[2.2.1]heptene" (also known as bicyclo[2.2.1]heptene) has a definition known to those skilled in the art. As used herein, "bicyclo[2.2.1]heptenyl" refers to a monovalent radical of bicyclo[2.2.1]heptene, i.e., the radical remaining after any one of the hydrogen atoms in bicyclo[2.2.1]heptene is removed. Representative examples of "bicyclo[2.2.1]heptenyl" include, but are not limited to, bicyclo[2.2.1]hept-5-en-2-yl, bicyclo[2.2.1]hept-5-en-3-yl, or bicyclo[2.2.1]hept-5-en-7-yl.

[0436] In this article, the term "adamantane" (also known as Tricyclo[3.3.1.1 3，7 ]decane) has a definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "adamantyl" refers to a monovalent radical of adamantane, i.e., the radical remaining after any hydrogen atom in adamantane is removed. Representative examples of "adamantyl" include, but are not limited to, 1-adamantyl, 2-adamantyl, 3-adamantyl, 4-adamantyl, 5-adamantyl, 6-adamantyl, 7-adamantyl, 8-adamantyl, 9-adamantyl, and 10-adamantyl.

[0437] As used herein, the term "noradamantane" (also known as noradamantane or octahydro-2,5-methanopentalene) has the definition known to those skilled in the art, and its structural formula is shown below, for example: As used herein, "noradamantyl" refers to a monovalent radical of noradamantane, i.e., the radical remaining after any hydrogen atom in noradamantane is removed. Representative examples of "noradamantyl" include, but are not limited to, 1-noradamantyl, 2-noradamantyl, 3-noradamantyl, 4-noradamantyl, 5-noradamantyl, 6-noradamantyl, 7-noradamantyl, 8-noradamantyl, and 9-noradamantyl.

[0438] As used herein, the term "adamantanamine" has the meaning known to those skilled in the art, i.e., refers to an adamantane having an amino substituent, wherein the amino group can replace a hydrogen on any carbon position of the adamantane. An example of an "adamantanamine" can be adamantane-1-amine (also known as adamantane-1-amine or Tricyclo[3.3.1.1 3，7 ]decan-1-amine; CAS: 768-94-5), having the following structural formula

[0439] The salts or pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, and polymorphs of the compounds of formula (I) described in the present disclosure are also encompassed within the scope of the present disclosure.

[0440] In all embodiments of the present disclosure, the salt or pharmaceutically acceptable salt of the compound of formula (I) refers to a non-toxic inorganic or organic acid and / or base addition salt. Examples include: sulfate, hydrohalide (including hydrochloride, hydrobromide), maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2-dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylmethanesulfonate, benzoic acid salt ... Acetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecylenate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate or p-toluenesulfonate, etc.

[0441] "Pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, such as a filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent, or encapsulating material, that carries or transports a compound useful in the present disclosure into or to a patient so that it can perform its intended function. Typically, such a construct carries or transports a compound from one organ or part of the body to another. A carrier must be "acceptable" if it is compatible with the other ingredients of the formulation (including the compound useful in the present disclosure) and is not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; phosphate buffered saline as a surfactant; and other nontoxic, compatible substances used in pharmaceutical formulations.

[0442] The term "room temperature" of the present disclosure refers to ambient temperature, for example, a temperature of 20-30°C.

[0443] As used herein, "stereoisomers" refer to compounds that have identical chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0444] As used herein, the term "solvate" refers to an association or complex of one or more solvent molecules and a compound of the present invention. Examples of solvents include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0445] As used herein, the term "chiral" refers to a molecule that is non-superimposable on its mirror image, while "achiral" refers to a molecule that is superimposable on its mirror image.

[0446] As used herein, the term "enantiomers" refers to two non-superimposable isomers of a compound that are mirror images of each other.

[0447] As used herein, the term "diastereoisomer" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high-resolution analytical procedures such as electrophoresis and chromatography, for example, HPLC.

[0448] In this document, "p-menthane" (also known as p-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "p-menthanyl" refers to a monovalent group of p-menthane, that is, the group remaining after any hydrogen on any carbon position of p-menthane is removed. Representative examples include but are not limited to

[0449] In this document, "m-menthane" (also known as m-methane) has a definition known to those skilled in the art, and its structural formula is shown below: In this article, "m-menthanyl" refers to a monovalent group of m-menthane, that is, the group remaining after any hydrogen on any carbon position of m-menthane is removed. Representative examples include but are not limited to

[0450] In this document, “quinuclidine” (also known as Quinuclidine), whose chemical name is 1-azabicyclo[2.2.2]octane, has the definition known to those skilled in the art, and its structural formula is shown below: In this article, "quinuclidine" refers to a monovalent group of quinuclidine, that is, the group remaining after any hydrogen on any carbon position of quinuclidine is removed. Representative examples include but are not limited to [0450.1] [Corrected 15.08.2024 according to Rule 91] Figure 1 shows the degradation effect of the compounds of the present invention on the target substrate protein. Example

[0451] In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. The present invention may be practiced without some or all of these specific details. In other cases, well-known process operations are not described in detail in order to avoid unnecessary obfuscation of the present invention. Although the present invention will be described in conjunction with specific embodiments, it should be understood that this is not intended to limit the invention to these embodiments.

[0452] The following abbreviations are used throughout the specification and examples:

[0453] AcOH acetic acid

[0454] Boc tert-Butoxycarbonyl

[0455] DCM dichloromethane

[0456] DIEA or DIPEA N,N-diisopropylethylamine

[0457] DMF N,N-dimethylformamide

[0458] DMSO dimethyl sulfoxide

[0459] EA Ethyl acetate

[0460] ESI electrospray ionization

[0461] equiv equivalent

[0462] EtOH alcohol

[0463] EtOAc

[0464] HPLC high performance liquid chromatography

[0465] HRMS High Resolution Mass Spectrometry

[0466] LC-MS liquid chromatography-mass spectrometry

[0467] LRMS low-resolution mass spectrometry

[0468] LC liquid chromatography

[0469] Me methyl

[0470] MeCN Acetonitrile

[0471] MeOH methanol

[0472] MS

[0473] MsCl methanesulfonyl chloride

[0474] MsO- methanesulfonyloxy

[0475] Ms2O methanesulfonic anhydride

[0476] 1 H NMR nuclear magnetic resonance spectroscopy

[0477] MeO-methoxy

[0478] ON S o-Nitrophenylsulfonyl

[0479] rt room temperature

[0480] tBu tert-butyl

[0481] TEA triethylamine

[0482] TFA trifluoroacetic acid

[0483] T f O-trifluoromethanesulfonyloxy

[0484] TLC thin layer chromatography

[0485] TMS trimethylsilyl

[0486] TsO- p-Toluenesulfonyloxy

[0487] Xantphos 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene

[0488] X-Phos 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl

[0489] In the present invention, 1 H NMR spectra were measured using a Bruker-500 MHz nuclear magnetic resonance instrument, using CD3OD (δ = 3.31 ppm) containing 0.1% TMS (as an internal standard) as the solvent; CDCl3 (δ = 7.26 ppm) containing 0.1% TMS (as an internal standard) as the solvent; or DMSO-d6 (δ = 2.50 ppm) containing 0.03% TMS (as an internal standard) as the solvent. LC-MS spectra were measured on a Sciex API 2000 mass spectrometer equipped with an Agilent 1100 binary pump, DAD, and ELSD, or on an Agilent 1260-6125B single quadrupole liquid chromatography-mass spectrometer equipped with an Agilent 1260 quaternary pump, DAD, and ELSD. HPLC preparations were measured on a SHIMADZU LC-20AP instrument, and HPLC purity was measured on a SHIMADZU LC-30AP or Waters 1525 instrument. All reactions were carried out under air atmosphere unless otherwise specified; the reactions were monitored by TLC or LC-MS.

[0490] Solvent and reagent treatment was as follows: the reaction solvents DCM, DMF, anhydrous EtOH, and anhydrous MeOH were purchased from Sinopharm Group; preparative-grade CH3CN and deionized water were used for HPLC preparation; other reaction substrates, reagents, and drugs, unless otherwise specified, were directly purchased from commercial channels or synthesized using or according to methods known in the art.

[0491] Unless otherwise specified, the materials and reagents used in the following examples can be purchased from commercial sources and used directly, or can be synthesized using or according to methods known in the art.

[0492] General synthetic method

[0493] The compounds and / or pharmaceutically acceptable salts thereof disclosed herein can be synthesized using commercially available raw materials by synthetic techniques known in the art. The synthetic schemes described below illustrate the preparation methods of most compounds. The starting materials or reagents used in each scheme can be purchased from commercial sources or prepared by methods known to those skilled in the art. Salts, racemates, enantiomers, phosphates, sulfates, hydrochlorides and prodrug forms of the compounds of formula (I) disclosed herein can be prepared by those skilled in the art according to conventional techniques in the art.

[0494] Synthesis Scheme 1:

[0495] In Scheme 1, Z6 represents C(O), CH2 or CD2. Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S).

[0496] In some embodiments, at least two of Z1, Z2, Z3, and Z4 of the step 1 product represent C(S). In some embodiments, at least three of Z1, Z2, Z3, and Z4 represent C(S). In some embodiments, Z1, Z2, Z3, and Z4 all represent C(S).

[0497] The sulfurizing agent Lawesson's reagent in Scheme 1 can also be replaced by other suitable sulfurizing agents, such as but not limited to carbon disulfide, hexamethyldisilathioethane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Belleau's reagent, and Davy's reagent.

[0498] In Scheme 1, the Br substituent of the reaction substrate in step 1 can be located at the 4-, 5-, 6-, or 7-position on the phenyl ring of the isoindolinyl group, and the Br substituent of the intermediate product and the -CH2-OH substituent of the product in step 2 are also located at the 4-, 5-, 6-, or 7-position on the phenyl ring of the isoindolinyl group. a1 、R a2 、R a3 、R a4 , and (R a5 ) m As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0499] Synthesis Scheme 2: (Sulfonate ester formation)

[0500] In Scheme 2, Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S).

[0501] In Scheme 2, the substituent -CH2-OH of the reaction substrate can be located at the 4-, 5-, 6-, or 7-position on the phenyl ring of the isoindolinyl group, and the substituent -CH2-OMs of the obtained products 2-2 and 2-3 are also located at the 4-, 5-, 6-, or 7-position on the phenyl ring of the isoindolinyl group. a1 、R a2 、R a3 、R a4 , and (R a5 ) m As defined in the compounds of formula (I) and various subembodiments thereof of the present disclosure.

[0502] Synthesis Scheme 3:

[0503] In Scheme 3, the group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. The group LE represents Cl, Br, I, OMs, OTs, or ONs. The substrate amine 2 is a compound corresponding to the X moiety containing an amino group or a nitrogen-containing heterocycle in the compound of formula (I). In some embodiments, the group R of the substrate amine 2 is b1 As defined in the group R1 of the compound of formula (I) and its various subembodiments, the group R b2 As defined in the group R2 of the compound of formula (I) and its various subembodiments. In some embodiments, the group R b1 and group R b2 Together with the nitrogen atoms to which they are attached, they form the The substituent represented by n1 substituents R d1 Substituted nitrogen-containing heterocycle A a , that is, the substrate amine 2 has the following structure:

[0504] And the product has the structure of the following formula:

[0505] The nitrogen-containing heterocyclic ring A a represents a 4- to 30-membered nitrogen-containing heterocyclic group (e.g., a 4- to 20-membered nitrogen-containing heterocyclic group or a 4- to 15-membered nitrogen-containing heterocyclic group), the group R a1 、Ra2 、R a3 、R a4 、(R a5 ) m 、Z1、Z2、Z3、Z4、R、(R d1 ) n1 、n1、R c , Ring B, m1, (R d2 ) n2 、n2、R e 、C、m2、(R d3 ) n3 and n3 are as defined in the disclosed compounds of formula (I) and various subembodiments thereof.

[0506] The amine alkylation reaction in Scheme 3 can be carried out, for example, in the presence of DIEA and sodium iodide, or triethylamine and sodium iodide, at room temperature to 80°C (e.g., 40°C to 60°C, 40°C to 50°C, or 50°C to 60°C). The molar ratio of substrate 1 to substrate 2 can be, for example, 1:1.1-2, 1:1.1-1.5, 1:1.1-1.2, or 1:1.2-1.3.

[0507] For example, the specific operations of solution 3 can be as follows:

[0508] Methanesulfonate substrate 1 (1.3 eq.) and substrate amine 2 (1.0 eq.) were dissolved in anhydrous DMF (3 mL). Triethylamine (3.0 eq.) and sodium iodide (1.0 eq.) were then added to the solution. The reaction mixture was stirred at room temperature for 3 hours. LCMS confirmed the reaction was complete. The reaction mixture was filtered, and the filtrate was purified by HPLC to yield the title compound.

[0509] Synthesis Scheme 4:

[0510] In Scheme 4, the group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. Step (2) Substrate amine HNR b1 R b2 is a compound corresponding to the X portion containing an amino group or a nitrogen-containing heterocycle in the compound of formula (I), and the group R b1 、Group R b2 As defined in the group R1, group R2 of the compound of formula (I) and its various sub-embodiments or synthesis scheme 3.

[0511] For example, the specific operations of solution 4 can be as follows:

[0512] The hydroxyl substrate (1.0 eq.) was dissolved in anhydrous DMF (0.5 mL) and DCM (5 mL), and then diisopropylethylamine (3.0 eq.) and methanesulfonic anhydride (0.9 eq.) were added to the solution. The reaction solution was stirred at room temperature for 5 minutes. After TLC detection of the reaction completion, a solution of the corresponding substrate amine (1.0 eq.) in DMF (0.5 mL) was added to the solution, and the reaction was continued to stir at room temperature for 3 hours. LCMS detection of the reaction completion was performed. The reaction solution was filtered and concentrated, and the residue was purified by high-performance liquid chromatography to obtain the target compound.

[0513] Synthesis Scheme 5:

[0514] In Scheme 5, Z7 of the compound of formula (A) represents C(O), CH2 or CD2; Z1 of the compound of formula (I) represents C(O), C(S), CH2 or CD2, Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); and the group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, L and X are as defined in the compounds of formula (I) and its various sub-embodiments disclosed herein. Step (2) Substrate amine HNR b1 R b2 is a compound corresponding to the X portion containing an amino group or a nitrogen-containing heterocycle in the compound of formula (I), and the group R b1 , group R b2 As defined in the group R1, group R2 of the compound of formula (I) and its various sub-embodiments or synthesis scheme 3.

[0515] The sulfurizing agent in Scheme 5 can be Lawesson's reagent, or other sulfurizing agents, such as but not limited to carbon disulfide, hexamethyldisilathioethane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Belleau's reagent, and Davy's reagent.

[0516] The specific operations of Solution 5 can be as follows:

[0517] Dissolve the compound of formula (A) (1.0 eq.) in 1,4-dioxane (10 mL), then add Lawesson's reagent (1.0 eq.). Heat the reaction mixture to 120°C and stir under nitrogen for 16 hours. After TLC, filter and concentrate the mixture. The residue is purified by HPLC to obtain the title compound.

[0518] Depending on the target compound, the above schemes and their reaction substrates, reaction conditions (including reaction amount, temperature, time, etc.), post-treatment, etc. can be appropriately modified and adjusted by techniques and methods well known to those skilled in the art to obtain the desired target compound, and the obtained target compound can be further modified by substituents, etc. according to methods well known to those skilled in the art to obtain other target compounds.

[0519] Example

[0520] Intermediate Example 1: Preparation of 3-(5-(hydroxymethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-06977)

[0521] The target compound (GT-06977) was prepared according to the method of Synthesis Scheme 1.

[0522] Step 1: To a solution of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (20 g, 61.891 mmol) in 1,4-dioxane (200 mL) was added Lawesson's reagent (11.26 g, 27.851 mmol). The reaction mixture was stirred at 110°C for 12 hours. The reaction was complete as determined by TLC. The reaction mixture was concentrated and the residue was purified by column chromatography to afford 3-(5-bromo-1-thioisoindolin-2-yl)piperidine-2,6-dione (10 g, 29.480 mmol, 47.64% yield) as an off-white solid.

[0523] Step 2: To a solution of 3-(5-bromo-1-thioisoindolin-2-yl)piperidine-2,6-dione (6 g, 17.688 mmol) and (tributyl-λ4-stannyl)methanol (8.52 g, 26.532 mmol) in 1,4-dioxane (60 mL) was added XPhos Pd G3 (0.1 g, 0.147 mmol). The reaction mixture was stirred at 100°C under argon for 3 hours. The reaction mixture was concentrated and the residue was purified by column chromatography to afford 3-(5-(hydroxymethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (1 g, 19.46% yield) as a gray solid. 1 H NMR (400MHz, DMSO) δ11.17 (s, 1H), 7.9l (d, J=7.9Hz, 1H), 7.66 (s, 1H), 7.55 (d, J=8.0Hz, 1H), 6.09-5.91 (m, 1H), 5.4 9 (t, J=5.7Hz, 1H), 4.91-4.67 (m, 4H), 3.13-2.93 (m, 1H), 2.79-2.58 (m, 2H), 2.16 (dd, J=8.9, 3.6Hz, 1H). LCMS (ESI) C14 H 15 N2O3S + [M+H]+: Calculated, 291.08 Found, 291.0.

[0524] Intermediate Example 2: Preparation of 3-(4-(hydroxymethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-06981)

[0525] The target compound (GT-06981) (gray solid, 0.8 g, yield 33.32%) was prepared by referring to the method of Synthesis Scheme 1 or the method of Intermediate Example 1. 1 HNMR (400MHz, DMSO) δ11.12 (s, 1H), 7.80 (d, J = 7.4Hz, 1H), 7.61 (d, J = 7.4Hz, 1H), 7.53 (t, J = 7.6Hz, 1H), 5.98 (d, J = 8.3Hz, 1H), 5.37 (d , J=5.4Hz, 1H), 4.79 (dd, J=49.7, 20.2Hz, 2H), 4.65 (d, J=4.1Hz, 2H), 2.96 (s, 1H), 2.64 (d, J=18.4Hz, 2H), 2.09 (dd, J=8.9, 3.5Hz, 1H). 13 C NMR (101MHz, DMSO-d6) δ194.06, 173.08, 170.28, 139.30, 138.79, 137.62, 130.10, 128.82, 124.03, 61.22, 56.07, 31.53, 22.58.LCMS (ESI) C 14 H 15 N2O3S + [M+H]+: Calculated, 291.08 Found, 291.0.

[0526] Intermediate Example 3: Preparation of 3-(6-(hydroxymethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05566)

[0527] The target compound (GT-05566) (gray solid, 1 g, yield 38.91%) was prepared by referring to the method of Synthesis Scheme 1 or the method of Intermediate Example 1. 1HNMR (400MHz, DMSO) δ11.06 (d, J=31.4Hz, 1H), 7.86 (d, J=19.3Hz, 1H), 7.60 (d, J=7.8Hz, 2H), 5.95 (d, J=8.9Hz, 1H), 5.41 ( t, J=5.7Hz, 1H), 4.82-4.60 (m, 4H), 3.00-2.90 (m, 1H), 2.64 (d, J=17.9Hz, 1H), 2.54 (s, 1H), 2.16-2.05 (m, 1H). LCMS (ESI) C 14 H 15 N2O3S + [M+H]+: Calculated, 291.08 Found, 291.0.

[0528] Intermediate Example 4: Preparation of 3-(5-bromo-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-09531)

[0529] The target compound (GT-09531) was prepared by referring to the method of step 1 of synthesis scheme 1 or the method of intermediate example 1.

[0530] To a solution of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (1.0 eq.) in 1,4-dioxane (20 mL) was added Lawesson's reagent (0.4 eq.). The reaction mixture was stirred at 110°C for 12 hours. TLC confirmed the reaction was complete. The reaction mixture was concentrated, and the residue was purified by column chromatography to afford the title compound (GT-09531) as an off-white solid (yield 48%). 1 H NMR (400MHz, DMSO) δ11.11 (s, 1H), 7.94 (s, 1H), 7.79 (dd, J=23.5, 8.2Hz, 2H), 5.91 (dd, J=12.8, 4.5Hz, 1H), 4.77 (dd, J=52.4, 20.3Hz, 2H), 3.03-2.86 (m, 1H), 2.59 (dd, J=39.1, 11.0Hz, 2H), 2.15-2.03 (m, 1H). LCMS (ESI): [M+H] + ; Calculated value: 338.97; Measured value: 339.0.

[0531] Intermediate Example 5: Preparation of 3-(1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05563)

[0532] XPhos Pd G3 (0.02 eq.) was added to a solution of 3-(5-bromo-1-thioisoindolin-2-yl)piperidine-2,6-dione (1.0 eq.) in 1,4-dioxane (10 mL). The reaction mixture was stirred at 100°C under argon for 3 hours. The reaction mixture was concentrated, and the residue was purified by column chromatography to afford the title compound (GT-05563) as a gray solid (yield 9.5%). 1 H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 7.92 (d, J=7.6Hz, 1H), 7.68 (d, J=3.3Hz, 2H), 7.61-7.53 (m, 1H), 6.145 .80 (m, 1H), 4.77 (dd, J=56.0, 20.0Hz, 2H), 3.042.90 (m, 1H), 2.782.54 (m, 2H), 2.172.05 (m, 1H).LCMS (ESI) C 13 H 13 N2O2S + [M+H] + : Calculated value, 261.07 Measured value, 261.1.

[0533] Intermediate Example 6: Preparation of (2-(2,6-dioxopiperidin-3-yl)-1-thioisoindolin-5-yl)methyl methanesulfonate (GT-09596)

[0534] The target compound GT-09596 (343 mg, crude product, yield 112%) was prepared according to the method of synthesis scheme II-2. LCMS (ESI) C 15 H 17 N2O5S2 + [M+H] + : Calculated value 369.06, measured value 369.1.

[0535] Intermediate Example 7: Preparation of (2-(2,6-dioxopiperidin-3-yl)-1-thioisoindolin-4-yl)methyl methanesulfonate (GT-09597)

[0536] The target compound GT-09597 (500 mg, crude product, yield 120%) was prepared according to the method of synthesis scheme II-2. LCMS (ESI) C 15 H 17 N2O5S2 + [M+H] + : Calculated value 369.06, measured value 369.1.

[0537] Intermediate Example 8: Preparation of (2-(2,6-dioxopiperidin-3-yl)-3-thioisoindolin-5-yl)methyl methanesulfonate (GT-09598)

[0538] The target compound GT-09598 (190 mg, crude product, yield 115%) was prepared according to the method of synthesis scheme II-2. LCMS (ESI) C 15 H 17 N2O5S2 + [M+H] + : Calculated value 369.06, measured value 369.1.

[0539] Example 1: Preparation of 3-(5-((4-diphenylmethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05104)

[0540] The target compound GT-05104 (23 mg, white solid, yield 24%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 10.57 (s, 1H), 7.10 (d, J=7.9Hz, 1H), 7.85 (s, 1H), 7.72 (d, J=8 .0Hz, 1H), 7.51-7.40 (m, 3H), 7.38-7.25 (m, 5H), 7.24-7.18 (m, 2H), 5.95 (d, J=9.0Hz, 1H), 4.85 (d, J =20.4Hz, 1H), 4.7l (d, J = 20.3Hz, 1H), 4.54-4.35 (m, 2H), 3.34-3.27 (m, 3H), 3.20-3.08 (m, 3H), 2.96 -2.93(m,2H),2.84-276(m,2H),2.71-2.60(m,1H),2.33-2.25(m,2H),2.15-2.02(m,1H).LCMS(ESI)C 31 H 33 N4O2S + [M+H] + : Calculated value 525.23, measured value 525.3.

[0541] Example 2: Preparation of 3-(5-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05103)

[0542] The target compound GT-05103 (24 mg, white solid, yield 25%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.10 (s, 1H), 10.99 (s, 1H), 8.64 (d, J=4.2Hz, 1H), 8.08-7.95 (m, 1H), 7.88 (t, J=6.5Hz, 1H), 7.82 (s, 1H), 7.76 (d, J=7.1Hz, 1H), 7.70 (d, J=7.6Hz, 1H), 7.53 (d, J=7.2Hz, 2H), 7 .48(s, 1H), 7.38(t, J=7.3Hz, 3H), 7.35-7.27(m, 1H), 5.33-5.26(m, 1H), 4.51-4.39(m, 2H), 3.40-3 .14(m, 6H), 3.02-2.75(m, 5H), 2.71-2.58(m, 2H), 2.17-2.09(m, 1H), 1.38-1.43(m, 1H).LCMS(ESI)C 30 H 32 N5O2S + [M+H] + : Calculated value 526.23, measured value 526.2.

[0543] Example 3: Preparation of 3-(5-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05106)

[0544] The target compound GT-05106 (13 mg, white solid, yield 13%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 9.8l (s, 1H), 7.97 (d, J = 8.0Hz, 1H), 7.80 (s, 1H), 7.68 (d, J = 7.9Hz , 1H), 7.29 (t, J=7.9Hz, 4H), 7.01 (t, J=7.3Hz, 2H), 6.81 (d, J=7.7Hz, 4H), 5.95 (d, J=9.0Hz, 1H), 4.86 (d , J=20.2Hz, 1H), 4.73 (d, J=20.0Hz, 1H), 4.39 (d, J=4.2Hz, 2H), 4.26-4.19 (m, 1H), 3.43-3.40 (m, 3H), 3. 20-3.17(m, 3H), 2.99-2.93(m, 1H), 2.67-2.63(m, 1H), 2.10-2.07(m, 3H), 1.62-1.59(m, 1H).LCMS(ESI)C 31 H 33 N4O2S +[M+H] + : Calculated value 525.23, measured value 525.2.

[0545] Example 4: Preparation of 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05151)

[0546] The target compound GT-05151 (18 mg, white solid, yield 17%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 7.99-7.87 (m, 1H), 7.83-7.55 (m, 2H), 7.42 (d, J=8.0 Hz, 2H), 7.11 (d, J=8.0Hz, 2H), 5.97-5.93 (m, 1H), 4.83 (d, J=21.2Hz, 1H), 4.70 (d, J=19.4H z, 1H), 3.27-3.19 (m, 4H), 3.10-3.06 (m, 2H), 2.98-2.89 (m, 2H), 2.70-2.62 (m, 2H), 2.35-2 .18(m, 4H), 2.15-2.06(m, 2H), 2.01(brs, 3H), 1.46-1.42(m, 3H), 0.95(s, 6H).LCMS(ESI)C 33 H 40 ClN4O2S + [M+H] + : Calculated value 591.26, measured value 591.3.

[0547] Example 5: Preparation of 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05109)

[0548] The target compound GT-05109 (18 mg, white solid, yield 19%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 10.18 (s, 1H), 8.02-7.95 (m, 1H), 7.76-7.72 (m, 1H), 7.50-7.46 (m, 3H ), 7.40-7.38(m, 2H), 7.22-7.14(m, 1H), 6.99(dd, J=7.5, 1.5Hz, 1H), 6.85-6.76(m, 1H), 6.71-6.69(m, 1H), 5.98-5.95 (m, 1H), 4.88 (d, J = 20.2Hz, 1H), 4.74 (d, J = 20.6Hz, 1H), 4.42 (d, J = 4.5Hz, 2H), 3.31-3.28 (m, 2H) , 3.00-2.94(m, 4H), 2.67-2.61(m, 2H), 2.11-2.05(m, 3H), 2.01-1.93(m, 1H), 1.67-1.50(m, 2H).LCMS(ESI)C 31 H 32 ClN4O2S + [M+H] + : Calculated value 559.19, measured value 559.2.

[0549] Example 6: Preparation of 3-(5-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-04474)

[0550] The target compound GT-04474 (7 mg, white solid, yield 35%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO) δ11.14 (s, 1H), 10.37 (s, 1H), 8.01 (d, J=9.6Hz, 1H), 7.88 (s, 1H), 7.7 7 (t, J=5.8Hz, 1H), 7.41-7.32 (m, 3H), 7.23-7.15 (m, 1H), 6.01-5.93 (m, 1H), 4.89 (d, J=2 0.4Hz, 1H), 4.76 (d, J=19.9Hz, 1H), 4.59 (brs, 2H), 3.54-3.4l (m, 4H), 3.15-3.04 (m, 3H) , 3.00-2.94(m, 1H), 2.67-2.60(m, 2H), 2.59-2.56(m, 2H), 2.14-2.06(m, 1H).LCMS(ESI)C 24 H 25 Cl2N4O2S + [M+H] +: Calculated value 503.11, measured value 503.1.

[0551] Example 7: Preparation of 3-(5-((4-(2,3-dichlorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05149)

[0552] The target compound GT-05149 (9 mg, white solid, yield 10%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ 11.15 (s, 1H), 10.67 (s, 1H), 8.00 (d, J = 7.8Hz, 1H), 7.9l (s, 1H), 7.79 (d, J = 7.9Hz, 1H), 7.63 (d, J=7.9Hz, 1H), 7.40 (t, J=7.8Hz, 1H), 7.25 (dd, J=7.7, 1.5Hz, 1H), 5.97 (d, J=10.3Hz, 1H), 5.75 (s, 1H), 4.89 (d, J = 20.4Hz, 1H), 4.76 (d, J = 20.3Hz, 1H), 4.59 (s, 2H), 3.90-3.75 (m, 2H), 3.66-3.61 (m, 1H), 3.06-2.90(m, 1H), 2.89-2.74(m, 1H), 2.73-2.62(m, 2H), 2.56-2.51(m, 2H), 2.14-2.09(m, 1H).LCMS(ESI)C 25 H 24 Cl2N3O2S + [M+H] + : Calculated value 500.10, measured value 500.1.

[0553] Example 8: Preparation of 3-(5-((4-(2,3-dichlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05150)

[0554] The target compound GT-05150 (4 mg, white solid, yield 4%) was prepared according to the method of Synthesis Scheme 4. LCMS (ESI) C 25 H 26 Cl2N3O2S + [M+H] + : Calculated value 502.11, measured value 502.1.

[0555] Example 9: Preparation of 3-(5-((4-(5-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05110)

[0556] The target compound GT-05110 (16 mg, white solid, yield 19%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 9.44 (brs, 1H), 7.98-7.94 (m, 1H), 7.92-7.86 (m, 1H), 7.86-7.82(m, 1H), 7.82-7.70(m, 1H), 5.98-5.93(m, 1H), 4.86(d, J=20.4Hz, 1H), 4 .72(d, J=20.2Hz, 1H), 4.63(s, 1H), 3.37-3.32(m, 4H), 3.28-3.12(m, 3H), 3.03-2.91(m , 2H), 2.68-2.63(m, 2H), 2.57-2.54(m, 1H), 2.47(s, 3H), 2.14-2.04(m, 1H).LCMS(ESI)C 23 H 27 N4O2S2 + [M+H] + : Calculated value 455.16, measured value 455.2.

[0557] Example 10: Preparation of 3-(5-((4-(4-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05113)

[0558] The target compound GT-05113 (27 mg, white solid, yield 32%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.11 (s, 1H), 7.96-7.88 (m, 2H), 7.84 (d, J=7.9Hz, 1H), 7.13 (d, J=2.3Hz, 1H), 6.82 (d, J=3.2Hz, 1H), 4.63-4.55 (m, 2H ), 3.42-3.39(m, 2H), 3.32-3.21(m, 5H), 3.05-2.99(m, 3H), 2.93-2.76(m, 2H), 2.64-2.60(m, 2H), 2.21-2.15(m, 1H), 2.10(s, 3H).LCMS(ESI)C 23 H 27 N4O2S2 +[M+H] + : Calculated value 455.16, measured value 455.2.

[0559] Example 11: Preparation of 3-(5-((4-(5-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05112)

[0560] The target compound GT-05112 (23 mg, white solid, yield 27%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 10.25 (s, 1H), 7.99 (d, J=7.8Hz, 1H), 7.88 (s, 1H) , 7.75 (d, J = 7.9Hz, 1H), 6.69-6.59 (m, 2H), 5.96 (d, J = 11.7Hz, 1H), 4.88 (d, J = 20.4Hz, 1 H), 4.75 (d, J=20.3Hz, 1H), 4.46 (d, J=4.5Hz, 2H), 3.43 (d, J=11.8Hz, 2H), 3.15-2.91 (m , 5H), 2.67-2.63(m, 2H), 2.38(s, 3H), 2.10-2.08(m, 3H), 1.97-1.81(m, 2H).LCMS(ESI)C 24 H 28 N3O2S2 + [M+H] + : Calculated value 454.16, measured value 454.1.

[0561] Example 12: Preparation of 3-(5-((4-(4-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05146)

[0562] The target compound GT-05146 (4 mg, white solid, yield 5%) was prepared by referring to the method of Synthesis Scheme 4. LCMS (ESI) C 24 H 28 N3O2S2 + [M+H] + : Calculated value 454.16, measured value 454.1.

[0563] Example 13: Preparation of 3-(5-((4-(furan-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05148)

[0564] The target compound GT-05148 (5 mg, white solid, yield 6%) was prepared by referring to the method of Synthesis Scheme 4. LCMS (ESI) C 23 H 26 N3O3S + [M+H] + : Calculated value 424.17, measured value 424.2.

[0565] Example 14: Preparation of 3-(5-((4-(5-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05111)

[0566] The target compound GT-05111 (24 mg, white solid, yield 29%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 10.55 (s, 1H), 7.99 (d, J=7.8Hz, 1H), 7.89 (s, 1H), 7.76 (d, J=8.0 Hz, 1H), 6.95 (d, J=3.4Hz, 1H), 6.74 (d, J=2.4Hz, 1H), 5.97 (d, J=15.9Hz, 1H), 5.90 (s, 1H), 4.88 (d, J=2 0.4Hz, 1H), 4.75 (d, J=20.3Hz, 1H), 4.574.51 (m, 2H), 3.803.75 (m, 2H), 3.61-3.58 (m, 1H), 3.29-3.20 ( m, 1H), 2.97-2.93 (m, 1H), 2.77 (s, 2H), 2.71-2.58 (m, 2H), 2.41 (s, 3H), 2.15-2.03 (m, 1H). LCMS (ESI) C 24 H 26 N3O2S2 + [M+H] + : Calculated value 452.15, measured value 452.2.

[0567] Example 15: Preparation of 3-(5-((4-(4-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05145)

[0568] The target compound GT-05145 (3 mg, white solid, yield 4%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 10.52 (s, 1H), 8.00 (d, J=7.9Hz, 1H), 7.90 (s, 1H), 7.78 (d , J=7.7Hz, 1H), 7.44 (d, J=3.1Hz, 1H), 7.20 (s, 1H), 6.04-5.91 (m, 1H), 5.79 (s, 1H), 4.89 (d, J=20 .5Hz, 1H), 4.75 (d, J=20.7Hz, 1H), 4.63-4.49 (m, 2H), 3.86-3.70 (m, 2H), 3.66-3.59 (m, 1H), 3.06 -2.91(m,2H),2.85-2.76(m,1H),2.72-2.51(m,4H),2.23(s,3H),2.13-2.07(m,1H).LCMS(ESI)C 24 H 26 N3O2S2 + [M+H] + : Calculated value 452.15, measured value 452.1.

[0569] Example 16: Preparation of 3-(5-((4-(furan-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05147)

[0570] The target compound GT-05147 (14 mg, white solid, yield 19%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.15 (s, 1H), 10.65 (s, 1H), 7.99 (d, J=8.0Hz, 1H), 7.90 (s, 1H), 7.7 8(d, J=7.9Hz, 1H), 7.68(s, 1H), 6.59-6.48(m, 2H), 6.09(s, 1H), 5.99-5.91(m, 1H), 4.88(d, J=20.1Hz, 1H), 4.75(d, J=20.5Hz, 1H), 4.66-4.48(m, 2H), 3.86-3.71(m, 2H), 3.67-3.63(m, 1H), 3.05-2.89(m, 2H), 2.78-2.65(m, 3H), 2.63-2.57(m, 1H), 2.13-2.09(m, 1H).LCMS(ESI)C 23 H 24 N3O3S + [M+H] + : Calculated value 422.15, measured value 422.2.

[0571] Example 17: Preparation of 3-(5-((3-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptane-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05182)

[0572] The target compound GT-05182 (16 mg, white solid, yield 17%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 8.007.93 (m, 1H), 7.907.87 (m, 1H), 7.83 (d, J=8.4Hz, 1H) ,7.79-7.71(m,1H),7.45-7.33(m,2H),5.98-5.94(m,1H),4.92-4.66(m,3H),4.60-4.42(m,1H), 4.36 (d, J=5.8Hz, 1H), 3.91 (d, J=12.7Hz, 1H), 3.78-3.75 (m, 2H), 3.25-3.15 (m, 1H), 3.07-2.95 (m, 2H), 2.72-2.54 (m, 2H), 2.41-2.39 (m, 1H), 2.35-2.28 (m, 1H), 2.17-2.02 (m, 1H).LCMS (ESI) C 25 H 25 Cl2N4O2S + [M+H] + : Calculated value 515.11, measured value 515.1.

[0573] Example 18: Preparation of 3-(5-(((1S,4S)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05183)

[0574] The target compound GT-05183 (18 mg, white solid, yield 19%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 9.93 (s, 1H), 7.98-7.92 (m, 2H), 7.83-7.78 (m, 1H), 7.19-7.17 (m, 1H), 7.12-7.10 (m, 1H), 6.97 (d, J=8.6Hz, 1H), 6.02-5.89 (m, 1H), 4.87-4.74 (m, 1H), 4.71 (brs, 1H), 4.54 (brs, 1H), 4.48-4.43 (m, 1H), 4.40 (brs, 1H), 3.97-3.90 (m, 1H), 3.71-3.55 (m, 2H), 3.26-3.19 (m, 3H), 3. 04-2.91(m, 1H), 2.68-2.66(m, 1H), 2.63-2.56(m, 2H), 2.19-2.16(m, 1H), 2.14-2.03(m, 1H).LCMS(ESI)C 25 H 25 Cl2N4O2S + [M+H] + : Calculated value 515.11, measured value 515.1.

[0575] Example 19: Preparation of 3-(5-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05089)

[0576] The target compound GT-05089 (35 mg, white solid, yield 38%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.15 (s, 1H), 8.15 (brs, 1H), 8.04-7.91 (m, 2H), 7.86-7.82 (m, 1H), 7.72 (dd, J=9. 0, 2.0Hz, 1H), 7.34 (td, J=9.1, 2.0Hz, 1H), 5.96 (d, J=13.1Hz, 1H), 4.90 (d, J=20.5Hz, 1H), 4.78 (d, J=20.5 Hz, 1H), 4.63 (s, 1H), 4.52 (d, J=4.5Hz, 2H), 3.55 (d, J=11.1Hz, 2H), 3.48-3.42 (m, 1H), 3.17-3.13 (m, 2H), 3.06-2.86(m, 1H), 2.67-2.63(m, 2H), 2.67-2.58(m, 1H), 2.33-2.30(m, 1H), 2.15-2.03(m, 1H).LCMS(ESI)C 26 H26 FN4O3S + [M+H] + : Calculated value 493.17, measured value 493.2.

[0577] Example 20: Preparation of 3-(5-((4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05243)

[0578] The target compound GT-05243 (10 mg, white solid, yield 14%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.15 (s, 1H), 10.95 (s, 1H), 10.22 (s, 1H), 8.01 (d, J=8.0Hz, 1H), 7.91 (s, 1H), 7.78 (d, J=8.2Hz, 1H), 7.68-7.59 (m, 1H), 7.14-7.09 (m, 2H), 6.84 (t, J=8.1Hz, 1H), 5.98-5.9 5 (m, 1H), 4.90 (d, J = 20.3Hz, 1H), 4.76 (d, J = 20.0Hz, 1H), 4.50 (d, J = 4.3Hz, 2H), 3.48 (d, J = 9.8Hz, 2H), 3.16-3.10(m, 3H), 3.04-2.95(m, 3H), 2.65(d, J=15.4Hz, 2H), 2.16-2.01(m, 3H).LCMS(ESI)C 27 H 28 FN4O2S + [M+H] + : Calculated value 491.19, measured value 491.2.

[0579] Example 21: Preparation of 3-(5-((4-(5-fluoroindolin-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05244)

[0580] The target compound GT-05244 (8 mg, white solid, yield 9%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 10.51 (s, 1H), 7.98 (d, J = 8.0Hz, 1H), 7.90 (s, 1H), 7.76 (d, J = 8.2Hz, 1H), 6.90 (d, J=6.5Hz, 1H), 6.79 (t, J=9.1Hz, 1H), 6.47 (dd, J=8.6, 4.3Hz, 1H), 5.99-5.92 (m, 1H), 4.88 (d, J=20.4Hz, 1H), 4.75 (d, J=20.4Hz, 1H), 4.44 (d, J=4.7Hz, 2H), 3.68-3.60 (m, 1H), 3.28 (t, J=8.3Hz, 3H), 3.05-2.94 (m, 3H) , 2.87(t, J=8.3Hz, 2H), 2.67-2.63(m, 2H), 2.14-2.08(m, 2H), 2.02-1.94(m, 2H), 1.84-1.81(m, 2H).LCMS(ESI)C 27 H 30 FN4O2S + [M+H] + : Calculated value 493.21, measured value 493.2.

[0581] Example 22: Preparation of 3-(5-((4-(7-fluoroquinolin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05245)

[0582] The target compound GT-05245 (7 mg, white solid, yield 8%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.34 (s, 1H), 11.15 (s, 1H), 8.98 (d, J=4.6Hz, 1H), 8.41-8.31 (m, 1H), 8.02 (d, J= 3.2Hz, 1H), 8.01-7.93 (m, 1H), 7.91-7.81 (m, 2H), 7.66-7.55 (m, 1H), 7.46 (d, J=4.4Hz, 1H), 5.99 (d, J=6.7 Hz, 1H), 5.88 (s, 1H), 4.91 (d, J=20.5Hz, 1H), 4.77 (d, J=20.6Hz, 1H), 4.67-4.63 (m, 2H), 3.87 (brs, 2H), 3 .42-3.41(m, 2H), 3.28-3.13(m, 1H), 3.08-2.91(m, 2H), 2.77-2.61(m, 2H), 2.19-2.05(m, 1H).LCMS(ESI)C 28 H 26 FN4O2S + [M+H] + : Calculated value 501.18, measured value 501.1.

[0583] Example 23: Preparation of 3-(5-((4-(isoquinolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05246)

[0584] The target compound GT-05246 (8 mg, white solid, yield 9%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.12 (s, 1H), 10.35 (s, 1H), 9.69 (s, 2H), 8.92 (d, J = 7.1Hz, 1H), 8.85 (d, J = 6.9Hz , 1H), 8.50 (dd, J=5.8, 3.6Hz, 1H), 8.09 (dd, J=6.5, 2.9Hz, 2H), 7.95 (d, J=8.0Hz, 1H), 7.91 (s, 1H), 7.8l (d , J=8.0Hz, 1H), 6.15 (s, 2H), 5.93 (d, J=8.4Hz, 1H), 5.86 (s, 1H), 4.84 (d, J=20.5Hz, 1H), 4.69 (d, J=20.4Hz , 1H), 3.78(s, 2H), 3.423.39(m, 2H), 3.04-2.88(m, 1H), 2.77-2.60(m, 3H), 2.14-2.02(m, 1H).LCMS(ESI)C 28 H27 N4O2S + [M+H] + : Calculated value 483.18, measured value 483.2.

[0585] Example 24: Preparation of 3-(5-((4-(6-fluoro-1-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05247)

[0586] The target compound GT-05247 (9 mg, white solid, yield 10%) was prepared by referring to the method of Synthesis Scheme 4. LCMS (ESI) C 28 H 28 FN4O2S + [M+H] + : Calculated value 503.19, measured value 503.2.

[0587] Example 25: Preparation of 3-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05248)

[0588] The target compound GT-05248 (7 mg, white solid, yield 8%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.89 (s, 1H), 11.15 (s, 1H), 10.47 (s, 1H), 8.24 (t, J=6.6Hz, 2H), 8.01 (d, J=7. 7Hz, 1H), 7.91 (s, 1H), 7.79 (d, J=7.9Hz, 1H), 7.68 (s, 1H), 7.13 (dd, J=8.0, 4.8Hz, 1H), 6.18 (s, 1H), 6.0 2-5.95 (m, 1H), 4.90 (d, J = 20.7Hz, 1H), 4.76 (d, J = 19.7Hz, 1H), 4.674.54 (m, 2H), 3.86-3.81 (m, 2H), 3.6 9-3.66(m, 1H), 2.99-2.97(m, 2H), 2.88-2.84(m, 2H), 2.69-2.67(m, 1H), 2.13-2.06(m, 2H).LCMS(ESI)C 26 H 26 N5O2S + [M+H] + : Calculated value 472.18, measured value 472.2.

[0589] Example 26: Preparation of 3-(5-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05091)

[0590] The target compound GT-05091 (38 mg, white solid, yield 43%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ 11.15 (s, 1H), 11.04 (s, 1H), 8.11 (t, J = 8.0Hz, 2H), 8.00 (d, J = 7.9Hz, 1H), 7. 94 (s, 1H), 7.80 (d, J=7.8Hz, 1H), 7.59 (t, J=7.7Hz, 1H), 7.47 (dd, J=14.1, 7.0Hz, 1H), 5.97 (d, J=7.5H z, 1H), 4.89 (d, J = 20.4Hz, 1H), 4.76 (d, J = 20.9Hz, 1H), 4.58 (brs, 2H), 4.08 (d, J = 12.9Hz, 2H), 3.48- 3.42(m, 4H), 3.06-2.88(m, 2H), 2.67-2.61(m, 2H), 2.57-2.53(m, 1H), 2.15-2.01(m, 1H).LCMS(ESI)C 25 H 26 N5O2S2 + [M+H] + : Calculated value 492.15, measured value 492.1.

[0591] Example 27: Preparation of 3-(5-((4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05088)

[0592] The target compound GT-05088 (39 mg, white solid, yield 43%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ 11.16 (s, 1H), 10.94 (s, 1H), 8.0l (d, J = 7.9Hz, 1H), 7.96 (s, 1H), 7.82 (d, J = 8.1Hz, 1H), 7.76 (d, J=5.5Hz, 1H), 7.70 (d, J=8.1Hz, 1H), 7.48 (d, J=5.5Hz, 1H), 7.31 (t, J=7.8Hz, 1H), 6.96 (d, J=7.6Hz, 1H), 5.97 (d , J=8.2Hz, 1H), 4.90 (d, J=20.4Hz, 1H), 4.76 (d, J=20.3Hz, 1H), 4.60 (d, J=4.5Hz, 2H), 3.59-3.51 (m, 4H), 3.41-3.38 (m, 2H), 3.22-3.16 (m, 2H), 3.05-2.90 (m, 1H), 2.67-2.59 (m, 1H), 2.59-2.51 (m, 1H), 2.17-2.04 (m, 1H). LCMS (ESI) C 26 H 27 N4O2S2 + [M+H] + : Calculated value 491.16, measured value 491.2.

[0593] Example 28: Preparation of 3-(5-((4-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05092)

[0594] The target compound GT-05092 (38 mg, white solid, yield 36%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 10.84 (s, 1H), 8.00 (d, J = 7.9Hz, 1H), 7.94 (s, 1H), 7.81 (d, J = 8.0Hz, 1H), 7.32 (d, J = 7 .8Hz, 1H), 7.23 (s, 1H), 7.20-7.13 (m, 2H), 7.10 (d, J=8.0Hz, 1H), 7.02-6.89 (m, 1H), 6.41 (d, J=7.6Hz, 1H), 5.97 (d, J=8.1Hz , 1H), 4.90 (d, J=20.4Hz, 1H), 4.76 (d, J=20.4Hz, 1H), 4.58 (d, J=4.1Hz, 2H), 3.49-3.46 (m, 2H), 3.41-3.39 (m, 2H), 3.28-3.1 0(m,5H),3.03-2.89(m,1H),2.68-2.63(m,1H),2.59-2.56(m,1H),2.32(s,3H),2.23(s,3H),2.14-2.07(m,1H).LCMS(ESI)C 32 H 35 N4O2S2 + [M+H] + : Calculated value 571.22, measured value 571.2.

[0595] Example 29: Preparation of 3-(1-thioxo-5-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione (GT-05090)

[0596] The target compound GT-05090 (30 mg, white solid, yield 35%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.12 (s, 1H), 7.90 (d, J=7.9Hz, 1H), 7.70 (s, 1H), 7.58 ( d, J=8.0Hz, 1H), 5.96 (d, J=8.9Hz, 1H), 4.83 (d, J=20.1Hz, 1H), 4.69 (d, J=20.2H z, 1H), 4.19 (t, J=5.4Hz, 2H), 3.98 (d, J=5.4Hz, 4H), 3.02-2.97 (m, 2H), 2.96-2. 92(m, 1H), 2.67-2.62(m, 1H), 2.51-2.49(m, 1H), 2.15-2.01(m, 1H).LCMS(ESI)C 20 H 20F3N6O2S + [M+H] + : Calculated value 465.13, measured value 465.1.

[0597] Example 30: Preparation of 3-(5-((6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05093)

[0598] The target compound GT-05093 (27 mg, white solid, yield 35%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 11.03 (s, 1H), 7.99 (d, J=7.9Hz, 1H), 7.93 (s, 1H), 7.81 (s, 1H), 7 .46 (d, J=5.0Hz, 1H), 6.89 (d, J=5.0Hz, 1H), 5.97 (d, J=7.6Hz, 1H), 4.89 (d, J=20.2Hz, 1H), 4.75 (d, J=2 0.8Hz, 1H), 4.72-4.51(m, 2H), 4.22(brs, 2H), 3.82-3.76(m, 1H), 3.47-3.40(m, 2H), 3.15(t, J=16.4Hz , 2H), 3.06-2.90 (m, 1H), 2.65 (d, J=17.0Hz, 1H), 2.57 (d, J=12.3Hz, 1H), 2.21-1.99 (m, 1H).LCMS (ESI) C 21 H 22 N3O2S2 + [M+H] + : Calculated value 412.11, measured value 412.1.

[0599] Example 31: Preparation of 3-(6-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05041)

[0600] The target compound GT-05041 (8 mg, white solid, yield 8%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 8.66 (d, J = 4.1Hz, 1H), 8.04-8.00 (m, 1H), 7.91 (d, J = 7.7Hz, 1H), 7.78 -7.70 (m, 2H), 7.68 (t, J=7.6Hz, 1H), 7.55 (d, J=7.3Hz, 2H), 7.49 (d, J=11.5Hz, 1H), 7.39 (t, J=7.4Hz, 2H), 7 .33 (d, J=7.1Hz, 1H), 5.43-5.34 (m, 1H), 4.88 (d, J=20.6Hz, 1H), 4.73 (d, J=19.9Hz, 1H), 4.53-4.50 (m, 2H), 3.39-3.27(m, 4H), 3.25-3.21(m, 3H), 3.01-2.94(m, 4H), 2.14-1.99(m, 1H), 1.36-1.33(m, 1H).LCMS(ESI)C 30 H 32 N5O2S + [M+H] + : Calculated value 526.23, measured value 526.3.

[0601] Example 32: Preparation of 3-(6-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05033)

[0602] The target compound GT-05033 (17 mg, white solid, yield 19%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 10.42 (brs, 1H), 8.17 (s, 1H), 7.90 (d, J=6.9Hz, 1H), 7.79 (d, J=7.9Hz, 1H), 7.39-7.33 (m, 2H), 7.20 (d, J=7.0Hz, 1H), 6.02-5.89 (m, 1H ), 4.89 (d, J = 20.2Hz, 1H), 4.75 (d, J = 20.8Hz, 1H), 4.6l (brs, 2H), 3.45-3.40 (m, 4H), 3 .11-3.02(m,3H),2.98-2.94(m,2H),2.68-2.61(m,2H),2.15-2.02(m,1H).LCMS(ESI)C 24 H 25 Cl2N4O2S + [M+H] + : Calculated value 503.11, measured value 503.1.

[0603] Example 33: Preparation of 3-(6-((4-(3-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05032)

[0604] The target compound GT-05032 (17 mg, white solid, yield 20%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 10.37 (s, 1H), 8.17 (s, 1H), 7.88 (d, J=7.8Hz, 1H), 7.79 ( d, J=7.7Hz, 1H), 7.40 (d, J=5.1Hz, 1H), 6.92 (d, J=5.0Hz, 1H), 6.02-5.90 (m, 1H), 5.85 (s, 1H), 4.83(dd, J=57.9, 20.3Hz, 2H), 4.66-4.52(m, 2H), 3.83-3.74(m, 2H), 3.67-3.53(m, 1H), 3.04- 2.89(m, 2H), 2.86-2.73(m, 2H), 2.73-2.61(m, 3H), 2.24(s, 3H), 2.16-2.05(m, 1H).LCMS(ESI)C 24 H 26 N3O2S2 + [M+H] + : Calculated value 452.15, measured value 452.1.

[0605] Example 34: Preparation of 3-(6-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05031)

[0606] The target compound GT-05031 (9 mg, white solid, yield 10%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.13 (s, 1H), 10.14 (s, 1H), 8.16 (s, 1H), 8.13-8.04 (m, 1H), 7.89 (d, J= 8.0Hz, 1H), 7.80 (d, J=7.8Hz, 1H), 7.77-7.67 (m, 1H), 7.34 (t, J=9.4Hz, 1H), 5.98-5.94 (m, 1H), 4 .90 (d, J=20.3Hz, 1H), 4.76 (d, J=19.9Hz, 1H), 4.57-4.51 (m, 2H), 3.61-3.50 (m, 2H), 3.19-3.10 (m, 2H), 2.97-2.92 (m, 1H), 2.68-2.61 (m, 2H), 2.37-2.24 (m, 3H), 2.21-2.03 (m, 3H).LCMS (ESI) C 26 H 26 FN4O3S + [M+H] + : Calculated value 493.17, measured value 493.2.

[0607] Example 35: Preparation of 3-(6-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05040)

[0608] The target compound GT-05040 (6 mg, white solid, yield 7%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.14 (s, 1H), 8.17-8.10 (m, 3H), 7.86-7.82 (m, 2H), 7.60 (t , J=7.7Hz, 1H), 7.47 (t, J=7.3Hz, 1H), 6.01-5.95 (m, 1H), 4.90 (d, J=20.1Hz, 1H), 4. 76 (d, J=20.2Hz, 1H), 4.63 (brs, 2H), 4.12 (d, J=12.0Hz, 2H), 3.52-3.46 (m, 3H), 3.1 0-2.84(m, 2H), 2.74-2.57(m, 2H), 2.15-2.09(m, 2H), 1.41-1.26(m, 1H).LCMS(ESI)C 25 H 26 N5O2S2 + [M+H] + : Calculated value 492.15, measured value 492.2.

[0609] Example 36: Preparation of 3-(6-((4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05035)

[0610] The target compound GT-05035 (20 mg, white solid, yield 24%) was prepared by referring to the method of Synthesis Scheme 4. 1 H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 8.18 (s, 1H), 7.92 (d, J=7.0Hz, 1H), 7.81 (d, J=7.9Hz, 1H), 7.77 (d, J=5. 5Hz, 1H), 7.71 (d, J=8.0Hz, 1H), 7.50 (d, J=5.6Hz, 1H), 7.31 (t, J=7.9Hz, 1H), 6.96 (d, J=7.6Hz, 1H), 6.02-5.9 3 (m, 1H), 4.90 (d, J = 20.9Hz, 1H), 4.76 (d, J = 20.4Hz, 1H), 4.64 (d, J = 4.7Hz, 2H), 3.57 (d, J = 12.7Hz, 2H), 3.46 ( t, J=9.8Hz, 4H), 3.13 (d, J=11.8Hz, 2H), 3.04-2.91 (m, 1H), 2.67-2.57 (m, 2H), 2.19-2.03 (m, 1H). LCMS (ESI) C 26 H 27 N4O2S2 + [M+H] + : Calculated value 491.16, measured value 491.2.

[0611] Example 37: Preparation of 3-(6-((4-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione (GT-05038)

[0612] The target compound GT-05038 (17 mg, white solid, yield 16%) was prepared by referring to the method of Synthesis Scheme 4. 1H NMR (400MHz, DMSO-d6) δ11.16 (s, 1H), 10.31 (s, 1H), 7.90 (d, J = 7.0Hz, 1H), 7.80 (d, J = 8.0Hz, 1H), 7.3 3(d, J=7.8Hz, 1H), 7.24 (s, 1H), 7.13 (dd, J=17.0, 6.2Hz, 4H), 7.02-6.93 (m, 1H), 6.40 (d, J=8.1Hz, 1H ), 4.90 (d, J = 20.8Hz, 1H), 4.76 (d, J = 20.6Hz, 1H), 4.65-4.60 (m, 2H), 3.54-3.39 (m, 4H), 3.15-3.09 (m , 3H), 3.01-2.90(m, 1H), 2.64-2.61(m, 1H), 2.32(s, 3H), 2.23(s, 3H), 2.15-2.03(m, 1H).LCMS(ESI)C 32 H 35 N4O2S2 + [M+H] + : Calculated value 571.22, measured value 571.2.

[0613] Example 38: Preparation of 3-(6-((6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methyl)-1-thioisoindolin-2-...

Claims

1. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof, in Z1 represents C(O), C(S), CH2 or CD2, Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); R a1 、R a2 、R a3 and R a4 Each independently represents hydrogen, deuterium, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy or halogenated C 1-6 alkoxy; (R a5 ) m represents that the isoindoline ring connected thereto is optionally replaced by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, or C 2-6 Alkynyl; m represents an integer 0, 1, 2 or 3; R represents O, S, S(O), S(O)2, alkenylene, alkynylene or N(R a6 ), where R a6 Indicates H or C 1-3 Alkyl, or R represents a bond; or R stands for: Among them, each ring A 1 are the same or different and each independently represent a nitrogen-containing heterocyclic group, an arylene group or a heteroarylene group, y1 represents an integer of 1 or 2, (R y1 ) a1 Represents each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; Each ring A 2 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, y2 represents an integer of 0 or 1, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; L means: where R w1 Connect R, R w2 Connect X; R w2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl; Each ring A 3 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; Each ring A 4 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y4 represents an integer of 0, 1, 2 or 3, (R y4 ) a4 Represents each ring A 4 Independently optionally by a4 R y4 Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a4 represents an integer of 0-20; Each ring A 5 are the same or different and each independently represent a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, y5 represents an integer of 0, 1, 2 or 3, (R y5 ) a5 Represents each ring A 5 Independently optionally a5 R y5 Group substitution, each R y5 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a5 represents an integer of 0-20; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1- 20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof; X means: NR1R2, C(O)NR3R4, NHC(O)R5, NHC(O)NR6R7, OR8, SR9, S(O)2NR 10 R 11 or N(R 12 )S(O)2R 13 , where R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, and wherein R2, R8 and R 13 each independently represents an optionally substituted straight-chain or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclyl group or an optionally substituted heteroaryl group, or wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 30-membered nitrogen-containing heterocyclyl group; or wherein ring A represents a heterocyclylene group, a cycloalkylene group, an arylene group or a heteroarylene group, (R d1 ) n1 Indicates that ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1- 6 alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20; R c Indicates NR c1 、C(O),CR c2 R c3 or key, where R c1 represents H, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclic group or an optionally substituted heteroaryl group, R c2 and R c3 each independently represents H, halogen, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocyclyl group, or an optionally substituted heteroaryl group; Each ring B is the same or different and independently represents a heterocyclylene group, a cycloalkylene group, an arylene group, or a heteroarylene group, m1 represents an integer of 0, 1, 2 or 3, (R d2 ) n2 Indicates that each ring B is independently optionally substituted with n2 R d2 Group substitution, each R d2 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20; R e Indicates S, O, CR e1 R e2 or key, where R e1 and R e2 each independently represents H, halogen, optionally substituted linear or branched alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; and Each ring C is the same or different and independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group, m2 represents an integer of 0, 1, 2 or 3, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Each independently represents deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer from 0 to 20; or Where -X1-X2- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2)1-5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-; p1, p2, p3 each independently represent an integer of 1, 2, 3 or 4; and The ring containing -X1-X2- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 Alkenyl or any combination thereof; or Where -X3-X4- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1- 5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-; p4, p5 each independently represent an integer of 1, 2, 3 or 4; and The benzo-fused ring containing -X3-X4- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1- 6 alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

2. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein (i)R a1 、R a2 、R a3 and R a4 Each independently represents H; and / or (ii) Z1 represents C(O), C(S), CH2 or CD2, Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least two of Z1, Z2, Z3 and Z4 represent C(S); or At least three of Z1, Z2, Z3 and Z4 represent C(S); or Z1, Z2, Z3 and Z4 all represent C(S); and / or (iii) R represents O, S, S(O), S(O)2, C 2-6 Alkenylene, C 2-6 Alkynylidene or N(R a6 ), where R a6 Indicates H or C 1-3 Alkyl; preferably, R represents O, S, S(O), S(O)2, C 2-4 Alkenylene, C 2-4 Alkynylidene or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl; or R represents a bond; or R stands for: Among them, each ring A 1 are the same or different and each independently represent a 4- to 30-membered nitrogen-containing heterocyclic group, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably, 4 to 20 membered nitrogen-containing heterocyclic group, C 5-20 arylene or 5 to 20 membered heteroarylene; or more preferably, 4 to 15 membered nitrogen-containing heterocyclic group, C 5-15 arylene or 5- to 15-membered heteroarylene), y1 represents an integer of 1 or 2, (R y1 ) a1 Represents each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0-20; Each ring A 2 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably, 4 to 20 membered heterocyclylene, C 3-20 Cycloalkylene, C 5-20 arylene or 5 to 20 membered heteroarylene; or more preferably, 4 to 15 membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y2 represents an integer of 0 or 1, (R y2 ) a2 Represents each ring A 2 Each independently optionally represented by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; and / or (iv) L represents: where R w1 Connect R, R w2 Connect X; R w2 represents a bond, C(O), C(O)NH, NHC(O), or N(R a6 ), where R a6 Indicates H or C 1-3 alkyl; Each ring A 3 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably, 4 to 20 membered heterocyclylene, C 3-20 Cycloalkylene, C 5-20 arylene or 5 to 20 membered heteroarylene; or more preferably, 4 to 15 membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y3 represents an integer of 0, 1, 2 or 3, (R y3 ) a3 Represents each ring A 3 Independently optionally a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; Each ring A 4 are the same or different and each independently represent a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably, 4 to 20 membered heterocyclylene, C 3-20 Cycloalkylene, C 5-20 arylene or 5 to 20 membered heteroarylene; or more preferably, 4 to 15 membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y4 represents an integer of 0, 1, 2 or 3, (R y4 ) a4 Represents each ring A 4 Independently optionally by a4 R y4 Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a4 represents an integer of 0-20; Each ring A 5 The same or different and each independently represents a 4 to 30-membered heterocyclylene group, a C 3-30 Cycloalkyl, C 5-30 Arylene or 5 to 30 membered heteroarylene (preferably, 4 to 20 membered heterocyclylene, C 3-20 Cycloalkylene, C 5-20 arylene or 5 to 20 membered heteroarylene; or more preferably, 4 to 15 membered heterocyclylene, C 3-15 Cycloalkylene, C 5-15 arylene or 5- to 15-membered heteroarylene), y5 represents an integer of 0, 1, 2 or 3, (R y5 ) a5 Represents each ring A 5 Independently optionally a5 R y5 Group substitution, each R y5 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a5 represents an integer of 0-20; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 Alkylene, wherein the linear or branched C 1- 20 Any one or more methylene groups of the main carbon chain skeleton of the alkylene group may be optionally replaced by one or more groups selected from the following: a 、R b and any combination thereof, each group R a Each independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl, and when the linear or branched C 1-20 Any two or more methylene groups of the main carbon chain skeleton of the alkylene group are replaced by two or more groups R a When substituted, each group R a Not directly connected to each other; each group R b are each independently selected from optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 arylene, an optionally substituted 4- to 30-membered heterocyclylene, an optionally substituted 5- to 30-membered heteroarylene, C 2-6 Alkenylene or C 2-6 Alkyne (preferably, optionally substituted C 3-20 Cycloalkylene, optionally substituted C 5-20 arylene, an optionally substituted 4- to 20-membered heterocyclylene, an optionally substituted 5- to 20-membered heteroarylene, C 2-4 Alkenylene or C 2-4 Alkynylidene; or more preferably, optionally substituted C 3-15 Cycloalkylene, optionally substituted C 5-15 Arylene, an optionally substituted 4- to 15-membered heterocyclylene group, an optionally substituted 5- to 15-membered heteroarylene group, a C 2-4 Alkenylene or C 2-4 alkynylene) or any combination thereof; and / or (v) X represents: NR1R2, C(O)NR3R4, NHC(O)R5, NHC(O)NR6R7, OR8, SR9, S(O)2NR 10 R 11 or N(R 12 )S(O)2R 13 , where R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents H, an optionally substituted linear or branched C 1-10 Alkyl (preferably, optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (preferably, optionally substituted C 3-20 More preferably, optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (preferably, optionally substituted C 5-20 Aryl; More preferably, optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (preferably, an optionally substituted 4- to 20-membered heterocyclyl; more preferably, an optionally substituted 4- to 15-membered heterocyclyl) or an optionally substituted 5- to 30-membered heteroaryl (preferably, an optionally substituted 5- to 20-membered heteroaryl; more preferably, an optionally substituted 5- to 15-membered heteroaryl), and R2, R8 and R 13 Each independently represents an optionally substituted linear or branched C 1-10 Alkyl (preferably, optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (preferably, optionally substituted C 3-20 More preferably, optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (preferably, optionally substituted C 5-20 Aryl; More preferably, optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (preferably, an optionally substituted 4- to 20-membered heterocyclyl; more preferably, an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (preferably, an optionally substituted 5- to 20-membered heteroaryl; more preferably, an optionally substituted 5- to 15-membered heteroaryl), or wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 30-membered nitrogen-containing heterocyclyl; or wherein ring A represents a 4- to 30-membered heterocyclylene group (preferably, a 4- to 20-membered heterocyclylene group; more preferably, a 4- to 15-membered heterocyclylene group), C 3-30 Cycloalkylene (preferably, C 3-20 Cycloalkylene; more preferably, C 3-15 Cycloalkylene), C 5-30 Arylene (preferably C 5-20 Arylene; more preferably, C 5-15 arylene) or 5- to 30-membered heteroarylene (preferably, 5- to 20-membered heteroarylene; more preferably, 5- to 15-membered heteroarylene), (R( d1 ) n1 Indicates that ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20; R c Indicates NR c1 、C(O),CR c2 R c3 or key, where R c1 represents H, an optionally substituted straight or branched chain C 1-10 Alkyl (preferably, optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (preferably, optionally substituted C 3-20 More preferably, optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (preferably, optionally substituted C 5-20 Aryl; more preferably, Optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (preferably, an optionally substituted 4- to 20-membered heterocyclyl; more preferably, an optionally substituted 4- to 15-membered heterocyclyl) or an optionally substituted 5- to 30-membered heteroaryl (preferably, an optionally substituted 5- to 20-membered heteroaryl; more preferably, an optionally substituted 5- to 15-membered heteroaryl), R c2 and R c3 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl (preferably, optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (preferably, optionally substituted C 3-20 More preferably, optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (preferably, optionally substituted C 5-20 Aryl; More preferably, optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (preferably, an optionally substituted 4- to 20-membered heterocyclyl; more preferably, an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (preferably, an optionally substituted 5- to 20-membered heteroaryl; more preferably, an optionally substituted 5- to 15-membered heteroaryl); Each ring B is the same or different and each independently represents a 4- to 30-membered heterocyclylene group (preferably, a 4- to 20-membered heterocyclylene group; more preferably, a 4- to 15-membered heterocyclylene group), C 3-30 Cycloalkylene (preferably, C 3-20 Cycloalkylene; more preferably, C 3-15 Cycloalkylene), C 5-30 Arylene (preferably C 5-20 Arylene; more preferably, C 5-15 arylene) or 5- to 30-membered heteroarylene (preferably, 5- to 20-membered heteroarylene; more preferably, 5- to 15-membered heteroarylene), m1 represents an integer of 0, 1, 2 or 3, (R d2 ) n2 Indicates that each ring B is independently optionally substituted with n2 R d2 Group substitution, each R d2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20; R e Indicates S, O, CR e1 R e2 or key, where R e1 and R e2 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl (preferably, optionally substituted linear or branched C 1-6 alkyl), optionally substituted C 3-30 Cycloalkyl (preferably, optionally substituted C 3-20 More preferably, optionally substituted C 3-15 cycloalkyl), optionally substituted C 5-30 Aryl (preferably, optionally substituted C 5-20 Aryl; More preferably, optionally substituted C 5-15 aryl), an optionally substituted 4- to 30-membered heterocyclyl (preferably, an optionally substituted 4- to 20-membered heterocyclyl; more preferably, an optionally substituted 4- to 15-membered heterocyclyl), or an optionally substituted 5- to 30-membered heteroaryl (preferably, an optionally substituted 5- to 20-membered heteroaryl; more preferably, an optionally substituted 5- to 15-membered heteroaryl); and Each ring C is the same or different and each independently represents a 4- to 30-membered heterocyclic group (preferably, a 4- to 20-membered heterocyclic group; more preferably, a 4- to 15-membered heterocyclic group), C 3-30 Cycloalkyl (preferably C 3-20 Cycloalkyl; more preferably, C 3-15 Cycloalkyl), C 5-30 Aryl (preferably C 5-20 Aryl; more preferably, C 5-15 aryl) or 5- to 30-membered heteroaryl (preferably, 5- to 20-membered heteroaryl; more preferably, 5- to 15-membered heteroaryl), m2 represents an integer of 0, 1, 2 or 3, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C z- 6 alkenyl, and n3 represents an integer from 0 to 20; or Where -X1-X2- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2)1-5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-; p1, p2, p3 each independently represent an integer of 1, 2 or 3; and The ring containing -X1-X2- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 Alkenyl or any combination thereof; or Where -X3-X4- represents -(CH2) 1-6 -、-(CH2) 1-5 O-, -CH2O(CH2) 1-4 -、-(CH2) 1-4 OCH2-, -(CH2) 1- 5NH-, -CH2NH(CH2) 1-4 -, or -(CH2) 1-4 NHCH2-; p4 and p5 each independently represent an integer of 1, 2 or 3; and The benzo-fused ring containing -X3-X4- is optionally substituted by one or more deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1- 6 alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl, C 2-6 The present invention is substituted with alkenyl or any combination thereof.

3. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph according to claim 1 or 2, wherein (i) R represents O, S, S(O), S(O)2, vinylene, ethynylene, NH or N(CH3), or R represents a bond; or (ii) Each ring A 1 Each independently represents: piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, thiomorpholinylene, azepanylene, diazepanylene, azaoctylene, diazaoctylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2 .2]octanylidene, diazabicyclo[3.1.1]heptaneylidene, diazabicyclo[2.2.1]heptaneylidene, diazabicyclo[3.2.1]octanylidene, diazabicyclo[2.2.2]octanylidene, 3-azaspiro[5.5]undecaneylidene, 8-azaspiro[4.5]decaneylidene, 2-oxa-8-azaspiro[4.5]decaneylidene, 3-methyl-2-oxa-8-azaspiro[4. 5] decanylidene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, phenyl oxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazoleylene, benzo[2,1,3]oxadiazoleylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolylene, isoquinolylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl subunit, 1H-pyrrolo[3,2-b]pyridinyl subunit, 1H-pyrrolo[2,3-b]pyridinyl subunit, pyrrolo[2,1-b]thiazolyl subunit, or imidazo[2,1-b]thiazolyl subunit; or preferably, Each ring A 1 Each independently optionally represented by a1 R y1 Group substitution, each R y1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl; and a1 represents an integer of 0-20; and / or Each ring A 2 Each independently represents: Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazepanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 Spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazole group, benzo[2,1,3]thiadiazolylidene, benzo[1,2,3]thiadiazolylidene, quinolinylene, isoquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylidene, or imidazo[2,1-b]thiazolylidene; or each ring A 2 Each independently expresses Each ring A 2 independently optionally by a2 R y2 Group substitution, each R y2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0-20; Preferably, R represents: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substitution of alkenyl groups by substituents; and / or (iii) Ring A 3 , Ring A4 and Ring A 5 Each independently represents: Azolidinyl, oxetanylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, azepanylene, azepanylene, dioxanylene, azepanylene, azepanylene, diazepanylene, diazepanylene, diazepanylene, 6-azabicyclo[3.1.1]heptanylene, 2,5-diazabicyclo[2.2.1]heptanylene, 3,6 -diazabicyclo[3.1.1]heptanylene, 3-azabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 3,8-diazabicyclo[3.2.1]octanylene, 2,5-diazabicyclo[2.2.2]octanylene, 5- to 20-membered azaspirocyclic group, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, C 5-15 Spirocyclylene, adamantylene, noradamantylene, norbornylene, phenylene, naphthylene, furylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridylene, pyrimidylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene azoles, benzoisothiazolylidenes, benzotriazoles, benzo[2,1,3]oxadiazoles, benzo[2,1,3]thiadiazolylidenes, benzo[1,2,3]thiadiazolylidenes, quinolylene, isoquinolylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene pyridine subunit, pyrrolo[2,1-b]thiazolyl subunit, or imidazo[2,1-b]thiazolyl subunit; or each ring A 3 Ring A 4 and Ring A 5 Each independently represents: and y3 represents an integer of 0, 1, 2 or 3, each ring A 3 Each independently optionally represented by a3 R y3 Group substitution, each R y3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0-20; y4 represents an integer of 0, 1, 2 or 3, and each ring A4 is independently optionally replaced by a4 R y4 Group substitution, each R y4 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 alkenyl, and a4 represents an integer of 0-20; or y5 represents an integer of 0, 1, 2 or 3, each ring A 5 Each independently optionally represented by a5 R y5 Group substitution, each R y5 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxyl, C 2-6 Alkynyl or C 2-6 alkenyl, and a5 represents an integer of 0-20.

4. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein the part of the general formula of L express: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, C 2-6 Alkynyl or C 2-6 Substitution of alkenyl groups by substituents; and / or R w1 represents a key, or R w1 express: -C 1-15 Alkylene-; -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(R a (C(R a1 o)(R a11 )) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a11 )) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -(R a (C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1 -((C(R a12 )(R a13 )) r3 R a ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R a ) s1 -((C(R a12 )(R a13 )) r3 R a ) s2 -((C(R a14 )(R a15 )) r4 R a ) s3 -*; -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3 ) s2 -(R b (C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R b ) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R b ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R b ) s2 -((C(R a14 )(R a15 )) r4 R b ) s3 -*; -(C(R a8 )(R a9 )) r1 -(R a -R b -(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(R a (C(R a10 )(R a11 )) r2 ) s1 -(R b (C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(R b -R a -(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(R b (C(R a10 )(R a11 )) r2 ) s1 -(R a (C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -R a -R b ) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r 2R a ) s1 -((C(R a12 )(R a13 )) r3 R b ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -R b -R a ) s1 -*;or -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 R b ) s1 -((C(R a12 )(R a13 )) r3 R a ) s2 -*; in, Each group R a independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 )、N(R a7 )S(O)2、C(O)N(R a7 )、N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each independently represents H or C 1-6 Alkyl; each group R b are independently selected from optionally substituted cycloalkylene (eg, optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 Alkyne), alkenylene (e.g. C 2-6 alkenylene) and any combination thereof, wherein said The cycloalkylene, the arylene, the heterocyclylene and the heteroarylene are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11、 R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halo 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; The symbol * indicates the point of attachment to R; and The C 1-15 Any one or more hydrogen atoms of the main carbon chain of the alkylene group may be optionally replaced by a substituent selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

5. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein R w1 Represents the following structure: -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2 ) s1 -(O(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(O(C(R a10 )(R a11 )) r2 ) s1 -(O(C(R a12 )(R a13 )) r3 ) s2 -(O(C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 O) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 O) s1 -((C(R a12 )(R a13 )) r3 O) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 O) s1 -((C(R a12 )(R a13 )) r3 O) s2 -((C(R a14 )(R a15 )) r4 O) s3 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -(N(R a7 )(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )(C(R a10 )(R a11 )) r2 ) s1 -(N(R a7 )(C(R a12 )(R a13 )) r3 ) s2 -(N(R a7 )(C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 N(R a7 )) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 N(R a7 )) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 N(R a7 )) s2 -((C(R a14 )(R a15 )) r4 N(R a7 )) s3 -*; -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) r3 ) s2 -(C(O)N(R a7 )-(C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -C(O)N(R a7 )) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 -C(O)N(R a7 )) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 -C(O)N(R a7 )) s2 -((C(R a14 )(R a15 )) r4 -C(O)N(R a7 )) s3 -*; -(C(R a8 )(R a9 )) r1 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 ) s1 -(O-(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 -(O(C(R a12 )(R a13 )) r3 ) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a1 1)) r2 -C(O)N(R a7 )) s1 -((C(R a12 )(R a13 )) r3 O) s2 -*; -(C(R a8 )(R a9 )) r1 -(C(R a10 )(R a1 1)) r2 -C(O)N(R a7 )-((C(R a12 )(R a13 )) r3 O) s1 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 ) s1 -(O-(C(R a12 )(R a13 ))) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 ) s1 -(O-(C(R a12 )(R a13 )) r3 ) s2 -(O-(C(R a14 )(R a15 )) r4 ) s3 -*; -(C(R a8 )(R a9 )) r1 -N(R a7 )C(O)-(C(R a10 )(R a11 )) r2 -(O(C(R a12 )(R a13 )) r3 ) s1 -*; -(C(R a8 )(R a9 )) r1 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a11 )) r2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -N(R a7 )C(O)) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -N(R a7 )C(O)) s1 -((C(R a12 )(R a13 ))) r3 -O) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -N(R a7 )C(O)) s1 -((C(R a12 )(R a13 )) r3 b) s2 -((C(R a14 )(R a15 )) r4 O) s3 -*; -(C(R a8 )(R a9 )) r1 -(C(R a10 )(R a11 )) r2 -N(R a7 )C(O)-((C(R a12 )(R a13 )) r3 O) s1 -*; -(C(R a8 )(R a9 )) r1 -(arylene-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(arylene-(C(R a10 )(R a11 )) r2 ) s1 -arylene-(C(R a12 )(R a13 )) r3 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -arylene) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -arylene) s1 -(C(R a12 )(R a13 )) r3 -arylene-*; -(C(R a8 )(R a9 )) r1 -(Heterocyclylene-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(Heterocyclylene-(C(R a10 )(R a11 )) r2 ) s1 -(Heterocyclylene-(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heterocyclylene) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heterocyclylene) s1 -((C(R a12 )(R a13 )) r3 -heterocyclylene) s2 -*; -(C(R a8 )(R a9 )) r1 -(heteroarylene-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(heteroarylene-(C(R a10 )(R a11 )) r2 ) s1 -(heteroarylene-(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heteroarylene) s1 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -heteroarylene) s1 -((C(R a12 )(R a13 )) r3 -heteroarylene) s2 -*; -(C(R a8 )(R a9 )) r1 -(cycloalkylene-(C(R a10 )(R a11 )) r2 ) s1 -*; -(C(R a8 )(R a9 )) r1 -(cycloalkylene-(C(R a10 )(R a11 )) r2 ) s1 -(cycloalkylene-(C(R a12 )(R a13 )) r3 ) s2 -*; -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -cycloalkylene) s1 -*;or -(C(R a8 )(R a9 )) r1 -((C(R a10 )(R a11 )) r2 -cycloalkylene) s1 -((C(R a12 )(R a13 )) r3 -cycloalkylene) s2 -*; Among them, each R a7 independently represents H or C 1-6 alkyl; The cycloalkylene group (eg C 3-20 Cycloalkylene), the arylene group (such as C 5-20 arylene), the heterocyclylene (e.g., 4- to 20-membered heterocyclylene) and the heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; R a8 、R a9 、R a10 、R a11 、R a12 、R a13 、R a14 and R a15 Each independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, halo C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and r1, r2, r3, r4, s1, s2, s3 each independently represent an integer 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and The symbol * indicates the point of attachment to R.

6. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein R w1 express: -CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-(CH2)7-、-(CH2)8-、-(CH2)9-、-(CH2) 10 -、-(CH2)11-、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -;-O-CH2-、-O-(CH2)2-、-O-(CH2)3-、-O-(CH2)4-、-O-(CH2)5-、-O-(CH2)6-、-O-(CH2)7-、-O-(CH2)8-、-O-(CH2)9-、-O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10 -、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH 2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(CH2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、-(CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O-( CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1- 、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5-、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-CH(CH3)-O-(CH2)9-、-CH(CH3)-O-(CH2) 10 -、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2-(O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2- (O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)7-、-(CH2)1-N(R a7 )-(CH2)8-、-(CH2)1-N(R a7 )-(CH2)9-、-(CH2)1-N(R a7 )-(CH2) 10 -、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)7-、-N(R a7 )-(CH2)8-、-N(R a7 )-(CH2)9-、-N(R a7 )-(CH2) 10 -、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)7-、-(CH2)2-N(R a7 )-(CH2)8-、-(CH2)2-N(R a7 )-(CH2)9-、-(CH2)2-N(R a7 )-(CH2) 10 -、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-CH(CH3)-N(R a7 )-(CH2)7-、-CH(CH3)-N(R a7 )-(CH2)8-、-CH(CH3)-N(R a7 )-(CH2)9-、-CH(CH3)-N(R a7 )-(CH2) 10 -、-(CH2)1-N(R a7 )-、-(CH2)2-N(R a7 )-、-(CH2)3-N(R a7 )-、-(CH2)4-N(R a7 )-、-(CH2)5-N(R a7 )-、-(CH2)6-N(R a7 )-、-(CH2)7-N(R a7 )-、-(CH2)8-N(R a7 )-、-(CH2)9-N(R a7 )-、-(CH2) 10 -N(R a7 )-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, - (CH2)2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C (O)NH(CH2)4-, -(CH2)5C(O)NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(C H2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC (O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2 )4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC(O)(CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(C H2)4NHC(O)(CH2)8-、-(CH2)2NHC(O)(CH2)2-O-(CH2)2-、-(CH2)4NHC(O)CH2-、-phenylene-CH2-、-phenylene-(CH2)2-、-phenylene-(CH2)3-、-phenylene-(CH2)4-、-phenylene-(CH2)5-、-phenylene-(CH2)6-、-phenylene-(CH2)7-、-phenylene-(CH2)8-、-CH2-phenylene-CH2-、-CH2-phenylene-(CH2)2-、-CH2-phenylene-(CH2)3-、-CH2-phenylene- (CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene -CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene H2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, -(CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6-phenylene -(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-,-(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-, -(CH2)8-phenylene-(CH2)7-, -N(R, a7 )-CH2-phenylene-CH2-、-N(R a7 )-CH2-phenylene-(CH2)2-, -N(R a7 )-CH2-phenylene-(CH2)3-、-N(R a7 )-CH2-phenylene-(CH2)4-、-N(R a7 )-CH2-phenylene-(CH2)5-、-N(R a7 )-CH2-phenylene-(CH2)6-、-N(R a7 )-CH2-phenylene-(CH2)7-、-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)2-, -CH2-N(R a7 )-CH2-phenylene-(CH2)3-, -CH2-N(R a7 )-CH2-phenylene-(CH2)4-, -CH2-N(R a7 )-CH2-phenylene-(CH2)5-, -CH2-N(R a7 )-CH2-phenylene-(CH2)6-, -CH2-N(R a7 )-CH2-phenylene-(CH2)7-, -CH2-N(R a7 )-CH2-phenylene-(CH2)8-, -CH2-N(R a7 )-(CH2)2-phenylene-CH2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)2-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)3-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)4-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)5-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)6-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)7-, -CH2-N(R a7 )-(CH2)2-phenylene-(CH2)8-, -(CH2)2-N(R a7 )-CH2-phenylene-CH2-、-(CH2)2-N(Ra7)-CH2-phenylene-(CH2)2-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)4-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)6-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)7-, -(CH2)2-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)3-N(R a7 )-CH2-phenylene-CH2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)3-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)4-N(R a7 )-CH2-phenylene-CH2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)4-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)5-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)6-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)8-, -(CH2)7-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-CH2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)2-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)5-, -(CH2)8-N(R a7 )-CH2-phenylene-(CH2)6-, -piperidinylene-CH2-, -piperidinylene-(CH2)2-, -piperidinylene- (CH2)3-, -piperidinylene-(CH2)4-, -piperidinylene-(CH2)5-, -piperidinylene-(CH2)6-, -piperidinylene-(CH2)7-, -piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7-, -CH2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2 -piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2 3-Piperidinylene-(CH2)6-, -(CH2)3-Piperidinylene-(CH2)7-, -(CH2)3-Piperidinylene-(CH2)8-, -(CH2)4-Piperidinylene-CH2-, -(CH2)4-Piperidinylene-(CH2)2-, -(CH2)4-Piperidinylene-(CH2)3-, -(CH2)4-Piperidinylene-(CH2)4-, -(CH2)4-Piperidinylene-(CH2)5-, -(CH2)4-Piperidinylene-(CH2)6-, -(CH2)4-Piperidinylene-(CH2)7-, -(CH2)4-Piperidinylene-(CH2)8-, -(CH2)5-Piperidinylene-(CH2)1-, -(CH 2) 5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-(CH2)1-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-, -(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-,-(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene-(CH2)4-, -(CH2)7-piperidinylene alkyl-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R, a7 )-CH2-piperidinyl-CH2-、-N(R a7 )-CH2-piperidinyl-(CH2)2-、-N(R a7 )-CH2-piperidinyl-(CH2)3-、-N(R a7 )-CH2-piperidinyl-(CH2)4-、-N(R a7 )-CH2-piperidinyl-(CH2)5-、-N(R a7 )-CH2-piperidinyl-(CH2)6-、-N(R a7 )-CH2-piperidinyl-(CH2)7-、-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-CH2-piperidinyl-CH2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -CH2-N(R a7 )-(CH2)2-piperidinyl-CH2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)2-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)3-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)5-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)6-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)7-, -CH2-N(R a7 )-(CH2)2-piperidinyl-(CH2)8-, -(CH2)2-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)6-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)7-, -(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)3-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)4-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)8-、- (CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)8-, -(CH2)7-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-CH2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)2-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)3-, -(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)4-、-(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)5-, -(CH2)8-N(R a7 )-CH2-piperidinylene-(CH2)6-, -piperazinylene-CH2-, -piperazinylene-(CH2)2-, -piperazinylene-(CH2)3-, -piperazinylene-(CH2)4-, -piperazinylene-(CH2)5-, -piperazinylene-(CH2)6-, -piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7-, -piperazinylene-(CH2)8-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -CH2-piperazinylene-(CH2)6-, -CH2-piperazinylene-(CH2)7 -, -CH2-piperazinylene-(CH2)8-, -(CH2)2-piperazinylene-(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)6-, -(CH2)2-piperazinylene-(CH2)7-, -(CH2)2-piperazinylene-(CH2)8-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -( -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-(CH2)6-, -(CH2)3-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2)3-piperazinylene-(CH2)8-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-(CH2)6-, -(CH2)4-piperazinylene-(CH2)7-, -(CH2) -(CH2)4-piperazinylene-(CH2)8-, -(CH2)5-piperazinylene-(CH2)1-, -(CH2)5-piperazinylene-(CH2)2-, -(CH2)5-piperazinylene-(CH2)3-, -(CH2)5-piperazinylene-(CH2)4-, -(CH2)5-piperazinylene-(CH2)5-, -(CH2)5-piperazinylene-(CH2)6-, -(CH2)5-piperazinylene-(CH2)7-, -(CH2)5-piperazinylene-(CH2)8-, -(CH2)6-piperazinylene-(CH2)1-, -(CH2)6-piperazinylene-(CH2)2-, -(CH2)6-piperazinylene-(CH2)3-,-(CH2)6-piperazinylene-(CH2)4-, -(CH2)6-piperazinylene-(CH2)5-, -(CH2)6-piperazinylene-(CH2)6-, -(CH2)6-piperazinylene-(CH2)7-, -(CH2)6-piperazinylene-(CH2)8-, -(CH2)7-piperazinylene-(CH2)1-, -(CH2)7-piperazinylene-(CH2)2-, -(CH2)7-piperazinylene -(CH2)3-, -(CH2)7-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, -(CH2)8-piperazinylene-(CH2)5-, or -(CH2)8-piperazinylene-(CH2)6-; Among them, each R a7 independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl); The phenylene group may be optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1- 6-alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3- 6-membered cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; and The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 The substituents are substituted by cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof.

7. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, or polymorph according to claim 1, wherein L represents: a key, C(O), C(O)NH, NHC(O), -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2)11-, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14 -, -(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O- (CH2)8-、-O-(CH2)9-、-O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1-、-CH(CH3)-O-(CH2)2-、-CH(CH3)-O-(CH2)3-、-CH(CH3)-O-(CH2)4-、-CH(CH3)-O-(CH2)5 -、-CH(CH3)-O-(CH2)6-、-CH(CH3)-O-(CH2)7-、-CH(CH3)-O-(CH2)8-、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、- CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-、-(CH2)2-N(R a7 )-、-(CH2)3-N(R a7 )-、-(CH2)4-N(R a7 )-、-(CH2)5-N(R a7 )-、-(CH2)6-N(R a7 )-、-(CH2)7-N(R a7 )-、-(CH2)8-N(R a7 )-、-(CH2)9-N(R a7 )-、-(CH2) 10 -N(R a7 )-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O)N H(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2- , -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4 -、-(CH2)4NHC(O)(CH2)4-、-(CH2)5NHC(O)(CH2)5-、-(CH2)2NHC(O)(CH2)2-O-(CH2)2-、-(CH2)4NHC(O)CH2-、-CH2-phenylene-CH2-、-CH2-phenylene-(CH2)2-、-CH2-phenylene-(CH2)3-、-CH2-phenylene-(CH2)4-、-CH2-phenylene-(CH2)5-、-CH2-phenylene-(CH2)6-、-(CH2)2-phenylene-(CH2)1-、-(CH2)2-phenylene-(CH2)2-、-(CH2)2-phenylene-(CH2)3- , -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -CH2-piperidinylene-CH2-,-CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH 2) 3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2-piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2-piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-( -(CH2)1-, -(CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene-(CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3-piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, -(CH2)3-piperazinylene-(CH2)5-, -(CH2) 4-piperazinylene-CH2-, -(CH2)4-piperazinylene-(CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4-piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, -(CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8-piperazinylene-(CH2)5-; Among them, each R a7 independently represents H or C 1-6 Alkyl (e.g., methyl, ethyl, n-propyl, or isopropyl); The phenylene group may be optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 Alkyl, halogenated C 1- 6-alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3- 6-cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; The piperazinyl and piperidinyl groups are each independently optionally selected from deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 Cycloalkyl, halogenated C 3-6 Cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclic group, and any combination thereof; or L means: wherein the above groups are optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

8. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein X represents: NR1R2, C(O)NR3R4, NHC(O)R5, NHC(O)NR6R7, OR8, SR9, S(O)2NR 10 R 11 or N(R 12 )S(O)2R 13 , where R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 and R 12 Each independently represents H, an optionally substituted linear or branched C 1-10 Alkyl, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, an optionally substituted 4- to 30-membered heterocyclyl or an optionally substituted 5- to 30-membered heteroaryl, and R2, R8 and R 13 Each independently represents an optionally substituted linear or branched C 1-10 Alkyl, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, optionally substituted 4- to 30-membered heterocyclyl, or optionally substituted 5- to 30-membered heteroaryl, or wherein R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted 4- to 30-membered nitrogen-containing heterocyclyl; or wherein ring A represents a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5- to 30-membered heteroarylene, (R d1 ) n1 Indicates that ring A is optionally replaced by n1 R d1 Group substitution, each R d1 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n1 represents an integer from 0 to 20; R c Indicates NR c1 、C(O),CR c2 R c3 or key, where R c1 represents H, an optionally substituted straight or branched chain C 1-10 Alkyl, C replaced by the Scripture 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, an optionally substituted 4- to 30-membered heterocyclyl, or an optionally substituted 5- to 30-membered heteroaryl, R c2 and R c3 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, an optionally substituted 4- to 30-membered heterocyclyl, or an optionally substituted 5- to 30-membered heteroaryl; Each ring B is the same or different and independently represents a 4- to 30-membered heterocyclylene group, C 3-30 Cycloalkylene, C 5-30 Arylene or 5 to 30 membered heteroarylene, m1 represents an integer of 0, 1, 2 or 3, (R d2 ) n2 Indicates that each ring B is independently optionally substituted with n2 R d2 Group substitution, each R d2 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n2 represents an integer from 0 to 20; R e Indicates S, O, CR e1 R e2 or key, where R e1 and R e2 Each independently represents H, halogen, an optionally substituted linear or branched C 1-10 Alkyl, optionally substituted C 3-30 Cycloalkyl, optionally substituted C 5-30 aryl, optionally substituted 4- to 30-membered heterocyclyl, or optionally substituted 5- to 30-membered heteroaryl; and Each ring C is the same or different and independently represents a 4- to 30-membered heterocyclic group, C 3-30 Cycloalkyl, C 5-30 aryl or 5 to 30 membered heteroaryl, m2 represents an integer of 0, 1, 2 or 3, (R d3 ) n3 Indicates that each ring C is independently optionally substituted with n3 R d3 Group substitution, each R d3 Deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 alkenyl, and n3 represents an integer of 0-20; Wherein each straight chain or branched chain C 1-50 Each alkyl group is independently optionally selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, nitro, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, optionally substituted C 3-30 Cycloalkyl, 4- to 10-membered heterocyclic group, C 2-6 Alkynyl or C 2-6 Substitution of the alkenyl group with a substituent; and Each C 3-30 Cycloalkylene, each C 5-30 arylene, each 4 to 30 membered heterocyclylene, each 5 to 30 membered heteroarylene, each C 3- 30 Cycloalkyl, each C 5-30 Aryl, each 4 to 30 membered heterocyclyl and each 5 to 30 membered heteroaryl are each independently optionally selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxy, mercapto, cyano, oxo, C 2-6 Alkynyl or C 2-6 The substituents of the alkenyl group are substituted.

9. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph as claimed in claim 1, wherein (i)R1, R3, R4, R5, R6, R7, R9, R 10 、R 11 、R 12 and R c1 Each independently represents: H or an optionally substituted linear or branched C 1-10 alkyl; Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxyl Generation C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazacanyl, bridged heterocyclic radicals (e.g., 6- to 20-membered bridged heterocyclic radicals, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3 5- to 20-membered azaspirocyclyl, for example, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (for example, 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl oxazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1 ,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, Halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; and / or (ii) R2, R8 and R 13 Each independently represents: Optionally substituted linear or branched C 1-10 alkyl: Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazacanyl, bridged heterocyclic radicals (e.g., 6- to 20-membered bridged heterocyclic radicals, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3 5- to 20-membered azaspirocyclyl, for example, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (for example, 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indole yl, isoindolyl, indolinyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b] [1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo- 1H-pyrrolo[3,2-d]pyrimidinyl, 1H-pyrrolo[3,2-d]pyrimidinyl, 1H-pyrrolo[3,2-d]pyrimidinyl, 1H-pyrrolo[3,2-b]pyrimidinyl, 1H-pyrrolo[3,2-b]pyrimidinyl, 1H-pyrrolo[3,2-d]pyrimidinyl, 1H-pyrrolo[3,2-b]pyrimidinyl, 1H-pyrrolo[3,2-d]pyrimidinyl, 1H-pyrrolo[4,5-c]pyrimidinyl, 1H-pyrrolo[4,5-d]pyrimidinyl, 1H-pyrrolo[1,5-a]pyrimidinyl, 1H-pyrrolo[1,5-a]pyrimidinyl, 1H-pyrrolo[3,2-b ...3,2-b]pyrimidinyl, 1H-pyrrolo[3,2 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; and / or (iii)R c2 、R c3 、R e1 and R e2 Each independently represents: H, halogen or an optionally substituted linear or branched C 1-10 alkyl; or Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazepanyl, bridged heterocyclic ring ( For example, 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclic groups (such as 5- to 20-membered azaspirocyclic groups, such as 2,6-diazaspiro[3.3]heptanyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[ 4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; and / or (iv) R3 and R4 together with the nitrogen atom to which they are attached form: azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, diazepanyl, diazaoctanyl, nitrogen-bridged heterocyclic groups (e.g., 6-20 membered nitrogen-bridged heterocyclic groups, such as 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.1]heptanyl, 2-azabicyclo[3.1.2]heptanyl, 3-azabicyclo[3.1.3]heptanyl, 3-azabicyclo[3.1.4]heptanyl, 3-azabicyclo[3.1.5]heptanyl, 3-azabicyclo[3.1.6]heptanyl, 3-azabicyclo[3.1.7]heptanyl, 3-azabicyclo[3.1.8]heptanyl, 3-azabicyclo[3.1.9]heptanyl, 3-azabicyclo[3.1.10]heptanyl, 3-azabicyclo[3.1 ... heterobicyclo[2.2.1]heptyl, 6-azabicyclo[3.1.1]heptyl, 2-azabicyclo[2.2.2]octyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octyl and quinuclidine), or nitrogen-containing spiro heterocyclic group (e.g., a 5- to 20-membered nitrogen-containing spiroheterocyclyl group, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or an octahydropyrrolo[3,4-c]pyrrolyl group, which is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; and / or (v) Each of Ring A and Ring B independently represents: Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydropentalenylene, octahydro-1H-indenylene, spirocycloalkylene (e.g., C5-C 20 Spirocycloalkylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, spiro[5.5]undecanylene), p-menthanylene, m-menthanylene, or bridged cycloalkylene (e.g., C6-C 20 Bridged cycloalkylene, for example adamantylene, noradamantylene, bornylene, norbornylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[ 2.2.1] heptanylene or bicyclo[2.2.1] heptenylene), which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or Azolidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, octanyl, dioxanyl, azepanyl heptyl, azacyclooctanyl, diazacycloheptanediyl (e.g., 1,4-diazacycloheptanediyl, 4,5-diazacycloheptanediyl, 1,3-diazacycloheptanediyl), diazacyclooctanyl, subbridged heterocyclic groups (e.g., 6- to 20-membered subbridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptandiyl, 2,5-diazabicyclo[2.2.1]heptandiyl, 3,6-diazabicyclo[3. 1.1] heptanediyl, 3-azabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 3,8-diazabicyclo[3.2.1]octanylidene, 2,5-diazabicyclo[2.2.2]octanylidene and quinuclidinyl), azaspirocyclyl (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptanylidene, 2,7-diazaspiro[3.4]heptanylidene, 5-azaspiro[3.5]nonanediyl, 2,8-diazaspiro[4.5]decanediyl, 3,9-diazaspiro[5.5]undecanediyl, 3-azaspiro[5.5]undecanediyl and 7-azaspiro[3.5]nonanediyl), or octahydropyrrolo[3,4-c]pyrrolediyl, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, sulfhydryl, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1- 6 alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Phenylene or naphthylene, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxyl, mercapto, nitro Group, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, triazinylene, indolylene, isoindolylene, indolylene, benzofuranylene, chromanylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, Benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolylene, benzo[b][1,4]oxazinylene, 3,4-dihydro-2H-benzo[b][1,4]oxazinylene, quinolinylene, isoquinolinylene, 1,2,3,4-tetrahydroquinolinylene, naphthyridinylene, cinnolinylene, quinazolinylene, quinoxalinylene, 1,2,3,4-tetrahydroquinoxalinylene, phthalazinylene, 5,6,7,8- Tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine subunit, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl subunit, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl subunit, thieno[2,3-d]pyrimidinyl subunit, thieno[3,2-d]pyrimidinyl subunit, isoxazolo[4,5-c]pyrimidinyl subunit, isoxazolo[4,5-c]pyrimidinyl subunit, isoxazolo[4,5-d]pyrimidinyl subunit, pyrazolo[1,5-a]pyridinyl subunit, pyrazolo[1,5-a]pyrimidinyl subunit, imidazole [1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; and / or (vi) Each ring C is the same or different and independently represents: Cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-1H-indenyl, spirocycloalkyl (e.g., C5-C 20 Spirocyclyl, for example, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[4.5]decyl, spiro[5.5]undecyl), p-menthanyl, m-menthanyl, or a bridged cycloalkyl group (e.g., C6-C 20 Bridged ring groups, such as adamantyl, noradamantyl, bornyl, norbornyl, bicyclo[2.2.1]heptanyl, 2-oxobicyclo[ 2.2.1]heptyl or bicyclo[2.2.1]heptenyl), which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydroxypiperidinyl, difluoropiperidinyl, morpholinyl, thiomorpholinyl, azepanyl, azocanyl, dioxanyl, azepanyl, azocanyl, diazepanyl (e.g., 1,4-diazepanyl, 4,5-diazepanyl, 1,3-diazepanyl), diazaoctanyl, bridged heterocyclic groups (e.g., 6- to 20-membered bridged heterocyclic groups, such as 6-azabicyclo[3.1.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 3,6-diazabicyclo[3.1.1]heptyl, 3-azabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.2]octanyl and quinuclidine), and azaspirocyclyl (e.g., 5- to 20-membered azaspirocyclyl, such as 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 2,8-diazaspiro[4.5]decyl, 3,9-diazaspiro[5.5]undecyl, 3-azaspiro[5.5]undecyl and 7-azaspiro[3.5]nonyl), or octahydropyrrolo[3,4-c]pyrrolyl, which is optionally substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof substituted with substituents; Phenyl or naphthyl, which may be optionally substituted by one or more (e.g. 1-10) selected from deuterium, halogen, hydroxy, mercapto, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl and any combination thereof; or furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, indolyl, benzofuranyl, chromanyl, isobenzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, benzo[b][1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, phthalazinyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[ 4,3-a]pyrazinyl, 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl, 5-oxo-6,7-dihydrothieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoxazolo[4,5-c]pyridinyl, isoxazolo[4,5-c]pyrimidinyl, isoxazolo[4,5-d]pyrimidinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl pyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, or 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, which may be substituted by one or more (e.g., 1-10) selected from deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogenated C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 The alkynyl group and any combination thereof are substituted with substituents.

10. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph according to claim 1, wherein X represents:

11. The compound of formula (I) or its salt, enantiomer, stereoisomer, solvate, polymorph according to claim 1, which is selected from: 3-(5-((4-diphenylmethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(phenyl(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(phenyl(pyridin-4-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(di(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(di(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(bis(3-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-Benzhydryl-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((5-Benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,4R)-5-benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,4S)-5-benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((8-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((5-Benzhydryl-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-Benzhydryl-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dionone; 3-(5-((4-Benzhydryl-3,5-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-Benzhydryl-2,6-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-benzhydryl-3,3-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-Benzhydryl-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((R)-4-Benzhydryl-2-methylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-benzhydryl-2-oxoimidazolidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(diphenylamino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(phenyl(pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((6-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((8-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-Fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4′-fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(4′-fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Furan-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Furan-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(furan-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Furan-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-phenylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(o-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(m-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(p-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,6-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,6-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,4-dimethylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-chloro-2-methylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-phenylpiperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chloro-3-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-difluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichlorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chloro-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(6-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,4-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,4-difluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-chloro-3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-fluoro-4-iodopyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromo-4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-chloro-6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-chloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4,5-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,4-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromopyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chloro-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-bromo-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromo-2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-difluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-fluoro-2-hydroxypyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-bromo-5-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3-chloro-5-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,5-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,6-dimethylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(perfluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-chloropyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(pyrazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dichloropyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(1,3,5-triazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(3,4-dichloropyridin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichloropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-difluoropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-([3,4′-bipiperidinyl]-1-ylmethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3,4-dichloro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4,5-dichloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((5-chloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2′,3′-dichloro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-fluoro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((2′,3′-difluoro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((6-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1R,4R)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((1S,4S)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-yl)methyl)-1-thioisoindolin-2-yl) Piperidine-2,6-dione; 3-(5-((5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((8-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(isoxazolo[4,5-c]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1H-indazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1-methyl-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1H-indazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoroindolin-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-1H-indazol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-fluoro-3,4-dihydroquinolin-1(2H)-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluoro-3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluorochroman-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluorochroman-4-ylidene)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoronaphthalen-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluoroquinolin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(isoquinolin-5-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-fluoronaphthalen-1-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(7-fluoroquinolin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(isoquinolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(7-fluorochroman-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(7-fluorochroman-4-ylidene)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(7-fluoroquinolin-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(5-fluoroindolin-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((3-(5-fluoro-1H-benzo[d]imidazol-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-bromothieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidin- 2,6-diketone; 3-(5-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-ethylpyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[2,3-d]pyrimidin-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-(piperazin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-(piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindoline-2-yl 1,6-dione; 3-(5-((4-(2-(pyrrolidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-(azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-morpholinothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-(piperazin-1-yl)thieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-5-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(4-(adamantan-1-yl)benzyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-(((adamantan-1-yl)amino)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 1-((1R,4R)-7,7-dimethyl-2-oxobicyclo[ 2.2.1]heptane-1-yl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-thioisoindolin-5-yl)methyl)methanesulfonamide; 3-(5-((((1R,4S)-bicyclo[2.2.1]heptan-2-yl)oxy)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-benzhydrylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(phenyl(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(phenyl(pyridin-4-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(di(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(di(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(bis(3-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-Benzhydryl-3,6-diazabicyclo[3.1.1]heptane-6-yl)methyl)-1-thioisoindolin-2-yl)piperidin-2,6-diol ketone; 3-(6-((5-Benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((8-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((5-Benzhydryl-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-benzhydryl-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-benzhydryl-3,5-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-Benzhydryl-2,6-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-benzhydryl-3,3-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-benzhydryl-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-(((R)-4-Benzhydryl-2-methylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-benzhydryl-2-oxoimidazolidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(diphenylamino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(phenyl(pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((6-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((8-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4′-fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidin-1-yl Pyridine-2,6-dione; 3-(6-((4-(4′-fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(4′-fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(furan-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(Furan-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(furan-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(Furan-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-phenylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(o-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(m-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(p-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,6-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,6-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,4-dimethylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-chloro-2-methylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-phenylpiperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chloro-3-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-difluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichlorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chloro-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 1-(6-((4-(3-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-oxoisoindolin-2-yl)dihydropyrimidine-2,4(1H,3H)-dione; 1-(6-((4-(3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-oxoisoindolin-2-yl)dihydropyrimidine-2,4(1H,3H)-dione; 3-(6-((4-(6-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(6-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,4-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,4-difluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-chloro-3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-fluoro-4-iodopyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromo-4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-chloro-6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-chloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4,5-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,4-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromopyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chloro-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-bromo-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromo-2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-difluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-fluoro-2-hydroxypyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-bromo-5-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3-chloro-5-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,5-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,6-dimethylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(perfluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-chloropyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(pyrazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dichloropyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(1,3,5-triazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(3,4-dichloropyridin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichloropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-difluoropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-([3,4′-bipiperidinyl]-1-ylmethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3,4-dichloro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4,5-dichloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((5-chloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((2′,3′-dichloro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-Fluoro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((2′,3′-difluoro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((6-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-(((1R,4R)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-(((1S,4S)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((8-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(Benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(isoxazolo[4,5-c]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluoro-1H-indazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 8-(6-((4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluoro-1-methyl-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoroindolin-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluoro-1-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-fluoro-3,4-dihydroquinolin-1(2H)-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(7-fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(7-fluoro-3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(7-fluorochroman-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(7-fluorochroman-4-ylidene)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoronaphthalen-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(7-fluoroquinolin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(isoquinolin-5-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-fluoronaphthalen-1-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(isoquinolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(7-fluorochroman-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(7-fluorochroman-4-ylidene)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(7-fluoroquinolin-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(5-fluoroindolin-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((3-(5-fluoro-1H-benzo[d]imidazol-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(5-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-bromothieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-ethylpyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidin- 2,6-diketone; 3-(6-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[2,3-d]pyrimidin-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-(piperazin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-(piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-(pyrrolidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-(azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-morpholinothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-(piperazin-1-yl)thieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-6-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-((4-(4-(adamantan-1-yl)benzyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(6-(((adamantan-1-yl)amino)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 1-((1R,4R)-7,7-dimethyl-2-oxobicyclo[ 2.2.1]heptane-1-yl)-N-((2-(2,6-dioxopiperidin-3-yl)-3-thioisoindolin-5-yl)methyl)methanesulfonamide; 3-(6-((((1R,4S)-bicyclo[2.2.1]heptan-2-yl)oxy)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-benzhydrylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(phenyl(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(phenyl(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(phenyl(pyridin-4-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(di(pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(di(pyridin-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(bis(3-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-Benzhydryl-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-Benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((1R,4R)-5-benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((1S,4S)-5-benzhydryl-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((8-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-Benzhydryl-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-Benzhydryl-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-Benzhydryl-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-Benzhydryl-3,5-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-Benzhydryl-2,6-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-benzhydryl-3,3-dimethylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-Benzhydryl-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((R)-4-Benzhydryl-2-methylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-benzhydryl-2-oxoimidazolidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(diphenylamino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(phenyl(pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((6-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((8-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)-2-(trifluoromethyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-Fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4′-Fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(4′-Fluoro-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)amino)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-chloro-[1,1′-biphenyl]-2-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-methylthiophen-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-methylthiophen-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Furan-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Furan-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-methylthiophen-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-methylthiophen-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(furan-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Furan-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-phenylpiperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-fluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-bromophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(o-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(m-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(p-tolyl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,6-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,5-dichlorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,6-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,4-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,5-difluorophenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,4-dimethylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-chloro-2-methylphenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-phenylpiperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-bromophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-chlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(2-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichlorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chloro-3-fluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-difluorophenyl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichlorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chloro-3-fluorophenyl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(6-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,4-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4,5-dichloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,4-difluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-chloro-3-fluoropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-fluoro-4-iodopyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromo-4-chloropyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-chloro-6-methylpyridin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-chloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4,5-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,4-dichloropyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromopyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chloro-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-bromo-3-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromo-2-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-difluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-fluoro-2-hydroxypyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-bromo-5-chloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3-chloro-5-fluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,5-dichloropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,6-dimethylpyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(perfluoropyridin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-chloropyridazin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(pyrazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dichloropyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dichloropyridazin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(1,3,5-triazin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(3,4-dichloropyridin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichloropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-difluoropyridin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-([3,4′-bipiperidinyl]-1-ylmethyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3,4-dichloro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4,5-dichloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-chloro-3′,6′-dihydro-[3,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((2′,3′-dichloro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-Fluoro-3′,6′-dihydro-[2,4′-bipyridyl]-1′(2′H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((2′,3′-difluoro-3,6-dihydro-[4,4′-bipyridyl]-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((6-(2,3-dichlorophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((1R,4R)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((1S,4S)-5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((5-(2,3-dichlorophenyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((8-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(2,3-dichlorophenyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Benzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(isoxazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluorobenzo[d]isoxazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(isoxazolo[4,5-c]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluorobenzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluoro-1H-indazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-Fluoro-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-Fluoro-1-methyl-1H-indol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluoro-1H-indazol-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-fluoroindolin-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-Fluoro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-Fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidin- Pyridine-2,6-dione; 3-(4-((4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-Fluoro-1-methyl-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluoro-1H-indazol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-fluoro-3,4-dihydroquinolin-1(2H)-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-Fluoro-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-fluoro-3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-fluorochroman-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-fluorochroman-4-ylidene)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-fluoronaphthalen-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-fluoronaphthalen-1-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-fluoroquinolin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(isoquinolin-5-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-Fluoronaphthalen-1-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(7-Fluoroquinolin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(isoquinolin-5-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(7-fluorochroman-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(7-fluorochroman-4-ylidene)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(7-fluoroquinolin-4-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(5-fluoroindolin-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((3-(5-fluoro-1H-benzo[d]imidazol-1-yl)azetidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidin- 2,6-diketone; 3-(4-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-bromothieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-1,4-diazepan-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidin- 2,6-diketone; 3-(4-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-ethylpyrimidin-2-yl)piperidin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-isopropylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-methylthieno[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[2,3-d]pyrimidin-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione: 3-(4-((4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-(piperazin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(piperidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(pyrrolidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-(azetidin-1-yl)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(thieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-morpholinothieno[3,2-d]pyrimidin-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-(piperazin-1-yl)thieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(1-thioxo-4-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)isoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-(4-(adamantan-1-yl)benzyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-(((adamantan-1-yl)amino)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 1-((1R,4R)-7,7-dimethyl-2-oxobicyclo[ 2.2.1]heptane-1-yl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-thioisoindolin-4-yl)methyl)methanesulfonamide; 3-(4-((((1R,4S)-bicyclo[2.2.1]heptan-2-yl)oxy)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; 3-(4-((4-((4′-chloro-[1,1′-biphenyl]-4-yl)methyl)piperazin-1-yl)methyl)-1-thioisoindolin-2-yl)piperidine-2,6-dione; (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-thioisoindolin-2-yl)piperidine-2,6-dione; and (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-thioisoindolin-4-yl)oxy)methyl)phenyl)piperazin-1-yl)-3-fluorobenzonitrile.

12. A compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, or polymorph thereof as claimed in any one of claims 1 to 11, which is a hydrohalide salt (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-gluconate, α-D-glucoheptonate, glycolate, mucate, L-ascorbate, orotate, picrate, glycinate, alanine, arginine, cinnamate, laurate, pamoate, sebacate, benzenesulfonate, methanesulfonate, ethanesulfonate, edisylate, formate, acetate, 2,2- dichloroacetate, pivalate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulate, 2-hydroxyethanesulfonate, nitrate, gentisate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphorsulfonate, dodecylsulfonate, phosphate, thiocyanate, dihydrogenphosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, glycolate, or p-toluenesulfonate.

13. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, and at least one pharmaceutically acceptable carrier or excipient.

14. The pharmaceutical composition of claim 13, further comprising a second therapeutic agent, such as an anticancer agent.

15. A compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 12, for use in preventing or treating a disease or condition selected from the group consisting of: tumors or cancer, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

16. The compound of formula (I) according to claim 15, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), CML, chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD 20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal (thymic) large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory Primary mediastinal (thymic) large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; glioma; Peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis; keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS ), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

17. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 12, or a pharmaceutical composition as claimed in claim 13 or 14, for preparing a medicament for preventing or treating a disease or condition selected from the group consisting of tumors or cancers, infectious diseases, inflammatory diseases, autoimmune diseases, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure or diabetes.

18. A method for treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 13 or 14, wherein the disease or condition is selected from the group consisting of: tumor or cancer, infectious disease, inflammatory disease, autoimmune disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, or diabetes.

19. The use of claim 17 or the method of claim 18, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), CML), chronic myeloid leukemia, acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell chronic lymphocytic leukemia, anemia associated with leukemia, monocytic leukemia, myelomonocytic leukemia, T-lymphocytic leukemia, acute T-lymphocytic leukemia; lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20 Positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal (thymic) large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary Primary mediastinal (thymic) large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; glioma; astrocytoblastoma; ovarian cancer; bronchogenic carcinoma; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; glioma; Peripheral neuroepithelial tumor; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcomas, including rhabdomyosarcoma, various adipose tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct cancer; Bone cancer; cervical cancer; skin cancer; or Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis; keratoconjunctivitis sicca; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS ), COVID-19 novel coronavirus infection, Gram-negative bacterial infection, Gram-positive bacterial infection, tuberculosis, etc.; septic shock; tuberculosis; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; anemia; pediatric aplastic anemia; cardiovascular disease (such as coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); multiple organ failure caused by cachexia and septic shock; and acute liver failure.

20. A method for preparing a compound of formula (II), comprising reacting a compound of formula (M1) with a compound of formula (M2) to obtain a compound of formula (II): The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in claim 1; and in (i) Group LE represents Cl, Br, I, methanesulfonyloxy, p-toluenesulfonyloxy, or o-nitrobenzenesulfonyl, and the formula (M2) R b1 -X a -R b2 is R1-NH-R2, and X of the compound of formula (II) b Correspondingly represents NR1R2, wherein R1 and R2 are as defined in any one of claims 1 to 11; or (ii) the group LE represents Cl, Br, I, methanesulfonyloxy, p-toluenesulfonyloxy, or o-nitrobenzenesulfonyl, and the group X a represents NH, group R b1 and group R b2 Together with their connected X a The nitrogen atoms together form the formula The substituent represented by n1 substituents R d1 Substituted nitrogen-containing heterocycle A a , that is, the compound of formula (M2) has the following structure: And X of the compound of formula (II) b The structure represented by the following general formula is represented accordingly: The nitrogen-containing heterocyclic ring A a represents a 4- to 30-membered nitrogen-containing heterocyclic group (preferably, a 4- to 20-membered nitrogen-containing heterocyclic group; more preferably, a 4- to 15-membered nitrogen-containing heterocyclic group), (R d1 ) n1 、n1、R c , Ring B, m1, (R d2 ) n2 、n2、R e 、C、m2、(R d3 ) n3 and n3 as defined in any one of claims 1 to 11; or (iii) (a) The group LE represents C(O)Cl or COOH, and R of formula (M2) b1 -X a -R b2 is R3-NH-R4, and X of the compound of formula (II) b Correspondingly represents C(O)NR3R4; or (b) group LE represents S(O)2Cl, R of formula (M2) b1 -X a -R b2 It is R 10 -NH-R 11 , and X of the compound of formula (II) b Correspondingly represents S(O)2NR 10 R 11 , where R3, R4, R 10 and R 11 As defined in any one of claims 1 to 11; or (iv) The group LE represents NH2, and R of formula (M2) b1 -X a -R b2 are: R5-C(O)-OH, R5-C(O)-Cl, R 13 -S(O)2-OH, or R 13 -S(O)2-Cl, and X of the compound of formula (II) b Correspondingly represents NHC(O)R5 or NHS(O)2R 13 , where R5 and R 13 As defined in any one of claims 1 to 11; or (v) The group LE represents Cl, Br or I, and R of formula (M2) b1 -X a -R b2 Is: R8-OH or R9-SH, and X of the compound of formula (II) b Correspondingly represents OR8 or SR9, wherein R8 and R9 are as defined in any one of claims 1-11.

21. The method for preparing a compound of formula (II) as claimed in claim 20, wherein when the group LE represents a methanesulfonyloxy group, the compound of formula (M1) is prepared by reacting a compound of formula (M3) with methanesulfonic anhydride or methanesulfonyl chloride: The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3, Z4 and R are as defined in claim 1.

22. The method for preparing a compound of formula (II) according to claim 20 or 21, wherein R of the compound of formula (M1), the compound of formula (II) and the compound of formula (M3) represents a bond.

23. The method for preparing a compound of formula (II) as claimed in claim 22, wherein the compound of formula (M3) is prepared by coupling reaction of a compound of formula (M4) with (tributyltin)methanol in the presence of a palladium catalyst: The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3 and Z4 are as defined in claim 1.

24. The method for preparing a compound of formula (II) as claimed in claim 23, wherein the thiocarbonyl compound of formula (M4) is prepared by sulfiding a carbonyl compound of formula (M5) with a sulfiding agent: wherein Z6 of the carbonyl compound of formula (M5) represents C(O), CH2 or CD2; In the thiocarbonyl compound of formula (M4), Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); and Group R a1 、R a2 、R a3 、R a4 and (R a5 ) m As defined in claim 1.

25. The method for preparing a compound of formula (II) as claimed in claim 24, wherein the sulfurizing agent comprises carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent, Belleau's Reagent, and Davy's Reagent.

26. A method for preparing a compound of formula (M4), comprising subjecting a carbonyl compound of formula (M5) to sulfurization with a sulfurizing agent to prepare a thiocarbonyl compound of formula (M4): wherein Z6 of the carbonyl compound of formula (M5) represents C(O), CH2 or CD2; and group R a1 、R a2 、R a3 、R a4 , Z1, Z2, Z3, Z4 and (R a5 ) m As defined in claim 1.

27. The method for preparing a compound of formula (M4) as claimed in claim 26, wherein the sulfurizing agent comprises carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent, Belleau's Reagent, and Davy's Reagent.

28. A method for preparing a compound of formula (M1), wherein the group LE represents a methanesulfonyloxy group, and the method comprises reacting a compound of formula (M3) with methanesulfonic anhydride or methanesulfonyl chloride to obtain a compound of formula (M1): The group R in the compound of formula (M1) and the compound of formula (M3) a1 、R a2 、R a3 、R a4 , R, Z1, Z2, Z3, Z4 and (R a5 ) m As defined in claim 1.

29. The method for preparing a compound of formula (M1) as claimed in claim 28, wherein R of the compound of formula (M1) and the compound of formula (M3) represents a bond.

30. The method for preparing a compound of formula (M1) as claimed in claim 29, wherein the compound of formula (M3) is prepared by coupling reaction of a compound of formula (M4) with (tributyltin)methanol: The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , Z1, Z2, Z3 and Z4 are as defined in claim 1.

31. The method for preparing a compound of formula (M1) as claimed in claim 30, comprising preparing a thiocarbonyl compound of formula (M4) by sulfiding a carbonyl compound of formula (M5) with a sulfiding agent: wherein Z6 of the carbonyl compound of formula (M5) represents C(O), CH2 or CD2; and group R a1 、R a2 、R a3 、R a4 , Z1, Z2, Z3, Z4 and (R a5 ) m As defined in claim 1.

32. The method for preparing a compound of formula (M1) as claimed in claim 31, wherein the sulfurizing agent comprises carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent, Belleau's Reagent, and Davy's Reagent.

33. A method for preparing a compound of formula (I), comprising subjecting a compound of formula (A) to sulfidation with a sulfiding agent to obtain a compound of formula (I): wherein Z7 of the compound of formula (A) represents C(O), CH2 or CD2; In the compound of formula (I), Z1 represents C(O), C(S), CH2 or CD2, and Z2, Z3 and Z4 each independently represent C(O) or C(S), wherein at least one of Z1, Z2, Z3 and Z4 represents C(S); and The group R a1 、R a2 、R a3 、R a4 、(R a5 ) m , R, L and X are as defined in claim 1.

34. The method for preparing a compound of formula (I) as claimed in claim 33, wherein the sulfurizing agent comprises carbon disulfide, hexamethyldisilathioane, sulfur, thiourea, hydrogen sulfide, phosphorus pentasulfide, Lawesson's Reagent, Belleau's Reagent, and Davy's Reagent.

Images